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3General introduction
1.1 Squamous cell carcinoma of the mouth
and oropharynx
1.1.1 Epidemiology
Cancer is a chronic disease with a relatively low incidence but high mortality rate
that represents the second most common cause of death world-wide. Squamous Cell
Carcinoma (SCC) is the most common malignant neoplasm of the upper aero-
digestive tract. Cancers of the lip, oral cavity and oropharynx comprise about half of
all squamous cell carcinomas in the head and neck area and around 2% of all new
cancer cases [Davis and Zitsch, 1999].
In the Netherlands the average number of new cases over the period 1989-1995 was
around 1,000 per annum. The incidence is rising with an annual increase of 4-6% in
absolute patient numbers, primarily attributed to demographic changes. European
Standardised incidence Rates (ESR) for the Netherlands are shown in Table 1.1.
Of all oral cavity cancers, 34 % is situated in the tongue, 30% in the floor of the
mouth, 16% in the buccal mucosa and 11% on the gums. Of all oropharyngeal can-
cers, 28% is situated at the base of the tongue, 42% in the lateral wall, including the
tonsils and 13% in the soft palate. Of the oral cancers, about 30% of the patients,
and of the oropharyngeal cancers already 50% present with advanced (Stage IV)
disease [Visser et al., 1998].
There is a wide geographical variation in occurrence of SCC’s at various sites of the
upper aero-digestive tract. The incidence figures in the Netherlands are roughly
comparable with statistics from the USA [Davis and Zitsch, 1999], but are consid-
erably lower than in France, India or Hong Kong, possibly due to variations in pre-
disposing factors involved [Batsakis, 1999].
Table 1.1. SCC of the lip, mouth and oropharynx. ESR per 100,000 persons (Visser et al., 1998)
Male Female
Lip 2.2 0.4
Oral cavity 5.4 2.8
Oropharynx 2.0 0.7
Total 9.6 3.9
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1.1.2 Aetiology
Predisposing factors for oral and oropharyngeal SCC that have been identified
include low socio-economic status, poor oral hygiene with poor dentition and dietary
deficiencies, particularly iron and avitaminosis of A and C [Batsakis, 1999]. The
most important and independent environmental factors are cigarette smoking and
alcohol consumption. Although nicotine and alcohol abuse have an independent
carcinogenic potential, its combined use is synergistic and leads to a 7-fold increase
of relative risk. Chewing betel quid and the use of smokeless tobacco or snuff,
probably induce a 4-fold increase of risk [Thomas and Wilson, 1993; Wray and
McGuirt, 1993; Batsakis, 1999].
There is increasing evidence that viruses are involved in the development of at least
a subset of Head and Neck Squamous Cell Carcinomas (HNSCC) [Scully, 1992;
Gillison et al., 1999]. The Epstein-Barr virus (EBV) is considered a direct
causative agent in development of nasopharyngeal carcinoma [Vasef et al.,1977;
Scully, 1992]. Several studies support an etiologic role for human papilloma virus
(HPV), particularly for poorly differentiated tumours arising from Waldeyer’s ton-
sillar ring [Gillison et al., 1999]. However, the association between HPV and oral
SCC is controversial and the actual mechanism by which it initiates malignant
transformation remains ill-defined [Bradford and Carey, 1999]. Variations
observed in the presence of HPV DNA may be related to detection methods,
source of tumour tissue and geographical variations [Miguel et al., 1998]. The
HPV subtypes 16 and 18 are typically classified as ‘high risk’ with an odds ratio of
about 4.3, but also types 6 and 11 are considered potentially carcinogenic
[Nishioka et al., 1999; Bradford and Carey, 1999]. Two possible mechanisms of
HPV tumour induction exist: HPV infections can increase the susceptibility for
tobacco carcinogens and HPV onco-proteins block the activity of tumour supressor
genes like p53 and the retinoblastoma gene [Li et al., 1992; Bradford and Carey,
1999].
Familial susceptibility to HNSCC is well known, with increased relative risks vary-
ing from 3.8 to 7.9 if a first degree relative had cancer of the head and neck
[Foulkes et al., 1996]. The application of molecular biology can reveal specific
genetic alterations or hereditary factors involved [Sikora, 1994; Bradford and
Carey, 1999]. The clinical importance to assess individual intrinsic cancer suscepti-
bility to HNSCC was demonstrated by Cloos et al. [1996].
4
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1.1.3 Prevention
Involvement in smoking prevention and cessation is a valuable contribution that doc-
tors can make to present and future health. Health education strategies, motivating
both the healthy population and patients to quit smoking should be encouraged.
However, excessive alcohol and tobacco consumption apparently are habits not easily
broken [Bolman and De Vries, 1998]. Moreover, after abstinence from smoking 15
to 30 years seem required to approximate the risk of non-smokers [Million, 1994].
Patients cured of their first HNSCC have about a 3-4% per year risk of developing
a second primary cancer [Day and Blot, 1992; Haughey et al., 1992; Jovanovic et
al., 1994; Van Es et al., 1996]. Prevention could also play a role in reducing this
risk. Initially it was hoped that retinoids could suppress the risk of a second cancer
[Hong et al., 1990]. Unfortunately, the extensive EORTC chemoprevention study
has proven otherwise: The 2-year supplementation of retinyl palmitate and/or N-
acetylcysteine yielded no benefit in terms of survival, event-free survival or second
primary tumours [Van Zandwijk et al., 2000]. Because no effective prevention
measures are available, our attention has to be mainly focussed on treatment of
already developed malignancies.
1.1.4 Conventional treatment and treatment failure
The management of SCC of the mouth and oropharynx requires a comprehensive
treatment plan that addresses all aspects of the disease process and the patient reha-
bilitation [O’Brien et al., 1992]. Conventional treatment with curative intent
depends on tumour site and tumour stage [Vokes et al., 1993]. It usually consists of
surgery, radiotherapy or a combination of both modalities for resectable lesions and
a combination of chemotherapy and radiotherapy for advanced tumours [Taylor et
al., 1997]. 
Ionising radiation can be delivered either by an external beam or by interstitial
implantation of radioactive sources [Almond, 1999]. Interstitial radiotherapy has
the advantage that it allows delivery of a high local dose of radiation to the tumour
without destroying local anatomy or inducing xerostomia [Close et al., 1993; Podd
et al., 1994].
Chemotherapy is usually delivered intravenously either concurrent with radiothera-
py or as induction therapy followed by radiotherapy [Stupp and Vokes, 1999].
Though regularly applied, the role of intra-arterial (i.a.) chemotherapy for
HNSCC remains controversial [Stupp and Vokes, 1999]. Reason why this therapy
is discussed under ‘alternative treatment modalities’ (see paragraph 1.2).
Today, it is still the classical triad of surgery, radiotherapy and chemotherapy that
dominates our therapeutic arsenal. However, during the past two decades survival
5
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rates of patients with advanced stage HNSCC have shown minimal improvement
[Heys et al., 1993]. Substantial numbers of patients are still dying from both loco-
regional recurrence and distant metastases despite continuing advances in surgical
and radiotherapeutic management, in spite of more radical operations and new
computer assisted irradiation techniques. To date, still about 25% of the patients
with oral cancer and 50% of the patients with oropharyngeal cancer eventually die
from their disease [Woolgar et al., 1999]. Relative survival rates of advanced oral
and oropharyngeal carcinomas are even as low as 20-30% [Visser et al., 1998].
HNSCC can spread to distant sites. Available data strongly suggest that a signifi-
cant percentage of distant metastases occur as a result of loco-regional treatment
failure [Slootweg et al., 1996; Million, 1999]. At present there is no clear evidence
from controlled studies that systemic chemotherapy has any benefit in long-term
control of oral SCC [Kovács et al., 1999]. Therefore, SCC of the mouth and
oropharynx must be considered primarily a loco-regional disease.
Improving the disappointing low cure rates of large head and neck cancers is a
major challenge. This requires alternative treatment modalities.
1.2 Alternative treatment modalities
Several therapeutic options may be considered as adjuvant or alternative treatment
modalities for HNSCC.
1.2.1 Intra-arterial chemotherapy
The pharmacokinetic rationale for i.a. or regional drug delivery is based on mathe-
matical models that link drug concentration of the target site with response
[Collins, 1984]. As such, selective i.a. infusion can offer a therapeutic advantage
over systemic drug administration. The goal of regional administration of
chemotherapy is to add anatomic selectivity to the inherent physiologic selectivity of
antineoplastic agents [August, 1996].
Nowadays, i.a. chemotherapy is routinely applied in treatment of malignancies of
the liver [Aigner, 1998] and extremities [Nijhuis et al., 1999]. For HNSCC, i.a.
mono-chemotherapy was initially given with palliative intent [Sullivan and Daly,
1961]. Later, various treatment schedules based on the combination of multi-drug
chemotherapy regimens and radiotherapy have been developed and used with cura-
tive intent [Noorman van der Dussen, 1986]. Unfortunately, a high complication
rate prevented its more general use. Recent advances made in interventional radiology
6
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allowed i.a. chemotherapy to make its comeback as alternative option in the man-
agement of HNSCC [Robbins et al., 1996; Kovács et al., 1999].
1.2.2 Immune-stimulation
The application of biological response modifiers to manipulate the anti-cancer host
defence is one of the alternative therapeutic approaches to both regional and dis-
seminated disease.
1.2.2.1 The Ribi-vaccine
At the end of the 1960s the group of Ribi [Ribi et al., 1973] demonstrated that
mycobacterial cell wall components were able to suppress tumour growth and to
induce regression of solid tumours. The compound consisted of certain fractions of
Bacillus Calmette-Guèrin (BCG) attached to minute oil droplets and became
known as ‘Ribi-vaccine’. It was one of the first biological response modifiers and
heralded the beginning of immunotherapy against cancer. Retarded tumour
growth, complete regressions and prolonged survival were obtained in guinea pig
hepato-cellular carcinoma and rabbit squamous cell carcinoma models [Ribi et al.,
1975; Edwards et al., 1975; Jeglum et al., 1985]. The Ribi-vaccine immunothera-
py has been applied to patients with HNSCC [Donaldson, 1972; Perlin, 1979].
Despite the encouraging results in the animal studies and the induction of signifi-
cant changes in the peri-tumoural infiltrate of human oral cancers, the value of
adjuvant BCG-immunotherapy in terms of tumour free survival has never been
demonstrated [Schlesinger et al., 1980]. The BCG vaccine is still used incidentally
together with other biological response modifiers as ‘adjuvant multi-modality
immunotherapy’ and claimed to be effective in treatment of oral cancer [Fukazawa
et al.,  1994].
1.2.2.2 The cytokine Interleukin-2
With increasing knowledge of the intercellular regulatory molecules that play an
important role in our immune system, attention soon focussed on more specific
stimulation of the immune system with cytokines. Cytokines are soluble proteins
secreted by a.o. lymphocytes and macrophages and act as intercellular regulatory
molecules in a paracrine manner. Since the second half of the 1980s, interest was
directed on the cytokine interleukin-2 (IL-2). IL-2 is a 14-17 kD glycoprotein
secreted by T-helper lymphocytes and is encoded by a single gene on chromosome
4 in humans [Reichert et al., 2000]. It was one of the first cytokines produced in
large quantities by means of recombinant DNA technology. IL-2, a major
autocrine growth factor for T lymphocytes, stimulates the growth of natural killer
7
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cells and enhances their cytolytic functions. It also acts as a growth factor for
human B cells and stimulates their antibody synthesis [Heys et al., 1993; Reichert
et al.,  2000].
Intra- or peri-tumoural application of low dose IL-2 in various experimental animal
models proved very effective in inducing regressions of both local and metastatic
tumours [Franzke et al., 1994, Den Otter et al., 1996]. In the mid-1990s IL-2
became an integral element in the treatment of patients with advanced renal cell
carcinoma, bladder cancer and metastatic malignant melanoma [Heys et al., 1993].
Conflicting data have been published on the treatment of an expanding range of
advanced other malignancies in humans. Until now, the treatment of HNSCC
patients with IL-2 regimens has shown little benefit [Matthijsen et al., 1994; Vlock
et al., 1994] which may in part be due to suboptimal regimens of IL-2 application
[Den Otter et al., 1996].
Current methods of cytokine immunotherapy consist of systemic bolus administra-
tion, repeated local injections or local delivery of cytokine gene-engineered cells
[Lang et al.,  1999]. Systemic administration of IL-2 is associated with prohibitive
toxicity and proved of limited benefit for patients. Repeated multiple painful peritu-
moural injections of free IL-2 are clinically not feasible due to discomfort for
HNSCC patients and the short half-live of the cytokines in vivo. Local sustained
delivery of cytokines using gene-modified tumour cells is difficult to implement in
clinical practice. The continuous local delivery of IL-2 via the intra-arterial route
[Tubaro et al., 1991; Gore et al., 1992; Lygidakis et al., 1995] seemed an ideal
solution to circumvent these obstacles. Unfortunately, considerable problems main-
taining the patency of arterial lines and local complications due to line-infections
were reported [Gore et al., 1992].
1.2.3 Interventional genetics
Gene therapy technology covers the field of getting foreign genes into cells so that
their DNA can be transcribed into mRNA and the encoded protein product syn-
thesised to produce a therapeutic effect. The therapeutic gene is transferred into
tumour cells using a vector. The mode of gene transfer can be classified into chemi-
cal, physical and viral. The most important method of transfer of DNA currently
being used is viral vectors [Robbins et al., 1998].
To date, four main types of genes can be introduced in tumour cells [Ganly et al.,
2000]:
8
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1. Anti-oncogenes, which suppress the expression of an oncogene. As yet, no
applications for HNSCC are reported.
2. Replacement-genes which restore a defective suppressor gene. The p53 sup-
pressor gene is mutated in almost 100% of the HNSCCs [Kropveld et al.,
1999]. Inactivation of p16 is reported in 80-90% of the HNSCCs. Recently,
phase I and II trials reintroducing p53 or p16 were carried out in patients with
advanced and recurrent HNSCC. Complete remissions were observed in 7-
11%. [Clayman et al., 1998; Rocco et al., 1998; Lamont et al., 2000].
3. Genes which enhance immune surveillance. Increasing the immunogenicity of
the tumour by transfecting MHC class I and II genes alone proved insufficient
for immune induction. Co-stimulatory molecules are also required [Lin et al.,
1993; Lang et al., 1999]. Alternatively, tumour cells can be transfected with
cytokine receptor genes such as IL-2 to improve the effectiveness of tumour
infiltrating lymphocytes.
4. Genes coding for an enzyme capable of activating an inert pro-drug into an
active cytotoxic agent. The most common gene used is the herpes simplex virus
thymidine kinase gene, which renders cells sensitive to the nucleoside analogue
ganciclovir, by converting ganciclovir into an active phosphorylated compound
that terminates DNA synthesis. This therapy caused reduced growth of
tumours in nude mouse models [Ganly et al., 2000; Morris et al., 2000].
Because the main obstacle of current gene therapy is the poor tumour transduction,
the use of a replication-competent virus, which selectively replicates in tumour but
not in normal tissue, is advantageous. Deleted adenoviruses are currently used for
this purpose, either by delivering a therapeutic gene into the tumour [Morris et al.,
2000] or by replicating themselves and so causing lysis of tumour cells infected.
The E1B 55kDa deleted adenovirus, Onyx-015, selectively replicates in and lyses
tumours with non-functional p53. In phase II trials 22% complete remissions were
obtained by combining Onyx-015 with i.v. cisplatin and 5-fluorouracil for patients
with recurrent HNSCC [Ganly et al., 2000].
Still, many hurdles in gene therapy technology have yet to be overcome, before we
will witness a reduction in the number of patients dying from cancer [Sikora, 1994;
Morris et al., 2000].
1.2.4 Inhibition of angiogenesis and Vascular targeting
Neo-vascularisation or angiogenesis involves the formation of new blood vessels.
This process can convert a small cluster of mutated cells or ‘in-situ cancer’, into a
large tumour mass capable of spreading to other organs. If angiogenesis of a
tumour is blocked, its growth is restricted up to a size of 1-2 mm, because of lack of
9
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readily available nutrients and oxygen [Folkman, 1996]. Tumours make two types
of proteins: One kind stimulates angiogenesis and the other inhibits it. The balance
between them determines whether the tumour can turn on angiogenesis and can
expand its growth. The ability to switch on angiogenesis depends mainly on a
decrease in the production of the inhibiting proteins [Folkman, 1996].
1.2.4.1 Anti-angiogenetic therapy
Anti-angiogenetic therapy is based on the application of drugs that interfere with
neo-vascularisation of the tumour. The treatment does not aim to destroy the
tumour itself, but prevents it from growing by limiting its blood supply. It keeps
tumours in a dormant state within their diffusion-restricted size as long as the drug
is administered. As such, it is a long-term treatment turning cancer into a chronic
disease with a low mortality rate, however without curing it [Folkman, 1996].
Among the many angiogenesis inhibiting compounds available, worth mentioning
are Endostatin, a 20kDa fragment of collagen XVIII, Angiostatin, a 38kDa frag-
ment of plasminogen and TNP-470, a synthetic fumagilline analogue. These
agents have proven to inhibit tumour angiogenesis and metastatic growth in animal
models. The TNP-470 has recently been tested in clinical trials for various tumours
[Bloemendal et al., 1999]. With respect to oral SCC, intra-tumoural injection of
TNP-470 induces significant tumour regression in a rabbit tongue carcinoma
model [Masumoto et al., 1999]. However, growth of human oral SCC-lines in
nude mice were unaffected by TNP-470 treatment [Gleich et al., 1998].
A very potent and specific compound stimulating angiogenesis, is the Vascular
Endothelial Growth Factor (VEGF). It is produced by virtually all tumours
[Folkman, 1996]. Monoclonal antibodies against VEGF have been reported to
block the growth of experimental tumours and to augment the effect of irradiation
[Gorski et al., 1999]. Recently, angiogenesis inhibition and gene therapy were
combined by transfection of antisense VEGF into HNSCC cell lines but no effect
on tumour growth was observed [Nakashima et al., 2000].
1.2.4.2 Vascular targeting with monoclonal antibodies
There are other means of compromising the vascularisation of tumours. Tumours
may be treated by starvation as a result of destruction, blockage or thrombosis of
their vessels. This can be achieved mechanically by super-selective embolisation of
the feeding arterioles with microspheres [Kato et al., 1994]. As tumour endothelial
cells are different from their counterparts in normal tissues, it can also be done on a
molecular level by using antibodies directed at unique or highly upregulated anti-
gens on tumour endothelial cells, ideally without cross-reactivity with cells outside
10
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the tumour [Bloemendal et al., 1999]. The phage display technology recently
allowed the generation of large quantities of human monoclonal antibodies
[Rossenu et al., 1997]. Specific antibodies against tumour endothelium-associated
surface antigens can be applied as selective carries to direct cytotoxic drugs,
radionuclides or immuno-modulating agents [Bloemendal et al., 1999].
Radiolabelled, tumour-selective monoclonal antibodies against tumour cell surface
antigens instead of tumour endothelium have also been tested. Until now only
modest results have been obtained in the application of these antibodies for the
treatment of patients with solid cancers [Bruland, 1995; De Nardo et al., 1999].
1.2.5 Photodynamic therapy
Photodynamic therapy (PDT) is a treatment modality that utilises a hematopor-
phyrin derivative compound also called ‘photo-sensitising drug’, which is inert until
activated by laser-generated light. After i.v. injection, the photosensitising agent is
preferentially retained in malignant cells. At a fixed time interval after injection, the
photo-sensitiser molecules are activated by red light of a specific wavelength (630
or 652 nm). The activated agent interacts with oxygen to produce reactive oxygen
species (e.g. free radicals), which are involved in the mediation of photodynamic
cytotoxicity and tissue destruction [Hsi et al., 1999]. PDT is currently used in
patients with early and advanced stage cancer of the lung, the digestive- and geni-
tourinary tract [Dougherty et al., 1998].
In treatment of HNSCC, PDT is effective for small cancers but it is not yet clear
in which cases such treatment is more effective than other currently acceptable
approaches. To date, PDT is mainly indicated for superficially spreading early can-
cers because the penetration of the light in the tissues is limited to 5-10 mm [Biel,
1995; Nauta et al.,  1996]. For large tumours, PDT might have a clinical benefit in
palliation [Ell and Glossner, 2000]. Its advantage is that it can be repeated and
does not interfere with conventional treatment modalities.
Many issues regarding pharmacokinetic data of photosensitizers, newer technology
involved in light sources, optimal treatment regimens that take advantage of the
pharmacophysiology of photoablation, and light dosimetry still require solution. As
technologic advances occur, especially interstitial PDT may have significant appli-
cation [Webber et al., 1999].
11
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1.3 Animal models for novel therapies against 
head and neck cancer
To evaluate the feasibility of novel treatment strategies against HNSCC, animal cancer
models are necessary. For HNSCC basically three types of animal tumour models exist:
1. Spontaneously occurring tumours, such as the sheep ear SCC [Harker and
Stephens, 1992] and the bovine ocular SCC [Den Otter et al., 1993].
However, these tumours are rare in the Netherlands and it is difficult to create
standardised experimental conditions for these models.
2. Tumours induced by topical application of carcinogens such as the 4-
Nitroquinoline-1-oxide (4NQO) mouse and rat SCC [Steidler and Reade,
1984; Nauta et al., 1995] and the 9,10-dimethyl-1,2-benzanthracene (DMBA)
hamster cheek pouch carcinoma [Shklar, 1972]. Unfortunately, tumour induc-
tion is rather time-consuming. Dysplastic lesions occur after 3 to 4 months of
application of the carcinogen and there is a latency period (which appears to be
in inverse proportion to the application period) of another 14-26 weeks before
carcinomas develop. Unlike the human SCC, these lesions not always lead to
infiltrating carcinomas and cervical lymph node metastases are rarely seen. Also
chromosomal alterations appear to be different from the SCC as seen in the
human situation [Lin et al., 1994]. Moreover there is an additional mortality of
the animals because of cumulative toxicity of the cancer inducing agents
[Hawkins et al., 1994].
3. Tumours induced by inoculation with a transplantable cell line, such as the
prostate derived SCC in the Fischer rat [Karanfilian et al., 1982] and the skin
SCC in the Wag-Rij rat [Schouwenburg et al., 1980].
Because of the small calibre of the external carotid artery branches, all HNSCC
models in rodents are inevitably dependent on microsurgical techniques if used for
studies on i.a. delivery of drugs [Schouwenburg et al., 1980]. To study the effects
of i.a. chemotherapy, Davidson et al. [1986], developed a macroscopic hind limb
SCC model in the rabbit. Harima et al. [1996] used the uterus and Päuser et al.
[1996] used the liver of the rabbit as tumour implantation site to study the effects
of chemo-embolisation. However, extrapolation to the head and neck area is debat-
able because of site-specific differences in the organ microenvironment, such as
vascularity, nature of tumour vessels and variations in lymphatics and draining
lymph nodes, as well as differences in local immune response and tissue specific
12
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paracrine factors [Fidler, 1995; Müller et al., 1998]. Rabbits possess large, translu-
cent ears. Tumour growth and tumour angiogenesis can be studied in detail at this
site [Tromberg et al., 1990]. A Vx2 auricle carcinoma model would couple the ease
of transplantability to a rather large laboratory animal with a sufficient calibre of the
external carotid artery branches, suitable to study i.a. delivery of drugs to the head
and neck area.
1.4 The Vx2 squamous cell carcinoma in rabbits
1.4.1 History
Naturally occurring cutaneous papillomas of domestic rabbits are induced by a
virus discovered by Shope and Hurst in 1933. Due to malignant transformation,
these papillomas give rise to squamous cell carcinomas. Inoculation of Shope-papil-
loma virus containing extracts at scarified skin spots induces carcinomas after about
10 months [Kidd et al., 1936]. Kidd et al. reported the first successful transplanta-
tion of such a carcinoma called ‘V1’ in 1936, but growth was lost on a second trans-
fer. In the experiment that led to the development of the ‘V2’ carcinoma cell line,
transplantation was successful in only 5% of the inoculated Dutch belted rabbits
initially. In the third tumour generation carcinomas already successfully grew in
21% of the inoculated animals. Transplantation is reported until the fourteenth gen-
eration. By then the V2 SCC was growing rapidly in most animals, into which it
was transplanted [Kidd and Rous, 1940]. During the course of serial transfers, the
V2 tumour became increasingly anaplastic in histologic appearance. In the 1950s,
transplantation of the V2 carcinoma appeared successful not only in other rabbit
species, but also at several sites in guinea pigs, mice, hamsters and rats [Greene,
1953]. Because of the now existing different stocks of cell lines world wide with
different transplant generations, the carcinoma became addressed as ‘Vx2’ tumour.
Stewart et al. (1959) gave a detailed description of the histology of the Vx2 tumour
in the New Zealand White (NZW) rabbit.
Since the 1960s, the Vx2 tumour is used in a large variety of experimental studies
(see paragraph 1.4.3):
1. To get insight into the various mechanisms of carcinogenesis, such as angiogen-
esis, dissemination and host immuno-competence.
2. To test various new treatment modalities against cancer, such as anti-angio-
genetic and intra-arterial therapies.
13
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1.4.2 In vitro growth of the Vx2 cell line
From the mid-1960s on, reports on the development of in-vitro cell lines from the
Vx2 carcinoma have appeared in the literature. Osato and Ito [1967] developed an
in-vitro Vx2 and less anaplastic Vx7 cell-line, but the Vx2 culture was lost and has
never been re-established. Later, others have reported about established in-vitro
Vx2 lines for various studies mainly on tumour prostaglandin E2 synthesis and
calcium metabolism [Voelkel et al., 1975; Yoneda et al., 1985]. However, these cell-
lines were not meant for re-implantation into the rabbit.
Galasko and Haynes [1976] demonstrated that a culture medium containing 10%
DMSO, an anti-freeze component to maintain sufficient cell viability after thawing,
is essential for successful storage of the Vx2 cells at -196°C in liquid Nitrogen.
Shah and Dickson [1978b] further reported on the preservation of the Vx2 tumour
in-vitro, but observed that the ability of their Vx2 cell line to re-grow in-vivo was
lost in due time: The Vx2 tumour cells grown in culture for over 3 weeks failed to
produce tumours when inoculated into rabbits. In 1982, Easty and Easty have
developed a Vx2 cell line that was successfully re-implanted after several months of
continuous culture and have described the culture conditions in detail.
The ability to maintain the Vx2 tumour in culture makes a variety of in-vitro stud-
ies possible and avoids the necessity for serial transplantation in rabbits, thus reduc-
ing the number of animals used for research. However, in practice most
investigators prefer the propagation of the Vx2 line in-vivo by intra-muscular pas-
sage in the hind paw [Muckle and Dickson, 1971; Herman et al., 1976; Tromberg
et al.,1990; Conlon et al., 1992; Wagner, 1994; Harima et al., 1996; Matsumoto et
al., 1999].
1.4.3 In-vivo Vx2 models and tumour transplantation
The Vx2 carcinoma cell line in the rabbit has been used in several studies:
1. To evaluate i.a. chemotherapy schedules in e.g. the liver [Wagner, 1994; Päuser
et al., 1996], the uterus [Harima et al., 1996], the kidney [Gadeholt-Göthlin
and Göthlin, 1995] and the bladder [Hoshi et al., 1997].
2. To study tumour angiogenesis [Brem and Folkman, 1975; Tamargo et al.,
1991; Matsumoto et al., 1999].
3. To evaluate host immuno-competence against tumours [Muckle and Dickson,
1971; Jeglum et al., 1985; Carroll et al., 1995].
The transplantation of the Vx2 cells can be achieved eighter by injecting tumour
cell suspensions [Herman et al., 1976; Wagner, 1994; Harima et al., 1996;
Matsumoto et al., 1999] or by implanting solid tumour pieces [Brem and
Folkman, 1975; Tamargo et al., 1991]. The use of cell suspensions is technically
14
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easy. It has the advantage of allowing to establish the percentage of vital cells inject-
ed by Trypan blue exclusion, and makes it possible to inject approximately equal
amounts of vital cells in each transplantation subsequently, yielding equally sized
tumours. However, the injection pressure can cause accidental infusion of tumour
cells into vessels resulting in early lung metastases, a phenomenon known as ‘seeding
at implantation’ as well as early lymph node metastases [Gadeholt-Göthlin and
Göthlin, 1995]. When assessing the effects of loco-regional i.a. anti-tumour therapy,
these artificially created lungmetastases are disadvantageous as they diminish the sur-
vival of the rabbits considerably. When assessing the effects of immunotherapy how-
ever, metastases are beneficial for determining systemic anti-tumour activity [Muckle
and Dickson, 1971].
1.5 Aims of the investigation
The primary aim of this study is to develop an animal model that can be used for
evaluation of new loco-regional treatment strategies against HNSCC. The second
aim is to evaluate the possibilities of new intra-arterial embolisation therapies,
eighter with dextran hydrogel microspheres that can slowly release anti-tumour
drugs or with radioactive poly(L-lactic acid) microspheres that contain the beta-
emitting isotope holmium-166 (166HoPLA).
More specifically:
• The study will evaluate, if the Vx2 carcinoma cell line transplanted into the rab-
bit auricle renders a suitable head and neck cancer model with respect to the
success rate of tumour transplantation, the tumour growth speed and the occur-
rence of lymph node and lung metastases. The effects of transplantation with
tumour suspensions either fresh or cryopreserved or with tumour pieces are
analysed (Chapters 2 and 5).
• This Vx2 head and neck cancer model is used to study the histologic effects of
peri-tumoural IL-2 and to establish whether IL-2 therapy can induce complete
remissions and a systemic immune response (Chapter 3).
For non-resectable head and neck cancers, theoretic considerations concerning the
application of intra-arterial embolisation therapies are presented (Chapter 4).
The Vx2 head and neck cancer model is subsequently used:
15
General introduction
Hoofdstuk 1  27-02-2001  13:27  Pagina 15
• To develop a technique for i.a. perfusion that is easy to handle and not depend-
ent on microsurgery (Chapter 5).
• To assess the possible use of dextran hydrogel microspheres for i.a. tumour
embolisation (Chapter 5).
• To evaluate the distribution of embolisation particles of a variable size in the
primary tumour, the lungs and the brain, both in-vivo and histologically after
sacrifice (Chapter 6).
• To analyse the effects of i.a. radio-embolisation with holmium-166 on Vx2
tumour growth. The efficiency of i.a. infusion of 166HoPLA microsphere sus-
pensions, the efficacy of retention of 166HoPLA microspheres within the pri-
mary tumour and the leaching of free holmium-166 into urine and faeces will
be assessed (Chapter 7).
16
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carcinoma as a model for head and neck
cancer in humans
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Abstract
Introduction: This study investigates whether the Vx2 carcinoma cell line, trans-
planted into the rabbit auricle, can be used as a head and neck cancer model. The
biologic behaviour of this model is evaluated, comparing tumour transplantation
with either tissue pieces or cell suspensions.
Materials and methods: 36 Adult NZW rabbits received s.c. injections of Vx2
Suspensions (Group S) and 11 rabbits received solid Vx2 Pieces (Group P) into
both auricles. In Group S, 16 rabbits were sacrificed at various days before (S1) and
15 after (S2) the 28th day following transplantation. In the other 5 rabbits transplan-
tation failed. Animals in Group P were sacrificed every 2 weeks after the 28th day.
At autopsy the size of the primary tumours and of lymph node, lung and other
metastases were assessed. If transplantation failed, the maximal tumour size and the
time at which regression took place were recorded. Exponential trend lines were
used to create growth curves of metastases. Differences between groups were evalu-
ated with the Chi-square test, correlations between parameters with Kendall’s tau.
Results: The tumour take-rate in Group S and P was 78% and 59% respectively.
The maximal size and time at which regression occurred was significantly different,
amounting 83 ±7 mm2 at 10.4 ±1.6 days (Group S) and 243 ±30 mm2 at 20.9
±2.0 days (Group P), respectively. Development of lymph node metastases was not
different. In Groups P and S2, over 90% of the necks contained lymph node metas-
tases. There was a trend for a higher incidence of lung metastases in Group S2
compared to Group P (47% vs. 14%). A significant correlation (p<0.05) between
weight loss and the size of lung metastases was found.
Conclusion: Transplantation of theVx2 tumour with cell suspensions produces a
useful head and neck cancer model for loco-regional disease in which anti-tumour
regimens against both the primary tumour and lymph node metastases can be test-
ed. Transplantation with tumour pieces is not advised as the take-rate is low and
spontaneous remissions occur at a late stage.
We thank W. den Otter for putting laboratory support at our disposal, A. Versluis and H. Boere for
taking care of the rabbits, P. Rothengatter for the photography and R. Broekhuizen for his efforts in
helping to establish an in-vitro Vx2 cell line.
18
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The Vx2 auricle carcinoma model
2.1 Introduction
Improving the disappointing cure rates of large head and neck cancers is a major
challenge, as relative survival rates of stage IV oral or pharyngeal carcinomas are
still as low as 20-30% [Visser et al., 1998]. Animal cancer models can be of use in
the development of new treatment strategies. For this purpose, the Vx2 carcinoma
cell line in the rabbit has been used in several studies (see also 1.4.3):
1. To evaluate intra-arterial (i.a.) chemotherapy schedules. 
2. To study tumour angiogenesis.
3. To evaluate host immuno-competence against tumours.
The transplantation of the Vx2 cells can be achieved either by injecting tumour cell
suspensions or by implanting solid tumour pieces. Cell suspensions have the advan-
tage of allowing to establish the percentage of vital cells injected by Trypan blue
exclusion, and make it possible to inject approximately equal amounts of vital cells
in each transplantation subsequently, yielding equally sized tumours. However, the
injection pressure can cause accidental infusion of tumour cells into vessels result-
ing in early lung metastases, a phenomenon known as ‘seeding at implantation’
[Gadeholt-Göthlin and Göthlin, 1995], as well as early lymph node metastases.
When assessing the effects of loco-regional i.a. anti-tumour therapy, these artificial-
ly created lung metastases are disadvantageous as they diminish the survival of the
rabbits considerably [Gadeholt-Göthlin and Göthlin, 1995]. When assessing the
effects of immunotherapy however, metastases are beneficial for determining sys-
temic anti-tumour activity [Muckle and Dickson, 1971; chapter 3].
The present study investigates whether the Vx2 carcinoma transplanted into the
rabbit auricle can be used as a head and neck cancer model. The success rate of
tumour transplantation and the occurrence of lymph node and lung metastases of
this rabbit Vx2 auricle carcinoma model is evaluated following transplantation with
either tumour suspensions or tumour pieces.
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2.2 Materials and methods
All animal experiments in this and the following chapters were performed in agree-
ment with ‘The Netherlands Experiments on Animals Act’ (1977) and ‘The
European Convention for the Protection of Vertebrate Animals used for
Experimental Purposes’ (Strasbourg, 18.III.1986). Approval was obtained from
‘The Utrecht University Animal Experiments Committee’ (FDC/DEC-GNK
numbers 96005, 98024 and 99053).
2.2.1 Animals
Adult female, specific pathogen free, Iffa Credo: New Zealand White
(ICO:NZW) outbred rabbits weighing 2.5-3.5 kg were purchased from the
Broekman Institute, Someren, the Netherlands. They were allowed to acclimatise
for at least 5 days before use and kept in a closed system without isolator. Housing
was in accordance with the guidelines of the Central Laboratory Animal Institute
(CLAI, Utrecht, the Netherlands) in individual steel cages, 75x47x40 cm (type
HD.1., UNO, Zevenaar, the Netherlands). Rabbits were fed with approximately
100 grams ‘complete diet’ pellets for rabbits (Type LKK 20, Hope Farms Ltd.,
Woerden, the Netherlands) per day, and acidified (hydrochloric acid, pH 2.7) tap
water ad libitum. Environmental temperature was regulated between 18° and 20ºC
and non-regulated relative air humidity was approximately 60%. Air was refreshed
at a rate of seven times per hour. Day/night cycle was 12/12h in artificial lighting
with white lights on at 7:00h during summer time and at 6:00h during wintertime.
All experiments were performed during daytime hours.
2.2.2 Tumour cells
2.2.2.1 Origin and propagation
From the German Cancer Research Institute (Deutsches Krebs Forschungs
Zentrum, DKFZ) an in-vitro Vx2 cell line [Kidd and Rous, 1940] was obtained,
which originally was derived from a Vx2 tumour growing in Yellow-Silver rabbits.
This line was successfully propagated in-vitro several times. However, re-trans-
plantation of this established line into ICO:NZW rabbits failed.
Subsequently, an in-vivo Vx2 cell line growing in NZW rabbits was obtained as a
gift from the department of Radiology, Benjamin Franklin Medical Centre, Free
University of Berlin in Germany. This cell line was successfully propagated in-vivo
in ICO: NZW rabbits but failed to grow in III/VO and AX rabbits.
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Despite several attempts, by using different tumour fragments from the primary
site, the lymph node and lung metastasis or by adding extra calcium to the culture
medium [Yoneda et al., 1985], we failed to establish an in-vitro culture of this now
well in-vivo growing Vx2 strain from Berlin.
The Heidelberg Vx2 strain might have failed to re-grow in the NZW rabbit in-
vivo, because the cell line originated from a Yellow-Silver breed and was propagated
in-vitro for too many cycles [Shah and Dickson, 1978b]. Therefore, tumour cells
had to be propagated by intramuscular passage in the upper hind limb.
2.2.2.2 Preparation
Dissected tumour tissue was fragmented and cautiously pressed through a nylon
sieve (mesh size 200 µm) and collected in ice-cold RPMI 1640 medium (Gibco,
Grand Island, New York, USA). After 2 centrifugation cycles and re-suspension,
the Vx2 cell suspension was standardised at a density between 15 and 30x107
cells/ml. The number of cells in suspension was counted using a haemocytometer.
Viability of cells was estimated by Trypan blue exclusion. To induce tumours, a
0.10-0.15 ml suspension containing 15 to 45x106 vital cells was injected with a 0.5 mm
needle s.c.
Tumour pieces were obtained from non-necrotic, well vascularised portions of an
aseptically excised hind paw tumour, as described earlier [Tamargo et al., 1991].
Portions were cut into 3x3 mm pieces in ice-cold RPMI 1640 medium and
implanted in a small subcutaneous pocket. Both suspensions and pieces were used
within 2 hours.
2.2.3 Tumour transplantation
All hair was removed from the auricle by shaving the skin with a pair of clippers.
Tumours were transplanted into the area between the central auricular artery and
caudal margin, at the dorsal middle-third of both auricles (Fig. 2.1).
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Figure 2.1. 
Vx2 twin tumour model.
Example of rabbit in Group S,
2 weeks after transplantation.
Tumours are located at the
dorsal lateral side of both
auricles (arrows).
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Rabbits were excluded from further analysis if tumour transplantation failed in both
auricles, i.e. if tumours did not grow progressively and regressed.
Group P consisted of 11 animals, i.e. 22 auricle implantations with solid pieces.
Rabbits from Group P were sacrificed every 2 weeks from day 28 after transplanta-
tion on, i.e. on days 28, 42, 56 and 70 respectively. 
Group S consisted of 36 animals, i.e. 72 auricle transplantations with tumour sus-
pensions. Time of sacrifice in Group S varied from day 3 to 67. Group S included 5
rabbits sacrificed at days 3, 7, 10, 14 and 21 after transplantation and 20 rabbits
sacrificed at various times after transplantation within 1 day after a tumour emboli-
sation experiment.
To compare Groups P and S, a Group S1 was composed of animals sacrificed
before day 28: sixteen rabbits, of which four were killed in weeks 1-2 and twelve in
weeks 3-4. Group S2 consisted of 15 rabbits sacrificed after day 28: Four rabbits in
weeks 5-6, six rabbits in weeks 7-8 and five rabbits in weeks 9-10. The other 5 rab-
bits were excluded because transplantation failed in both auricles.
2.2.4 Analgesia, sedation and euthanasia
Analgesia and sedation during interventions were achieved with fentanyl/flu-
anisone, 0.1 ml/kg i.m. (Hypnorm®, containing fentanyl 0.315 mg/ml and flu-
anisone 10 mg/ml, Janssen-Cilag Ltd., Saunderton, UK). Rabbits were sacrificed
with pentobarbital 0.3 ml/kg i.v. (Euthesate®, containing pentobarbital 200 mg/ml,
Apharmo b.v., Arnhem, the Netherlands). Signs of pain or distress as indicated by
the ‘Guidelines on choosing an appropriate endpoint in animal experiments’
(Canadian Council on Animal Care, 1998) were an indication for sacrifice.
2.2.5 Clinical measurements, histopathological investigations and statistics
Success of transplantation was characterised by the tumour take-rate. Body weight
was recorded biweekly. Weight loss at sacrifice was defined as 100% x (maximum
weight - weight at death)/maximum weight. At autopsy, the tumour size was meas-
ured with callipers in two dimensions and recorded as surface area (A, mm2).
Enlarged parotid (=first echelon), retromandibular (=second echelon) and cervi-
cal (=third echelon) lymph nodes were collected bilaterally. Both sides of the neck
were scored independently for lymph node metastases. The largest diameter of each
lymph node was measured with callipers and recorded. Inflated and fixed lung
specimens were prepared as described by Kim et al. [1993] from all rabbits of
Group P and 12 rabbits of Group S. A slice of each lung lobe was removed. The
diameter of the largest visible metastatic nodule was measured with callipers and
recorded. The abdominal organs were inspected for the presence of metastases. All
22
Hoofdstuk 2  27-02-2001  13:28  Pagina 22
23
The Vx2 auricle carcinoma model
tissues were placed in 10% buffered formalin and paraffin sections (5 µm) were
prepared. Sections were stained with haematoxylin and eosin and studied by an
experienced pathologist to confirm the presence of tumour cells.
If tumour transplantation failed, i.e. if there was no progressive growth or if sponta-
neous regression occurred, the Maximum Size (Amax, in mm2) of the primary
tumour and the time at which this size was reached (Tmax, in days) were noted.
Differences between Amax and Tmax of Groups S and P were assessed.
The size of lymph node and lung metastases was correlated with (1) time after
transplantation, (2) size of the primary tumour and (3) loss of body weight.
Kendall’s tau was used to test for bivariate correlations. The growth of lymph node
and lung metastases was assessed with exponential regression curves. Trend lines to
correlate the diameter of the metastases (D(t), in cm) with time (t) were presented as :
D(t)=D0.2
t/T
where D0 is the size in cm at t=0, and T represents the ‘tumour-size doubling
time’ (see chapter 5). The Chi-square test was used to assess differences between
the two Groups in tumour take-rate and the number of animals with metastases in
lymph nodes or lungs. P-values <0.05 were considered significant.
2.3 Results
2.3.1 Success of transplantation and spontaneous regressions
In Group S, 56 of the 72 transplantations succeeded (take-rate 78%). In Group P
only 13 of the 22 implantations were successful (take-rate 59%). The Chi-square
test showed a strong trend for a better take-rate in Group S (p<0.1).
Between Group P and S, differences in Amax and Tmax of the tumours that did
not grow progressively and subsequently regressed, were highly significant (Table
2.1): In Group P regressing tumours grew larger and went into remission later.
2.3.2 Lymph node metastases
Group P: In 12/13 (92%) of the necks that drained the primary tumour, a first ech-
elon parotid metastasis was present (Fig. 2.2). The only negative neck contained an
enlarged parotid lymph node, but no vital tumour cells were found. In 1/12 (8%) of
the positive necks also a second echelon (i.e. retromandibular) metastasis was present.
Group S: In 19/30 (63%) necks of the 16 rabbits of Group S1, a parotid metastasis
was present. Of the 15 rabbits of Group S2, in 25/26 (96%) necks a parotid metas-
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Figure 2.2. 
Typical image of first echelon
lymph node metastasis. 
A: Lymph node metastasis
(arrow) in the left parotid. 
a = angle of the mandible. 
B: Microscopy of lymph node
on section (HE-staining, x10).
A
B
Table 2.1. Success of transplantation and mode of inoculation (Chi-square test)
Group S Group P p-value
Transplanted tumours n=72 n=22
Take-rate 78% 59% .083
Amax (mm2)* 82.9 ±7.1 243.2 ±30.3 <.001
Tmax (days)* 10.4 ±1.6 20.9 ±2.0 <.001
*Amax = maximum tumour size before regression; Tmax = time at which Amax was reached.
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tasis was present and 7/26 (27%) necks had second echelon metastases. No third
echelon metastases were found in either group. Differences in development of sec-
ond echelon lymph node metastases between Group S2 and P were not significant.
There was also no significant difference in growth of lymph node metastases
between Groups S and P, with lymph node-size doubling-times of 22 and 33 days
respectively (Fig. 2.3).
2.3.3 Lung metastases
Group P: One of the 7 rabbits (14%), sacrificed at day 42, had lung metastases.
Group S: Five of the 16 rabbits (31%) in S1 and 7 of the 15 rabbits (47%) in S2
had lung metastases (Fig. 2.4). Three rabbits that were sacrificed because of symp-
toms of tachypnoe and cyanosis on days 37, 44 and 59 respectively, had lung metas-
tases larger than 14 mm in diameter. Differences in development of lung metastases
between Group S2 and P were not significant.
When relating the size of the largest lung metastasis with the time after transplanta-
tion, an exponential trend-line was found (according to D(t)=2.0 x 2 t/26) corre-
sponding to a lung tumour-size doubling-time T of 26 days (Fig. 2.5). The size of
the only metastasis in Group P did not differ from the sizes found in Group S. This
trend line reaches a size of 14 mm at week 10 after transplantation.
No significant correlation was found between the size of the primary tumour and
the development of lung metastases (Table 2.2). Only one rabbit (Group S1, sacri-
ficed at day 10) had a 1 mm lung metastasis without evidence of tumour in the
lymph nodes.
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Figure 2.3. 
Exponential trend lines
correlating the size of lymph
node metastases and time after
transplantation in Group S ()
and Group P ().
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Figure 2.4.
Typical image of lung
metastases in Group S, 6 weeks
after transplantation. 
A: Heart-lung specimen with
metastases (arrows). 
B: Microscopy of lung
metastasis (m) on section 
(HE-staining, x10).
Figure 2.5.
Exponential trend line
correlating size of lung
metastases in Group 
S () with time. 
The only metastasis in Group
P is depicted with a .
A
B
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2.3.4 Other metastases
A 5mm large endotracheal metastasis was found in one animal (3%) of Group S
(Fig. 2.6). This rabbit died 27 days after transplantation, during the night. It was
autopsied the next morning, revealing also multiple pulmonary metastases up to
5 mm in diameter. No metastases were found at other sites in this animal and any of
the other rabbits.
2.3.5 Weight loss
A significant correlation was found between weight loss and primary tumour-size
and between weight loss and size of lung metastases (Table 2.2). Weight loss of the
3 rabbits that had to be sacrificed because of massive pulmonary metastases ranged
from 11.7 to 22.2% (average 17.2%).
Figure 2.6. 
Endo-tracheal metastasis,
Group S, 27 days after
transplantation. 
A: Trachea cut open at dorsal
side. 
B: Microscopy of cross section
through metastasis 
(HE staining, x10).
A
B
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2.4 Discussion
2.4.1 Success of transplantation
In this study, successful transplantation of the Vx2 carcinoma was better using
tumour cell suspensions than tumour pieces, yielding a take-rate of 78%. Many
authors do not report their response rates explicitly [Muckle and Dickson, 1971;
Tromberg et al., 1990; Gadeholt-Göthlin and Göthlin, 1995; Päuser et al., 1996;
Harima et al., 1996; Hoshi et al., 1997; Matsumoto et al., 1999;]. Of those who
do mention their success, take-rates of Vx2 suspensions injected intramuscularly in
the hind limb vary from 95% to 100% [Herman et al., 1976; Wagner, 1994]. Take-
rates of the implantation of tumour pieces in corneas has also not been stated explic-
itly [Brem and Folkman, 1975; Tamargo et al., 1991] although Brem and Folkman
[1975] claim that spontaneous regressions did not occur.
‘Non-takes’ and spontaneous regressions are not easy to distinguish, because in the
first week after transplantation always a reactive swelling occurs. It is an important
issue however, because spontaneous regressions make statements on the efficacy of
anti-tumour treatment unreliable. The regressed tumours in Group S can be
addressed as ‘non-takes’, because the transplanted tumour mass subsided after 10
days with a maximum size of only 0.8 cm2. However the regressed tumours in
Group P are true remissions: A substantial tumour mass (2.4 cm2 on average)
developed up till 21 days after transplantation before growth ceased.
Table 2.2. Correlation of tumour parameters in Group S (Kendall’s tau)
Time Primary Lymph node Lung
Timea _
Primaryb <0.001 _
Lymph nodec <0.001 <0.001 _
Lungc 0.096 ns* ns* _
Weight loss ns* 0.015 ns* 0.020
a: time (days) after transplantation
b: size (cm2) of the primary tumour
c: diameter (mm) of the largest lymph node or lung metastasis
* ns: not significant.
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The poor take-rate of 59% in Group P can be explained by the presence of a signif-
icant number of dead Vx2 cells, despite the fact that we took care to obtain well-
vascularised tumour pieces. This may have had an immunisation effect stimulating
an effective immune response and preventing outgrowth of tumour. This phenome-
non is comparable with the transplantation failures seen when injecting cryopre-
served tumour cell suspensions (chapter 5), or the tumour regression induced by
local heating [Muckle and Dickson, 1971]. Furthermore the use of neonatal rab-
bits with an immature immune system [Brem and Folkman, 1975; Tamargo et al.,
1991] can explain better take-rates. Also the site of transplantation of the primary
tumour might influence the tumour take-rate: Kidd and Rous [1940] observed
that ‘as a rule the Vx2 cancer does badly in the subcutaneous tissue’. The fact that
our model is based on subcutaneous growth in the auricle explains a less favourable
take-rate when compared to models based on growth in muscle of the hind limb
[Herman et al., 1976; Wagner, 1994] or tongue [Matsumoto et al., 1999]. This is
why the transplantation of at least 20.106 vital cells into the auricle is advised (chap-
ter 5). The late spontaneous remissions in this study are a reason to advice against
transplantation of tumour pieces in the Vx2 auricle model.
2.4.2 Lymph node metastases
Injecting tumour suspensions can force tumour cells into lymph vessels resulting in
lymph node seeding at implantation. Nevertheless, in our model development of
lymph node metastases appears to be independent from the technique of transplan-
tation. The trend-lines correlating the size of lymph node metastases with time after
transplantation as well as the incidence of first echelon metastases did not differ
between the two groups. Though we found a trend for a higher incidence of second
echelon (retromandibular) metastases in Group S (26% vs 8%), it was not statisti-
cally significant.
By day 28 after transplantation, more than 90% of the necks in both groups con-
tained lymph node metastases. Matsumoto et al. [1999] even found 100% lymph
node metastases after injecting Vx2 suspensions in the tongue. It is convenient to
have an animal model in which both the primary tumour and the development of
lymph node metastases can be linked to effects of an anti-tumour regimen
[Matsumoto et al., 1999; chapter 3]. The easy accessibility of the first echelon
parotideal metastases for measurements in-vivo makes this model useful for experi-
mental studies on the effects of treatment regimens on regional lymph node metas-
tases as well.
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2.4.3 Lung metastases
Although a trend for a higher incidence of lung metastases was noted in Group S
when compared to Group P, pulmonary seeding at implantation does not play a sig-
nificant role in this model. The earliest sacrifice because of advanced pulmonary
disease was noted at day 37 after transplantation. A size of 14 to 16 mm seems to be
critical for pulmonary metastases in this model. At that point tachypnoe and
cyanosis demand sacrifice of the animal. The trend line correlating the size of lung
metastasis with time crosses this critical limit at 10 weeks after transplantation (Fig. 2.5).
The development of lung metastases does seem to be a problem when injecting Vx2
suspensions into well vascularised parenchymatous tissues such as the kidney, the
bladder, the uterus and also the tongue. Matsomoto et al. [1999], inducing tongue
tumours, found already 80% lung metastases at day 22. Hoshi et al. [1997], induc-
ing Vx2 bladder tumours, found 100% lung metastases at day 35. Gadeholt-
Göthlin and Göthlin [1995], inducing Vx2 renal tumours, noted that ‘all the
control rabbits had to be killed because of advanced pulmonary disease after 32-38
days’. Harima et al. [1996], inducing Vx2 uterus tumours, noted that in the 5th
week ‘metastases to the lungs resulted in death of more than 80% of the animals’.
These findings almost parallel the development of lung metastases when a Vx2 sus-
pension is injected directly intravenously as seen in the pulmonary metastases
model by Kim et al. [1993]. In contrast, Vx2 suspensions injected in skeletal mus-
cle do not seed at implantation: In a cachexia model [Conlon et al., 1993], lungs
were macroscopically free of tumour at 30-45 days and death from lung metastases
only occurred at week 10 after intramuscular Vx2 tumour-injection [Muckle and
Dickson, 1971]. This corresponds well with the findings in the present study and
probably demonstrates the natural tendency of dissemination of Vx2 cells to the
lung. Unfortunately, investigators that used Vx2 pieces as transplants do not report
whether lung metastases occurred [Brem and Folkman, 1975; Tamargo et al.,
1991]. From the data on the pulmonary metastases model by Kim et al. [1993] a
tumour-size doubling-time (T) of 9.8 days can be deduced for lung metastases.
This corresponds well with the T of the Vx2 at the auricle (chapter 5), varying from
4.5 to 9.9 days, but not with the T of the secondary lymph node and lung metas-
tases in this model varying between 22 and 33 days. A theoretical existence of two
different lung metastases growth curves, one related to the seeding at implantation
and one related to the natural dissemination tendency of the Vx2 tumour itself,
could not be discerned in this study.
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2.4.4 Other metastases
The endotracheal metastasis found in this study was either haematogenic or
originated from Vx2 cells entrapped in the submucosal lymph sinuses. Like other
investigators [Kidd and Rous, 1940; Muckle and Dickson, 1971; Gadeholt-
Göthlin and Göthlin, 1995; Hoshi et al., 1997], haematogenic metastases at sites
other than the lungs were not found in any of the animals. Also direct i.v. injection
of Vx2 suspensions does not induce metastases outside the thorax [Kim et al.,
1993]. Because the event is rare, it is not necessary to consider metastases at other
sites in practice when using this Vx2 auricle carcinoma model.
2.4.5 Weight loss
Weight loss appears to be strongly associated with the presence of lung metastases,
a phenomenon also observed in humans. When weight loss exceeds 10%, sacrifice
should be considered in the interest of the animal’s well fare. Also Gadeholt-
Göthlin and Göthlin [1995] report the sacrifice of ‘sick-looking rabbits’ with
weight loss exceeding 10-15%. Additional important signs are tachypnoe and
cyanosis. Because immature rabbits in study show weight gain, Conlon et al.
[1993] define cachexia as ‘>15% deviation from previously determined normal
growth’. In practice it is easier to use the definition of weight loss applied in this
study, because determination of ‘normal growth’ needs an extra control group of
non-tumour bearing rabbits. The weight loss seems related to loss of appetite
[Conlon et al., 1993], which was not quantified in this study.
2.5 Conclusions
The biological behaviour of this Vx2 head and neck tumour model closely mimics
head and neck cancer in humans. Tumour transplantation with solid pieces is not
advised because of spontaneous regressions. Transplantation with tumour suspen-
sions does not significantly raise the incidence of metastases to the lymph nodes or
lungs. Thus, the phenomenon of artificially created metastatic deposits due to seed-
ing at implantation does not play a significant role in this model. Also the occurrence
of metastases at other sites is very rare. Lymph node metastases develop in more
than 90% of the necks after the 4th week following transplantation. Therefore, this
model can be used for experimental studies on the effects of treatment regimens tar-
geting both the primary tumour and the metastases in draining lymph nodes.
Hoofdstuk 2  27-02-2001  13:28  Pagina 31
32
Hoofdstuk 2  27-02-2001  13:28  Pagina 32
3
chapter
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Abstract
Introduction: Head and neck cancer is associated with impaired cell-mediated
immune reactivity. A rabbit model with Vx2 Squamous cell carcinoma transplanted
into both auricles was used to test the effects of a regimen for local IL-2 therapy,
optimal in murine tumour models.
Materials and Methods: Peri-tumoural IL-2 treatment started when one of the
tumours exceeded 2 cm2 and consisted of 100,000 or 300,000 Chiron Units IL-2
or only solvent during 5 consecutive days.
Results: In 4/12 (33%) rabbits the treated primary tumours regressed completely,
simultaneously with the non-treated contra-lateral tumours. Also metastases in
draining lymph nodes of both treated and untreated primary tumours regressed in
three of these animals. Three (25%) of all 12 treated animals were cured. Tumour
cells injected in the cured animals were rejected. Histology of regressing tumours
in cured cases showed an active granulomatous reaction with a histiocytic response,
splitting up of tumour islands, and obstruction of blood vessels with fibrin thrombi.
Conclusion: These findings show local and systemic therapeutic effects of this
peri-tumoural IL-2 regimen in a Vx2 head and neck cancer model.
We thank C.H.P. Pellicaan for preparing the IL-2 solutions, A. van der Bilt for his mathematical
advice, A. Versluis and H. Boere for taking care of the rabbits, P. Rothengatter for the photography and
J. Klaversteijn for preparing the histological sections.
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Peri-tumoural IL-2 treatment
3.1 Introduction
Immune-stimulation with IL-2 is considered a valuable adjuvant therapy for vari-
ous human tumours such as advanced renal cell carcinoma, bladder cancer and
metastatic malignant melanoma [Heys et al., 1993]. Squamous cell carcinoma of
the head and neck (HNSCC) has been associated with impaired cell-mediated
immune reactivity [Wolf et al., 1987]. Therefore, stimulation of immune reactivity
with immune modulating agents such as Interleukin-2 (IL-2) may be therapeuti-
cally important. Animal models can assist in determining appropriate doses, time
intervals, and location of injections for clinical trials with IL-2. Carroll et al.
[1995] prevented progressive growth of the Vx2 Squamous cell carcinoma (SCC)
implanted into the rabbit hind paw by biweekly peri-lesional injections of 10,000 U
IL-2 (Hoffman-La Roche). However, complete tumor remissions did not occur.
Moreover, the Vx2 hind paw model does not mimic the situation of a HNSCC in
humans. Until now, variable results but no cures have been reported with peri-
lesional injections or local infusions of IL-2 in humans with HNSCC [Gore et al.,
1992; Vlock et al., 1994]. This may in part be due to different regimens of IL-2
application. Variable results have also been reported on peri-tumoural injections of
IL-2 in animals with transplanted carcinoma cells, such as adenocarcinomas in rats
[Hendriksson et al., 1992; Liu et al., 1996] and mice [Liu et al., 1994], hepatocel-
lular carcinomas in guinea pigs [Claessen et al., 1992; Balemans et al., 1993] and
alveolar carcinomas in mice [Dubinett et al., 1993]. Results in these studies varied
from growth retardation up to 24% complete remission of the carcinomas.
The aim of the following study is to establish whether a regimen for local IL-2
therapy that is optimal in murine tumor models [Den Otter et al., 1996], is capable
of inducing complete remissions in this new Vx2 head and neck cancer model.
3.2 Materials and methods
3.2.1 Rabbits
Fourteen adult female NZW rabbits were used under conditions as described in
chapter 2.2.1.
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3.2.2 Tumour cells
Vx2 tumour cell suspensions were prepared as described in chapter 2.2.2. The
number of cells in suspension was counted using a haemocytometer. Viability of
cells was estimated by Trypan blue exclusion.
3.2.3 Tumour induction and tumour challenge of animals with tumour remission
Hair was removed from the auricles. To induce tumours, 0.10 - 0.15 ml of a sus-
pension containing 15 to 35x106 vital tumour cells was injected with a 0.5 mm needle
s.c. into both auricles. The injection site was the area between the central auricular
artery and caudal margin, at the dorsal middle-third of each auricle.
In case of remission of the primary tumour, tumour resistance was tested by inject-
ing 30x107 vital Vx2 cells intramuscularly in the thigh of the hind paw.
3.2.4 IL-2 Injections
Human recombinant IL-2 was kindly provided by Chiron, Amsterdam, the
Netherlands. IL-2 was suspended in a solvent containing water, glucose 5% and
Haemaccel 10% [Hoechst Marion Roussel, Hoevelaken, the Netherlands]. The IL-2
solutions were frozen in 2 ml polypropylene cryo vials (Greiner BV, Alphen aan den
Rijn, the Netherlands) at -80°C by flash point freezing. The vials contained 100,000
or 300,000 Chiron U IL-2/0.2 ml or 0.2 ml solvent only. The treatment groups were:
Group A (n=6), treated with 100,000 U IL-2/0.2 ml/day
Group B (n=6), treated with 300,000 U IL-2/0.2 ml/day
Group C (n=2), treated with 0.2 ml solvent/day
IL-2 injections were started when the size of one of the auricle tumours exceeded 2
cm2. IL-2 was administered daily on 5 consecutive days. Each day, the total volume
of 0.2 ml was delivered in 4 portions of 0.05 ml in 4 quadrants immediately adja-
cent to only one tumour (the one that exceeded 2 cm2). The tumour in the other
auricle was left untreated. The animals were treated blindly and the code was bro-
ken after evaluation of tumour regression.
3.2.5 Biopsies and sacrifice
Three days after completion of the 5-day IL-2 treatment, that is on day 8, an inci-
sional biopsy was taken from the caudal quadrant of all treated tumours (n=14).
Of animals A3,4,5 and B2,3,4 also a biopsy from the non-treated contra-lateral
tumour was available. In case of progressive tumour growth, rabbits were sacrificed
in the 8th week after transplantation or earlier in case of excessive tumour burden as
indicated by loss of appetite, over 10% weight loss, tachypnoea, scratch infection of
the auricle, or other indications as observed by the animal tenders.
36
Hoofdstuk 3  27-02-2001  13:29  Pagina 36
3.2.6 Analgesia, sedation and euthanasia
For details on analgesia, sedation and euthanasia is referred to chapter 2.2.4.
Biopsies were taken under additional local anaesthesia with lidocaine 2%.
3.2.7 Evaluation of tumour growth
The tumour size was measured with callipers biweekly in two dimensions and
recorded as surface area (A, cm2). Enlargement of lymph nodes in the neck was
recorded biweekly by palpation and measured with a calliper. To calculate the time
point at which tumours went into regression, i.e. the interval between the start of
the IL-2 therapy and the first sign of remission, a mathematical model was used
assuming the tumour to grow and regress exponentially with a fixed rate
[Hasenclever et al., 1996]. Growth and regression are characterised by the relax-
ation times τ1 and τ2, respectively i.e. the time the tumour surface has increased or
decreased, respectively with a factor e (=2.72). Relaxation times were estimated by
the best fitting curve that applied to the following functions of A:
[1] increase A(t) = A0 . e
t/τ1
[2] decrease A(t) = A . e-(t-t1) /τ2
in which t1 is the time the tumour size is back at the level of A0.The resulting
tumour size is the composite of these two processes. This can be written as:
[3] A(t) = {A1(t).A2(t)} / {A1(t)+A2(t)}
Tumour regression is then assumed to commence at the time point at which the
derivative of the function [3] equals zero, i.e. at the top of the curve as shown in
Figure 3.2. In other words, the time at which tumours went into regression is the
interval between the start of the IL-2 therapy and the first sign of remission.
3.2.8 Histopathology
At autopsy, the primary tumours were excised. Parotid and retromandibular lymph
nodes were collected bilaterally. The thoracic and abdominal organs were inspected
and location, number, and size of the metastases were recorded.
Biopsy and autopsy tissues were placed in 10% buffered formalin. Paraffin sections
(5 µm) were prepared and stained with haematoxylin and eosin. All sections were
studied by a panel of 3 experienced pathologists. In later sessions consensus was
obtained during a panel discussion.
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3.3 Results
3.3.1 Clinical observations
The clinical observations are summarised in Tables 3.1 and 3.2. After transplanta-
tion, auricular tumours developed in 11/14 rabbits on both sides (i.e. twin tumours)
and 3 rabbits had only single tumours (rabbits A2, A6, and B1). Eleven to 21 days
were needed to reach the size of 2 cm2 of the quickest growing tumour (∆T, Table
3.1). Thereafter, IL-2 treatment started.
Complete regression of treated primary tumours occurred in 4 out of 12(33%) IL-2
treated animals. Of these 4 rabbits, three (A1, B2, B3) had twin tumours. In each
case the non-treated contra-lateral tumour regressed simultaneously with the peri-
lesionally injected tumour (Figs. 3.1 and 3.2). So, there were 7 regressing tumours.
The time point at which the tumours went into regression varied from 5 to 15 days
(mean 8.7 ± 4.2 days) after start of IL-2 therapy.
In rabbits with remission of their primary tumours, tumour resistance was tested by
an intra-muscular injection with Vx2 tumour cells in the hind paw. No tumours
developed within 2 weeks.
In 3 out of the 4 rabbits with complete regression of their primary tumours,
enlarged neck nodes suggestive of metastases were present at the start of IL-2 treat-
ment. In 2 of these 3 rabbits, the enlarged nodes disappeared simultaneously with
their primaries. In the third rabbit however, the lymph node contra-lateral to the
IL-2 injected primary, grew despite complete remission of both primaries (rabbit
B3, Table 3.1).
Tumours grew progressively in the auricles of the 2 controls and all 8 non-regressor
rabbits. This was accompanied by enlargement of the draining parotid lymph nodes
(Figs. 3.3 and 3.4). Progressive growth of the primary tumour coincided with
hyperaemia of the auricle and a purple discoloration of the skin adjacent to the
tumour. The disappearance of these vascular signs was an important first clinical
indication of tumour remission.
Start of the IL-2 injections in the non-responders varied from day 11-21 after
transplantation.
3.3.2 Autopsy findings
3.3.2.1 Rabbits with progressive tumour growth
Primary tumour growth progressed in the 2 controls and in 8 IL-2 treated animals,
comprising a total of 18 progressing primary tumours. Two rabbits developed pul-
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Table 3.1. Data of treated animals
∆T Tumour size (cm2) at day T† Metastases*
day 0 7 14 21 † day neck lung
Group A
1 L 11 1.4 3.0 2.9 2.7 0.2 56 - -
R# 2.5 4.3 5.6 4.9 0.0 -
2 L 18 - - - - - 38 - -
R# 2.3 3.5 3.1 3.3 6.2 +
3 L# 18 2.1 4.7 3.9 5.0 8.8 38 - -
R 2.0 2.6 2.3 2.5 4.8 -
4 L 14 1.2 2.3 4.3 6.8 13.0 30 + +
R# 2.3 4.8 7.5 9.6 13.1 +
5 L# 14 2.0 5.4 7.7 10.4 18.1 32 + -
R 1.4 3.0 4.2 5.0 8.8 +
6 L 21 - - - - - 38 - +
R# 2.2 3.0 4.6 5.9 14.6 +
Group B
1 L 17 - - - - - 42 - -
R# 2.4 3.1 2.4 1.4 0.0 -
2 L 11 2.4 2.7 1.7 0.7 0.0 76 - -
R# 3.2 5.2 4.3 1.9 0.0 -
3 L 11 2.2 2.3 1.2 0.3 0.0 76 + -
R# 2.3 3.4 1.6 0.4 0.0 -
4 L# 11 2.1 4.5 5.6 7.3 11.3 33 + ++
R 1.2 4.1 5.0 7.3 11.3 +
5 L# 11 2.2 5.2 7.2 8.1 14.3 42 + +
R 1.4 4.0 6.6 7.6 14.9 +
6 L 11 0.6 1.9 2.9 3.9 7.7 34 + -
R# 3.1 6.0 7.5 18.1 27.0 +
Group C
1 L 14 2.5 5.3 9.6 13.3 15.0 23 + ++
R# 2.9 5.6 10.0 13.1 15.2 +
2 L 11 2.1 5.5 6.5 8.4 15.2 35 + -
R# 2.3 5.7 7.4 9.9 17.0 +
L/R : Left / Right, #=IL-2 treated auricle; day 0 : start of IL-2 therapy, day † = day of sacrifice; ∆T : time between
tumour transplantation and start of IL-2 therapy; T† : time between start of IL-2 therapy and sacrifice; 
* : metastases microscopically confirmed: +/++ = some small (1-3 mm) / many large (8-15 mm) lung metastases
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Table 3.2. Summary of the therapeutic effects
Group N Remission of primaries Cures
A (100,000U)
Single tumour 2 0 / 2
Twin tumours 4 1 / 4 1 / 6 (17%)
B (300,000U)
Single tumour 1 1 / 1
Twin tumours 5 2 / 5 2 / 6 (33%)
C (solvent)
Twin tumours 2 0 / 2 0 / 2 (0%)
N = number of animals
Figure 3.2. 
Rabbit A1.
Fitted growth curves of both
auricle tumours.
Figure 3.1. 
Rabbit A1.
Simultaneous regression of
twin tumours at day 35 after
peri-tumoural IL-2 injections
of the right auricle.
Hoofdstuk 3  27-02-2001  13:29  Pagina 40
monary distress due to metastases. All parotid lymph nodes related to these 18 pri-
maries were enlarged. Retromandibular lymph nodes were enlarged in 12 of these
18 tumours. Lung metastases were present in 5/10 (50%) of these animals. These
metastases varied from some small (1-3 mm) nodules in 3 rabbits to many large (8-
15 mm) nodules in 2 rabbits (Table 3.1). No metastases were found at other sites.
3.3.2.2 Rabbits with tumour remission
The 4 animals with a total of 7 primary tumours that regressed completely were
killed at days 59, 67 and 87(2x) after transplantation, respectively. There was a
nodular, palpable scar at the primary site. Small draining parotid lymph nodes were
harvested in 5 of the 7 cases; they did not contain tumour. In one case no nodes were
found. Finally, as mentioned before, in one case there was a large tumour mass in the
parotid lymph node contra-lateral to the treated auricle tumour. No lung metastases
were seen. At the injection site of the intra-muscular challenge in the thigh of the
hind paw, the absence of tumour growth was confirmed microscopically.
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Figure 3.3. 
Rabbit C2, placebo.
Progressive growth of twin
tumours at day 35. Note
bilateral swelling of parotid
lymph nodes.
Figure 3.4. 
Rabbit C2. 
Actual growth curves of both
auricle tumours.
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3.3.3. Histopathology
3.3.3.1 Tumour biopsies
As mentioned, biopsies were taken 3 days after completion of IL-2 treatment. All
biopsies, both from controls and IL-2 treated tumours showed a variable degree of
ischaemic tumour necrosis, which is typical for the Vx2 tumour. Vital tumour cells
were already absent in 2 of the 6 biopsies (a biopsy of the non-treated tumour -A1-
was not available) from the tumours that subsequently went into regression. This is
notable, as measurable tumours were still present at day 21. So, the complete
regression of a tumour nodule requires time after all cancer cells have died.
In contrast, all biopsies from the 18 progressively growing tumours still contained
vital tumour cells. In large necrotic areas, blood vessels were seen surrounded by
strands of vital tumour cells. The border between vital and necrotic tumour tissue
was sharply demarcated. No inflammatory cells were seen at the tumour borders. A
subcutaneous inflammatory infiltrate was present in the biopsies of both responders
and non-responders. It consisted of neutrophylic (‘pseudo-eosinophylic’) granulo-
cytes, lymphocytes, macrophages, and variable numbers of plasma cells.
In the biopsies of the responders, degeneration of tumour cells was observed partic-
ularly in the border areas adjacent to the inflammatory infiltrate. The degenerated
tumour cells had a clear cytoplasm, blurred cell borders and occasionally pycnotic
nuclei. Moreover, there was an increase of granulomatous tissue splitting up the
tumour strands, leaving isolated degenerating tumour islands. The macrophages
showed phagocytic activity, sometimes with giant cell formation. In addition, the
thin-walled dilated blood vessels in the tumour were occasionally occluded by fibri-
noid coagulations. Remarkably, there were no microscopical differences between
regression of the IL-2 treated and the contra-lateral non-treated tumours.
3.3.3.2 Primary tumours at autopsy
All progressively growing primary tumours showed massive invasion of the sub-
cutis. In some cases the adjacent auricular tissues, i.e. cartilage and muscles were
also invaded. Extensive necrosis was always observed. Type and morphologic fea-
tures of this necrosis were similar as described for the biopsies.
There were 4 rabbits with complete remission of the primary tumour. Rabbits A1
and B1 were sacrificed at day 67 and 59, respectively. The primary sites contained
necrotic areas with ghosts of tumour cells. These areas were surrounded by an infil-
trate consisting mainly of plasma cells, foamy macrophages, giant cells, and few
lymphocytes (Fig. 3.5). Rabbits B2 and B3 were sacrificed at day 87. No tumour
tissue was present. Instead, dense fibrous scar tissue was noted containing throm-
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bosed vessels, some lymphocytes and focal clusters of foamy macrophages packed
with hemosiderin pigment.
3.3.3.3 Lymph nodes at autopsy
All lymph nodes showed a variable degree of lymphoid hyperplasia characterised by
hyperplastic paracortical zones and enlarged follicles with marked germ centres. In
the 10 animals with a total of 18 progressively growing primary tumours, metas-
tases were microscopically confirmed in 16/18 (89%) of the parotid lymph nodes
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Figure 3.6. 
Rabbit A1, 56 days after IL-2
therapy. 
A: Microscopy of section through
parotid lymph node showing a
regressed metastasis (R). P =
parotid salivary gland, original
magnification 10x. 
B:  Detail of regressed metastasis.
Foamy macrophages (M), plasma
cells (white arrows), lymphocytes
and syncitial giant cells (G),
Original magnification 100x, 
HE-staining.
Figure 3.5. 
Rabbit B1, 42 days after IL-2
therapy. 
A: Microscopy of transverse
section through the auricle at the
site of the regressed tumour. 
C = cartilage, original
magnification 10x. 
B: Detail of rectangular area.
Macrophages (M), plasma cells
(white arrows), lymphocytes and 
a syncitial giant cell (G), original
magnification 100x, HE-staining.
A B
A B
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and in 2/18 (11%) of the retromandibular lymph nodes.
The parotid lymph node of the rabbit B1 with complete regression of the primary
tumour showed no evidence of vital or necrotic tumour cells. Bilaterally, the parotid
lymph nodes of rabbit A1 with regression of both primary tumours were large and
showed a hyperplastic appearance indicating a marked immune response. In some
areas there were large fields with foamy macrophages indicating phagocytosis of
necrotic debris (Fig. 3.6). This image was comparable to the histologic findings of
the regressed primaries, suggesting the remission of a lymph node metastasis.
Bilaterally, the parotid lymph nodes of rabbits B2 and B3, killed at day 87, showed
a moderate lymphoid hyperplasia without evidence of tumour cells in all nodes but
one. As mentioned, this was the lymph node contra-lateral to the IL-2 injected pri-
mary in rabbit B3 (Table 3.1), that showed progressive growth despite complete
remission of both primaries.
3.4 Discussion
This study was primarily intended to assess whether any complete remissions could
be obtained with IL-2 therapy in this model for head and neck cancer. The results
were positive as complete tumour regressions could be obtained in 33% and cures
in 25% of the rabbits after peritumoral administration of 100,000 or 300,000 U
(Chiron) IL-2 during 5 consecutive days.
Carroll et al. [1995], injecting Vx2 carcinoma in the rabbit hind paw, failed to
achieve complete remissions with a regimen of biweekly injections of 10,000 U
(Hoffman-La Roche) IL-2. Possible explanations are:
1. Both the dose and the time intervals between IL-2 injections were not optimal
[Den Otter et al., 1996].
2. Killing rabbits 1 week after completion of the IL-2 injections is too early to assess
the effects of IL-2 therapy. In this study, the time point at which the first sign of
remission was observed was highly variable, ranging from 0 to 10 days after com-
pletion of the therapy. Complete tumour regression took at least 6 weeks.
3. Initiating IL-2 treatment already at the day of tumour transplantation is inef-
fective. Maas et al. (1991) and Everse et al. [1996], using the SL2 lymphosar-
coma model in DBA/2 mice, demonstrated that no therapeutic effect was
observed if the interval between transplantation and the start of the IL-2 thera-
py is less than 7 days. In this study all IL-2 treatments started at least 11 days
after transplantation, i.e. at the moment the tumours reached 2 cm2 in size.
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The approach of linking IL-2 treatment to the tumour size instead of the time after
transplantation, was chosen not only because of the different growth rate of tumours
in different rabbits in the Vx2 model (chapter 5), but also because the tumour size is
strongly correlated to the effect of the treatment in humans with HNSCC.
In a study with a LDLX40 adenocarcinoma in BALB/c mice, Liu et al. [1994]
possibly did not obtain complete remissions because the mice were already killed 2
days after the last IL-2 injection, so the follow-up was too short. In a later study
Liu et al. [1996] acquired 17% complete remissions 4 weeks after completion of
IL-2 treatment in a breast cancer model using a LDLX43 adenocarcinoma in
Wistar rats. Also Henriksson et al. [1992], using a prostatic adenocarcinoma in
rats, did not achieve complete remissions with a continuous subcutaneous IL-2
infusion of 1.1x106 Chiron U daily for 28 days. However, this cell line is a ‘slow
grower’, as it requires even 3 months after transplantation to reach a treatable size.
Such a tumour might also require a long regression period, whereas these authors
stopped their observations already at the end of the IL-2 treatment. In the slowly
growing, spontaneously occurring bovine ocular SCC, complete remission of IL-2
treated tumours also requires several months [Den Otter et al., 1993].
The effects of our study are comparable with the findings of Dubinett et al. [1993],
using a line 1 alveolar cell carcinoma in BALB/c mice. They obtained a 24% cure rate
injecting tumours twice daily with 50,000 Chiron Units per injection, which became
apparent at about 10 days after the IL-2 treatment. Dubinett’s experiment only differs
from ours with respect to the continuation of the IL-2 treatment for 3 weeks, an exten-
sion of treatment that probably is unnecessary [Den Otter et al., 1996].
The differences in comparing and converting ‘Hoffman-La Roche Units’ and
‘Chiron Units’ to ‘International Units’(IU) might be another explanation for the
variability of the therapeutic effects in different IL-2 studies. According to Liu et
al. [1996] 1 Chiron Unit has a comparable effectiveness of 6 IU, whereas Den
Otter et al. [1996] suggest 1 Chiron Unit to be only as effective as about 0.1 IU.
This study confirms the development of systemic therapeutic effects following local
treatment with IL-2 [Maas et al., 1991], since both the IL-2-treated and the non-
treated auricle tumours regressed. In addition, after a tumour challenge of cured
animals the tumour did not take. The mechanism of the IL-2 induced tumour
regression is as yet not fully understood. We assume that after tumour transplanta-
tion an early immune response develops, which is further boosted by IL-2 treat-
ment. Indeed, a peri-tumoural infiltrate, consisting of macrophages, lymphocytes,
and granulocytes was present in all biopsies. This results in a two-fold reaction:
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1. Tumour cell degeneration, in particular at the tumour borders where the
inflammatory infiltrate is present. This infiltrate gets a granulomatous charac-
ter, which leads to splitting up of the tumour, resulting in necrosis and phagocy-
tosis of tumour tissue.
2. The intra-tumoural vascular network may be vulnerable for IL-2 enhanced
immune mechanisms. The clinically observed diminution of hyperaemia and
purple discolouration around the tumour at the onset of tumour remission may
be an indication of this IL-2-mediated vascular response. Furthermore, the
rapidity of the tumour regression can only be explained if a vascular component
is operating, affecting the intra-tumoural blood flow. Also De Mik et al.
[1991] observed involvement of a vascular response in IL-2 induced tumour
regression. They noted vascular dilatations, intra-luminal occlusions and fea-
tures of stagnating circulation. This was also seen in some sections in the pres-
ent study. However, we are not sure whether the latter is a primary cause of
tumour necrosis or an epi-phenomenon.
Remarkably, in one rabbit a contra-lateral parotid lymph node metastasis persisted
despite complete and permanent remission of both primary auricle tumours.
Though unlikely, it is possible that this node contained a dedifferentiated Vx2
clone, resulting in a different immunogenic cell type. We are not aware of data dis-
cussing the development of such dedifferentiated Vx2 clones. Alternatively, the
anti-tumour effectivity of the immune response at the primary site and in lymph
node metastases might be different. Effects observed in this study mimic the histo-
logical changes found by Shah and Dickson [1978] after treating Vx2 hind limb
tumours with local hyperthermia. These investigators postulated that the rabbits
that died from metastases despite regression of the primary tumour had an ‘inade-
quate’ stimulation of their immune response. This finding supports the philosophy
of treating both the primary lesion as well as the neck nodes with peri- or intra-
tumoural IL-2 in humans [Vlock et al.,1994].
This pilot study shows that this Vx2 carcinoma model is suitable to investigate IL-2
treatment of HNSCC. The IL-2 treated primary tumour, the untreated primary
tumour at a distant site, as well as draining lymph node metastases may regress.
The mechanism of IL-2 mediated tumour regression is characterised by a granulo-
matous reaction causing slow tumour regression and it is likely that also inhibition
of the blood flow is involved.
Because this model was developed to perform selective intra-arterial tumour
embolisation with dextran hydrogel microspheres, also another treatment strategy,
i.e. the controlled release of IL-2 from these microspheres perfusing the tumour,
can be investigated.
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Intra-arterial embolisation therapy
4.1 Intra-arterial or regional therapy
4.1.1 Introduction
Anti-cancer therapy is potentially toxic to both neoplastic and normal tissues. So the
therapeutic efficacy of anti-tumour treatment depends on the relative selectivity of a
treatment modality for the tumour in preference to the normal tissues. For surgery
this therapeutic selectivity, which is based on anatomic discrimination, becomes
ineffective when an adequate tumour resection requires removal of normal tissues
whose function is indispensable or irreplaceable. For chemotherapy and radiothera-
py the therapeutic selectivity is based on physiologic and biochemical features that
are more prevalent in rapidly dividing cancer cells than in normal cells. The goal of
intra-arterial (i.a.) administration of chemotoxic drugs or radionuclides is to add
anatomic selectivity to the inherent physiologic selectivity of anti-neoplastic agents
[Collins, 1984; August, 1996]. Microspheres applied as intra-arterially infused
embolisation particles can play a significant role in targeting these anti-neoplastic
agents [Okamoto et al., 1985].
4.1.2 History and applications of intra-arterial chemotherapy
Following the discovery of various anti-microbiological agents at the beginning of
the 20th century, reports on their i.a. administration appear in German literature. In
1914, Heddäus [1914] is one of the firsts to use the carotid artery for i.a. injections
of antitoxin against tetanus. Glasser et al. [1945] give an overview on the history
of i.a. therapy and present the first application of i.a. penicillin against infections
of the extremities. In 1948 Kappert reviews various indications for i.a. treatment
and preparations used for this purpose. Klopp et al. [1950] are the first to report
on the i.a. injection of the anti-neoplastic agent nitrogen mustard Methyl Bis
(B-Chlororethyl) Amine Hydrochloride (HN2) and confirm a complete regression
following i.a. HN2 infusions into the external carotid artery in one of 7 patients
with HNSCC.
Initially i.a. mono-chemotherapy is given with palliative intent [Sullivan and Daly,
1961]. In the 1970s and 1980s various treatment schedules based on the combina-
tion of multi-drug chemotherapy regimens and radiotherapy have been developed
and used either as a sequential or as a concomitant (i.e. concurrent or simultaneous)
treatment with curative intent. In his thesis, Noorman van der Dussen [1986]
gives a thorough overview of these different modalities and their results. The com-
bination of neck dissection and postoperative concomitant i.a. chemo-radiotherapy
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induced a high percentage of complete remissions of non-resectable carcinomas,
resulting in a survival rate of 20-30%.
However, the morbidity and mortality of the therapy were high and related to the
combination of several factors:
1. I.a. catheter-technique related complications with downstream thrombosis,
extravasation of cytostatic agents and dislocation of the tip.
2. Systemic toxicity with myelo-suppression.
3. Massive local tumour-necrosis with pus formation in combination with swal-
lowing disorders and aspiration.
Advances in vascular interventional radiological techniques and availability of
implantable injection ports made it possible to overcome the catheter related prob-
lems. Intra-arterial chemotherapy alone is still employed as palliative treatment of
HNSCC [Eckardt and Kelber, 1994]. If curative treatment is planned, i.a.
chemotherapy must be part of a multi-modality treatment. It can be combined with
concurrent radiotherapy [Robbins et al., 1994] or used as an induction therapy
with subsequent surgery [Kovács et al., 1999; Szabo et al., 1999]. In the beginning
of the 1990s, the group of Robbins successfully initiated an organ preservation pro-
tocol to reduce dysfunction related to major oncological surgery [Robbins et al.,
1994 and 1996]. The treatment consisted of repetitive superselective i.a. infusions
of supradose cisplatin with simultaneous i.v. thiosulfate rescue and concomitant
radiotherapy. With this protocol a 60-70% 2-year overall survival with an accept-
able morbidity was obtained for advanced disease, which meant a renaissance of the
i.a. chemotherapy for HNSCC. However, repeated i.a catheter interventions carry
the risk of dislodging arteriosclerotic plaques [Kovács et al., 1999] and a substan-
tial amount of the supradose cisplatin still reaches the systemic circulation, urging
the use of a thiosulfate rescue [Robbins et al., 1994].
4.1.3 Pharmacokinetics
Regional drug delivery is an approach designed to improve an agent’s pharmacoki-
netic profile by increasing tumour exposure and decreasing normal tissue exposure
to the drug. Prerequisite for its success is that the relevant agent: 1) must be effec-
tive in the in-vivo tumour-microenvironment and 2) must reach the target cells in
optimal quantities [Jain, 1995].
The overall selectivity for regional drug administration, i.e. the benefit of regional
over systemic administration, is defined by the Ratio (Rd) of the target site concen-
trations to the systemic concentrations:
Rd= R target / R systemic
50
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and, based on a simple compartment model [Collins, 1984; August, 1996], can be
written as:
Rd = (1+ClTB/Q)/(1-E)
In which ClTB= the total body clearance
E = the fraction extracted by the first pass and
Q = the regional perfusion.
These latter three parameters i.e. the total body clearance, the fraction extracted by
the first pass and the regional perfusion are the only three factors that affect the
overall selectivity of the agent. Reducing the regional perfusion (Q), thus enhanc-
ing the benefit of intra-arterial over i.v. infusion in the target area (Rd), is the basic
rationale to combine the chemotherapeutic agents with an emboliser [Lin et al.,
1997]. This technique, called chemo-embolisation can be executed by two different
approaches:
1. Mixing cytotoxic agents with iodised oil (Lipiodol) or with microspheres such
as starch, gelfoam or polyvinyl foam.
2. The use of drug-carrier complexes or microcapsules slowly releasing its agents.
Release of the drug can be obtained by spontaneous or induced biodegradation
of the carrier or by diffusion of the drug from the microparticles.
Chemo-embolisation not only improves the overall selectivity, it will also reduce mul-
tiple vascular manipulations to a single procedure, with less morbidity for the main
carotid branches both in terms of physical damage as well as chemotoxic irritation.
4.2 Embolisation particles for tumour treatment
4.2.1 Types of embolisation particles
A particle has been defined as anything that is small in relation to the space around
it [Edmundson, 1967]. Thus electrons in an atom as well as stars in space are con-
sidered particles. Particles used for intra-arterial embolisation therapy may vary in
size, shape and composition.
Polygonal fragments are the result of crushing [Muller and Rossier, 1951] or cut-
ting [Harima et al., 1995] bulk material. Spherical fragments or microspheres are
obtained e.g. by a solvent evaporation technique [Nijssen et al., 1999].
Particles can be classified as degradable or non-degradable. Degradable particles
are usually polymer-based. Starch microspheres (Spherex®) consist of glucose
polymers, being degraded by serum α-amylases with a t1/2 of 15-30 min [Civalleri
et al., 1989; Johansson, 1996]. Poly(L-lactic acid) microspheres degrade by
51
Intra-arterial embolisation therapy
Hoofdstuk 4  27-02-2001  13:30  Pagina 51
52
Table 4.1. Embolisation particles. Types, sizes and target organs. 
Study Type Target 1) Size (µm) 2) 
Embolisation-only particles
Pillai 1991 Polystyrene A Vx2 hind paw 27
Päuser 1996 Starch A Vx2 liver 30-50
Anderson 1991 Albumin A Rat liver sarcoma (40 (18-54)
Lorelius 1984 Starch A Vx2 liver 40 ± 20
Bastian 1998 PLA3) A Rat liver hepatoma ≥ 40 
Meade 1987 ‘tracer’spheres A Rat liver adenocarcinoma ≥ 50
Päuser 1996 Gelfoam A Vx2 liver 90
Lorelius 1984 Gelfoam A Vx2 liver 80-200
Yang 1995a Ethylcellulose A Dog maxilla 50-301
Harima 1995 Gelfoam A Vx2 uterus ± 1,000
Civalleri 1989 Starch H Liver tumours 40 ± 5
Johanson 1996 Starch H Liver tumours 45
Layalle 1998 Gelfoam H Bone metastases 150-250
Layalle 1998 PVA4) foam H Bone metastases ± 600
Latchaw 1977 PVA4) foam H Vasc. Malform. HN5) 300-2,500
Radio-embolisation particles
Turner 1994 166Ho-resin A Pig liver 13 ± 2
Blanchard 1965 46Sn-resin/ceramic A Vx2 liver 15 ± 3
Stribley 1981 57Co-resin A Vx2 liver 15.3 ± 0.8
Ehrhardt 1987 90Y-resin A Dog liver 15-30
Mumper 1991 166Ho-PLA3) A Vx2 liver 10-75
Zimmerman 1995 90Y-resin A Pig kidney 45-75
Kim 1962 90Y-ceramic A Vx2 lung 60 ± 5
Andrews 1994 90Y-glass H Liver tumours 22
Müller 1951 198Au-carbon H Lung SCC 30-50
Yan 1993 90Y-glass H Liver tumours 35 (30-50)
Lang 1971 198Au-carbon H Lung SCC 812
Chemo-embolisation particles
Burton 1992 Doxorubicine-resin A Rabbit liver 17.5 ± 2.5
Yang 1995b Cisplatin-ethylcellulose A Dog maxilla 216-441
Bartkowski 1997 5 FU-PLA3) A Rat liver hepatoma ≥ 40
Spenlehauer 1988 Cisplatin PLA3) - In vitro 100-200
Kato 1979+’80+’96 Mitomycin-ethylcellulose H Various tumours + HNSCC 225 ± 55 (106-441)
Okamoto 1985 Cisplatin-ethylcellulose H HNSCC 396 ± 119
Tomura 1996+’98 Carboplatin-ethylcellulose H HNSCC 140-180
1)A = Animal, H = Human; 2) ≥ = minimal size advised; 3) PLA= poly(L-lactic acid); 4) PVA = Poly vinyl alcohol; 
5) HN = head and neck.
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hydrolysis which may take weeks to months, dependent on crystallinity, porosity
and surface size [Bergsma et al., 1993; Anderson and Shive, 1997]. Ethylcellulose,
oxidised cellulose (Oxycel®) and gelatine sponge (Gelfoam®) particles are also
metabolised in due time [Latchaw and Gold, 1979; Kato et al., 1980].
Resin-based particles [Stribley et al., 1981; Zimmerman et al., 1995], polyvinyl
alcohol foam particles and glass or carbon microspheres are presumed biocompati-
ble or bio-inert and do not degrade in-vivo [Latchaw and Gold, 1979;
Nakhgevany et al., 1988].
Non-degradable particles are preferably applied to carry radionuclides in order to
prevent leaching of radioactivity outside the tumour region. Carriers of chemother-
apeutic drugs are often biodegradable to release the encapsulated agents.
4.2.2 Size of embolisation particles
The size of microspheres used in various embolisation studies varies considerably
and ranges from 10 to 2,500 µm. An overview is given in Table 4.1. The average
particle size used for embolisation of visceral organs varies from 15 to about 75 µm,
whereas the particle size used for embolisation in the head and neck area ranges
from 100 to about 500 µm.
Theoretically, particles have to be small enough to create a diffuse distribution
throughout the whole tumour and have to be large enough to prevent them from
spilling to the systemic circulation. This includes either the venous circulation with
spill to the lungs or the collateral arterial system with possible stray emboli to other
organs. Three vessel-related variables can influence the spill of microspheres to the
lungs and stray emboli to other organs:
1. The structure of the tumour vessels itself.
2. The presence of arterio-venous (AV) shunts.
3. The presence of arterio-arteriolar (AA) connections.
Tumour vessels are different from normal vessels [Bloemendal et al., 1998]. They
often contain abnormal, irregular capillary-like distended vessels of a large size
[Stewart et al., 1959; Blanchard et al., 1965].
Spill of microspheres to the lungs via AV shunts and to other organs via AA con-
nections may occur at any site. However, the consequences of spill via AA connec-
tions depend on the organ that is embolised. In the head and neck area the
consequences of stray emboli are more serious than elsewhere: Emboli may lead to
permanent ophthalmic or neurologic deficits [Latchaw et al., 1979; Braun et al.,
1985; Mames et al., 1991; Morrissey, 1997]. Side effects may also be better recog-
nised in humans than in animals. Fear for these stray emboli could explain the
employment of relatively large sized particles (over 100 µm) in human HNSCC
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embolisation [Okamoto et al., 1985; Kato et al., 1996]. However, it is of doubt if
these large particles can cause a diffuse tumour-embolisation or merely get stuck in
the feeding arterioles before even reaching the tumour. Moreover it is questionable
if particles of a larger size will avoid stray emboli to the brain as e.g. the middle
meningeal artery has an average diameter of at least 500 µm in humans. Prevention
of stray emboli can be achieved by occlusion of non-tumour branches: Ligation of
non-tumour branches is performed in animal embolisation studies [Päuser et al.,
1996; Harima et al., 1996]. In humans, coil embolisation is a method of eliminat-
ing unwanted perfusion during i.a. chemotherapy [McCarter et al., 1995; Kato et
al., 1996]. In the head and neck region, AA shunts connecting the internal and
external carotid system can be visualised during arteriography and occluded if pres-
ent [Tomura et al., 1996].
In practice, the technical process of fabrication primarily dictates the particle size. A
solvent evaporation technique e.g. yields particles ranging in size from10-200 µm.
Selected sizes can be obtained by sieving these microspheres through differently
sized sieves, although a substantial yield of the total production is lost in this way
[Spenlehauer et al., 1988; Nijssen et al., 1999].
4.2.3 analysis of particle size
Because individual particles of a sample are rarely uniform in size it is useful to
define an average particle size to be able to compare different samples. In practice
the arrhythmic mean, defined as the sum of the variables X divided by the total fre-
quency F of the variables of a sample is most useful [Edmundson, 1967]: 
Arrythmic mean = ΣX/F
One can define different means, dependent on the properties of the particle that is
taken into account, such as its diameter, its surface or its volume. Two of these play an
important role in the description of microspheres used for i.a. embolisation of tumours.
1. The length-number or ordinary arrhythmic mean diameter: It is the size of most
frequent occurrence and a satisfactory definition of average particle size if the size
range is narrow and normally distributed.
2. The volume-weighted or weight moment mean diameter: This is the largest of the
averages and gives a mean diameter that corresponds with the mean volume or
weight of the particles.
If the size range is broad and not normally distributed, both mean diameters should be
given when describing the dimension of the particles used [Edmundson, 1967]. A
standard deviation or standard error of this mean may be added. However, in most
studies the definition of the mean particle size is not given. This makes comparison of
results difficult.
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4.3 Current applications of i.a. embolisation therapy
4.3.1 Embolisation without active anti-tumour pharmaceuticals
With respect to oncologic treatment, arterial embolisation can be performed to
facilitate subsequent surgical excision of highly vascular tumours to reduce opera-
tive blood loss. Or as palliative measure for tumours that cause troublesome bleed-
ing or pain despite radiotherapy. Tumours of the kidney and bone metastasis are
regularly embolised for these reasons. This therapy is intended as a temporary
occlusion of the feeding arteriolar vessels, rather than a diffuse embolisation of the
tumour as a whole. This is illustrated by the fact that the effect of these embolisa-
tions is short-lasting as collateral vascular supply takes over rather quickly
[Almgard, 1977; Miller, 1995; Layable, 1998].
4.3.2 Chemo-embolisation
To date, patients with unresectable liver and pancreatic cancer seem better off
with regional therapy and the application of chemo-embolisation has been well
documented to include controlled studies. Especially the combined use of cytotoxic
drugs with degradable starch microspheres gives better responses than chemotherapy
alone, although the survival rate has not shown significant improvement
[Johansson, 1996; August, 1996; Lin et al., 1997; Aigner, 1998]. Apart from the
pharmacokinetic benefit of co-injecting drugs with microspheres certain drugs
such as mitomycin and adriamycin are claimed to be even more effective under
hypoxic conditions which prevail during embolisation treatment [Johansson, 1996;
Aigner, 1998].
Selective chemo-embolisation of irresectable chest wall recurrences from breast
cancer or fungating primary breast cancers showed 83% complete remissions
[Aigner, 1998]. Coil embolisation of the distal internal mammary artery is effective
in eliminating unwanted perfusion of cytoxic agents to normal tissues [McCarter et
al., 1995].
4.3.3 Radio-embolisation
Intra-arterial radionuclide therapy is an internal radiation therapy, using micro-
spheres as carrier for selective delivery of radio-pharmaceuticals into tumours,
commonly addressed as ‘radio-embolisation’. Most frequently used radio-isotopes
are the beta-emitters yttrium-90 (90Y), rhenium-188 (188Re) and holmium-166
(166Ho).
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4.3.3.1 History
One of the first reports on anti-tumour treatment with internal radiotherapeutic
agents was by Müller [1946] on intra-tumoural injection of a suspension of radiozinc
(63Zn) in patients with uterus carcinoma. Müller and Rossier [1951] described the
first selective radio-embolisation of lung carcinoma with radiogold (198Au)
absorbed on carbon particles. Kim et al. [1962] reported on the application of
ceramic microspheres containing 90Y for various inoperable tumours.
4.3.3.2 Recent applications
Major advances in radio-pharmaceutical techniques over the past decade have
resulted in improved methods of delivery and therapeutic ratios [Novell et al.,
1991]. Nowadays, radio-embolisation of unresectable primary hepatocellular carci-
noma is considered an equally effective treatment modality as chemo-embolisation
but tolerance seems better with fewer side effects [Raoul et al., 1997; Novell and
Hilson, 1994].
Radio-embolisation of the liver can be achieved either with iodine-131 lipiodol and
gelatine sponge-particles [Raoul et al., 1997] or with 90Y and 166Ho incorporated
in resin, glass or poly-lactic acid microspheres. In theory, 90Y is a more suitable iso-
tope based on its greater beta-energy and range. Leaching of free 90Y with accumu-
lation in bone, resulting in myelosuppression, hampered the application of
90Y-containing microspheres. This problem is recently solved [Yan et al., 1993],
but the risk of shunting of the spheres into the systemic circulation leading to pul-
monary fibrosis still prevents wide clinical use of these particles.
To overcome the problems of high density and non-biodegradability of these 90Y-
microspheres, 166Ho containing poly(L-lactic-acid) (166HoPLA) microspheres
were developed [Mumper et al., 1991] and are nowadays tested in various animal
studies [Bastian et al., 1998; Nijsen et al., 1999]. These spheres are designed to
maintain their integrity until decay of 166Ho is complete. Because they are of low
density, these 166HoPLA spheres are more easily suspended in aqueous media as
compared to ceramic microspheres, allowing a more uniform distribution within
the tumour [Nijsen et al., 1999].
Though sophisticated molecular carriers such as monoclonal antibodies and
radioactive growth factor inhibitors, are being developed to get nuclear agents to
their effector sites, these approaches are still limited in effectiveness because of the
inability to deposit significant quantities of radioactivity in solid cancers.
Administering radionuclides in microspheres by a radiological catheter may be fast,
effective and safe [Novell and Hilson, 1994; Zimmerman et al.,1995].
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4.3.4 Embolisation of head and neck tumours
In head and neck oncology, superselective endovascular embolisation without active
anti-tumour pharmaceuticals is used in the management of haemorrhage in patients
with malignant disease [Morrissey et al., 1997] or in the treatment of vascular mal-
formations [Braun et al., 1985; Enjolras and Mulliken, 1996].
In Japan, chemo-embolisation with carboplatin-, mitomycin- or peplomycin-
containing microspheres called ‘microcapsules’, plays a significant role in regional
chemotherapy. Though being a controversial treatment modality, it is considered a
technique of choice for palliation of advanced tumours with acceptable morbidity
[Tomura et al., 1998; Kato et al., 1996]. Until now, to our knowledge no studies on
radio-embolisation of head and neck tumours were performed.
4.4 Possible strategies for embolisation-therapy 
of head and neck cancer
Embolisation particles for HNSCC can be applied in three possible ways:
1. Application of inactive degradable microspheres in combination with currently
used protocols that combine i.a. chemotherapy with external beam irradiation
such as the RadPlat protocol of Robbins et al. [1997]. Degradable starch or
poly(L-lactic acid) microspheres are potential candidates. A maximum regional
advantage should be achieved by a suboptimal dose of these spheres, producing
a partial vascular blockade [Johansson, 1996].
2. Application of microspheres as carriers that slowly release either classical
chemo-therapeutic drugs such as the platinum-based complexes, or drugs that
act as local biologic response modifier or inhibit angiogenesis. Dextran hydro-
gel microspheres with controlled degradation [Hennink et al., 1996; Franssen
et al., 1999] can play a role here.
3. Application of microspheres for internal radionuclide therapy, especially those
containing beta-emitting isotopes. The holmium-166 poly(L-lactic acid) micro-
spheres [Mumper et al., 1991; Nijsen et al., 1999] seem an attractive option.
As far as the size of the microspheres is concerned, additional studies will have to
clarify if the particle-size should match the size currently used for embolisation of
hepatic tumours and therefore would be in the range of 15-75 µm, or that the size
should be much larger in the range of 100-500 µm to match the particle size cur-
rently used for chemo-embolisation of HNSCC.
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It is appropriate to test the retention of microspheres smaller than 100 µm in the
Vx2 rabbit auricle model first because the diameter of the tumour vessels of the Vx2
carcinoma is smaller than 100 µm [Stewart et al., 1959; Blanchard et al., 1965] and
most other Vx2-embolisation studies employ particles sized between 13 and 90 µm
(see Table 4.1). Besides, the preparation of dextran hydrogel and 166HoPLA
microspheres via the solvent evaporation technique yields an average particle size in
the range of 10-100 µm [Franssen et al., 1997; Nijssen et al., 1999].
Other prerequisites, to achieve an optimal intra-arterial embolisation of tumours
with radioactive microspheres [Latchaw and Gold, 1979; Novell et al., 1991] are:
1. The vascular anatomy of the tumour is amenable for deposition of particles.
2. Availability of a technology to superselectively apply the particles.
3. Availability of particles with a high and stable load of tracer for imaging.
4. An appropriate sizing of particles to obtain maximal trapping in tumours with
minimal shunting.
5. Optimal characteristics of the isotope with respect to chemical inertness, range
and half-life of ionising radiation.
These aspects are addressed in the following studies by:
1. Analysing whether the Vx2 tumour vasculature is suitable for deposition of
labelled particles. Tumour angiogenisis of Vx2 tumours implanted into the auri-
cle must be observed beforehand (Chapter 5).
2. Developing a technique for super-selective infusion of microsphere-suspensions
via the caudal auricular artery and evaluating the retention of microspheres in
the cannulation system (Chapters 5 and 7).
3. The labelling of dextran hydrogel microspheres with a radioactive technetium-
99m tracer and the application of holmium-166 that emits 6.2% of its energy as
gamma-photons (Chapter 6).
4. The analysis of the entrapment of microspheres of a different size in the Vx2
rabbit auricle model (Chapters 6 and 7).
5. The assessment of the application of degradable holmium-166 poly(L-lactic-
acid) microspheres for embolisation of HNSCC, while also studying the leach-
ing of free holmium-166 in urine and faeces (Chapter 7).
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The Vx2 carcinoma in the rabbit auricle 
as an experimental model 
for intra-arterial embolisation 
of head and neck squamous cell carcinoma
R.J.J. van Es, O. Franssen, H.F.J. Dullens, M.R. Bernsen, F. Bosman, 
W.E. Hennink, P.J. Slootweg
Laboratory Animals 1999;33:175-184.
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Abstract
Introduction: There is a need for the development of a new head and neck can-
cer model to study the effects of novel intra-arterial therapies.
Materials and methods: The Vx2 carcinoma cell line is transplanted into both
auricles of New Zealand White rabbits. The speed of tumour growth is assessed.
The study is focussed on the vascular anatomy of the rabbit auricle and the effects of
intra-arterial embolisation of the carcinomas with dextran hydrogel microspheres.
Results: During the phase of exponential growth the tumour-surface doubling-
time was 7.1 ± 2.0 days. Standard deviation in growth of the tumours was signifi-
cantly larger between separate animals than between tumours growing in the left
and right auricle of each individual animal (2.0 versus 0.65 days). A fresh cell sus-
pension containing at least 10.106 vital tumour cells was necessary to yield a
tumour-take of 85%. The caudal auricular artery perfuses the caudal half of the
external ear and is very suitable for macroscopic cannulation. Histological evalua-
tion shows, that the use of dextran hydrogel microspheres of at least 25 micrometers
in combination with ligation of non-tumour perfusing branches of the central auric-
ular artery yields diffuse embolisation of the Vx2 carcinoma.
Conclusion: This rabbit Vx2 auricle carcinoma model can be of use in further
studies to optimise particle size and dosage for embolisation as well as to evaluate
the effect of different anti-neoplastic drugs, slowly released by controlled degrada-
tion of dextran microspheres.
We thank W. den Otter for placing laboratory support at our disposal, A. Versluis and H. Boere for
taking care of the rabbits, P. Rothengatter for the photography and P. Egyedi for his innovative ideas
and valuable remarks in preparing this manuscript.
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Embolisation of the Vx2 model
5.1 Introduction 
The role of regional or intra-arterial (i.a.) chemo- and immuno-therapy in the treat-
ment of head and neck squamous cell carcinoma (HNSCC) in humans remains
controversial [Harker and Stephens, 1992]. The i.a. embolisation of malignant
tumours with biodegradable microspheres containing anti-tumour drugs is consid-
ered to be one of the most effective ways of selective anti-tumour therapy
[Okamoto et al., 1985]. It precludes the need for indwelling arterial catheters and
prevents its associated morbidity with continuous long-term infusion systems
[Conn and Langer, 1978; Schouwenburg et al., 1980]. However, controlled degra-
dation of microspheres used for tumour embolisation was not possible until now.
Dextran hydrogels are especially developed for the controlled release of pharmaceu-
tically active compounds, either by diffusion [Hennink et al., 1996] or by degrada-
tion [Franssen et al., 1997].
As stated in chapter 1.3, basically three types of animal tumour models exist for
HNSCC: Spontaneously occurring tumours, tumours induced by the topical appli-
cation of carcinogens and tumours induced via transplantable cell lines. The trans-
plantation of the Vx2 cell line [Kidd and Rous, 1940] has frequently been used to
study novel i.a. chemotherapy strategies in various organs of the rabbit [Davidson
et al., 1986; Harima et al., 1996; Päuser et al., 1996]. Vx2 tumour growth and
angiogenesis can be studied in detail in the rabbit auricle [Tromberg et al., 1990].
The aim of the following study is twofold:
1. To develop an experimental HNSCC model in the rabbit, that is easy to handle
and does not depend on microsurgery, in which the effects of i.a. therapy can be
studied.
2. To assess the possible use of dextran hydrogel microspheres for i.a. tumour
embolisation in this model.
We present an investigation on the arterial supply of the auricle of New Zealand
White (NZW) rabbits and describe a technique of its i.a. cannulation. The trans-
plantation and growth of the Vx2 carcinoma in the auricle as well as its embolisation
with dextran hydrogel microspheres is evaluated.
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5.2 Materials and methods
5.2.1 Animals
Adult female NZW rabbits were used as described in chapter 2.2.1.
5.2.2 Vascular anatomy of the rabbit auricle
To get insight in the vascular supply of the auricle, two rabbits were sacrificed.
Details of interest for our study were subsequently corroborated in the ensuing
experiments reported in this article. The caudal auricular artery emerges from the
superficial temporal artery [Barone et al., 1973]. At the dorsocaudal base of the
auricle, the caudal auricular artery lies deep to the external ear muscles. At the point
where the artery emerges from under the superior margin of the cutaneous auricu-
lar muscles, the caudal auricular vein lies superficial and frequently medial to the
artery. Sometimes 2 or even 3 veins are encountered. The great auricular nerve is
also situated superficially to the artery and external ear muscles. The main stem of
the artery traverses to the apex of the auricle, in the axis, as central or intermediate
auricular artery. The anterior or rostral margin of the auricle is supplied via a sepa-
rate rostral marginal artery. In the apex region anastomoses between both marginal
and central vessels exist.
Infusion of a methylene blue dye solution shows that the caudal two-thirds of the
auricle are vascularised by the caudal auricular artery. Selective ligation of macro-
scopically visible arterial branches to the rostral half of the auricle, results in selective
perfusion of a region between the central artery and the caudal margin (Fig. 5.1).
This region was chosen for tumour implantation to study the effects of i.a. emboli-
sation.
5.2.3 Tumour cells
The Vx2 tumour cells were propagated by intramuscular passage as described in
chapter 2.2.2. Cell suspensions were used either fresh, i.e. within 2 hours, or cryo-
preserved for later use. The number of cells in suspension was counted using a
haemocytometer. Viability of cells was estimated by Trypan blue exclusion.
Cryopreservation was performed by freezing cells down in ice-cold RPMI 1640
[Gibco, Grand Island NY, USA], containing 20% FCS and 10% DMSO at a
concentration of 1-3.108cells/ml. The cell suspension was kept in a freezing con-
tainer (Cryo 1°C, Nalgene®, USA) at -70°C for at least 4 hours before storage in
liquid nitrogen [Morgan and Darling, 1993].
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5.2.4 Embolisation particles
Dextran hydrogel microspheres were prepared at the Utrecht Institute for
Pharmaceutical Sciences (Department of Pharmaceutics, Faculty of Pharmacy,
Utrecht University, the Netherlands) according the following protocol:
Deoxygenised aqueous solutions of methacrylated dextran (degree of substitution,
i.e. the number of methacrylates per 100 glucopyranose residues = 4, 1g, 40%
w/w), synthesised according to Van Dijk-Wolthuis et al. [1997a] and polyethylene
glycol (PEG, Mw20.000, 0.1g, 24% w/w) are vigorously mixed for 2 minutes with
a vortex under an Argon atmosphere. Part of this primary emulsion (0.25g) is
added to a PEG solution (Mw4.000, 4.75g, 24% w/w) immediately after mixing.
The emulsion is gently homogenated by hand. Subsequently, potassium peroxo-
disulfate (180 µl, 50mg/ml) and N,N,N’,N’-tetramethyl ethylenediamine (100 µl
20% v/v, pH neutralised with 4M HCL) are added and the mixture is incubated
without stirring for 30 min at 37°C to allow polymerisation of the methacrylic moi-
eties in the dextran chain. Thus obtained microspheres are then sieved (sieve:
Storck-Veco, Eerbeek, Holland; mesh 10 µm) to separate the smaller from the
large particles.
Particle size was analysed by a model 770 AccuSizer (Particle Sizing Systems, Santa
Barbara, California, USA) and expressed in micrometers as the ‘number mean
diameter’ (num) i.e. the ordinary arrhythmic mean diameter of the particles, and
the ‘volume mean diameter’ (vol), i.e. the diameter corresponding to the mean vol-
ume of the particles [Edmundson, 1967].
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Figure 5.1. 
Injection of methylene blue dye
in the left central auricular
artery after ligation of distal
and rostral branches. Note the
area of perfusion between
midline and caudal margin
(arrows). External (A) and
transmitting (B) light source.
C=caudal margin, R=rostral
margin.
A B
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5.2.5 Analgesia, sedation and euthanasia
For details on analgesia, sedation and euthanasia is referred to chapter 2.2.4.
5.2.6 Tumour induction
All hair was removed from the auricle by shaving the skin with a pair of clippers. To
induce tumours a 0.10-0.15 ml suspension (in RPMI 1640), containing 4-24.106 vital
cells, was injected (with a 0.5 mm needle) s.c. into the dorsal lateral portion (i.e. between
the central auricular artery and caudal margin) of the middle third of both auricles
(fresh suspensions: 10 rabbits; cryopreserved suspensions: 5 rabbits). Composition of
the cell suspensions was checked through cytospins stained with Haematoxylin and
Eosin (HE). More than 95% of the cells were of the carcinoma type.
5.2.7 Evaluation of tumour growth and statistics
To evaluate speed of growth, the size of 12 tumours (five paired and two single
tumours, in 7 rabbits) was recorded in time (t, days) by two-dimensional measure-
ments with callipers and presented as surface area (A, cm2). Based on a mathemati-
cal model assuming the tumour to grow exponentially with a fixed growth rate
[Hasenclever et al., 1996], speed of growth was characterised by a ‘Tumour-sur-
face doubling-time’ (T, days), i.e. the time in which the tumour surface has doubled
in size (from A0 to 2.A0).
During the phase of exponential tumour growth, T was estimated by the best fitting
curve that applied to the following function of A:
[1] A(t) = A0 . 2t/T
Standard deviation (Sd) of T was calculated for all tumours. For the five paired
tumours an ‘intra-rabbit’ standard deviation (Sd’) was calculated, according to
[2] Sd’= √{[Σni=1 (Tleft,i-Tright,i) 2] /2n}
where Tleft,i and Tright,i are the Tumour-surface doubling-times of each left and
right ear respectively and n is the number of paired tumours, i.e. 5 in this case.
The F-test [Armitage and Berry, 1988] was used to assess significance of the dif-
ference between Sd and Sd’. Statistics used were by SPSS for windows release 6.1.
To evaluate tumour growth and development of metastases, 5 rabbits (one rabbit
per time point) were sacrificed at days 3, 7, 10, 14 and 21 after transplantation. All
other rabbits that showed tumour growth were sacrificed between 5 and 9 weeks
after transplantation. To depict the vascularisation of the external ear and peritu-
moural blood vessels, the ear was placed on the flashlight with its medial side (TTL
Electronic flashlight type Metz 45CL4; Camera: Nikon F4; Objective: Mikro-
Nikkor 105mm F2.8, Diaphragm F22, picture size 1:2).
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5.2.8 Embolisation
Procedure: after shaving and disinfection of the auricle and its base, a cutaneous
incision is made parallel and slightly lateral to the caudal auricular vein. The vein is
kept aside and the artery can be found in the layer between the vein and the carti-
lage (auricular concha), emerging deep from the upper margin of the cutaneous
auricular musculature (Fig. 5.2). Slight tapping and some drops of lidocaine 2%
help to prevent arterial spasm. The arterial diameter at this site is suitable for
macroscopic cannulation with a 0.6 mm Microflex® needle infusion set (Vycon,
Belgium) or preferably, to avoid the risk of perforation, an Abbocath® catheter
(Abbott, Sligo, Republic of Ireland). The cannula is fixed with a peri-arterial suture
and is subsequently sutured to the skin to prevent inadvertent displacement.
Selective tumour perfusion is confirmed using methylene blue dye 4 mg/ml in glu-
cose 5% (Fig. 5.3).
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Figure 5.2.
Exposure of left central
auricular artery (A). Note the
relation to the great auricular
nerve (N), and central
auricular vein (V). C=caudal
margin, R=rostral margin.
Figure 5.3.
Control of tumour perfusion of
the left auricle with i.a.
methylene blue dye. C=caudal
margin, R=rostral margin.
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Embolisation with dextran hydrogel microspheres of various particle sizes (Table 5.1)
was performed in 7 tumours (in 4 rabbits: no.’s 6353, 6503, 6576 and 6577 respec-
tively on day 22 to 43 after transplantation). Sieved particles (mesh 10 µm) were used
in rabbit 6576 and 6577. Each tumour was embolised with 10-160 mg (wet weight)
microspheres in 1 ml phosphate buffer solution. Embolised rabbits were sacrificed
41-50 days after transplantation.
5.2.9 Evaluation of embolisation
After sacrificing, the animals were autopsied. Thoracal and abdominal organs were
inspected. To verify presence of tumour and microspheres, tissue samples from the
primary site, lymph nodes, lungs, spleen and lumbal backbone marrow were fixed
in formalin. Sections were embedded in paraffin and histologically evaluated after
staining with HE and Periodic Acid Schiff (PAS). Success of tumour embolisation
was judged on the basis of dispersion of microspheres in and around the tumour
and classified as ‘poor’ (i.e. hardly any microspheres retained in tumour vascula-
ture), ‘diffusely good’ (i.e. a diffuse and uniform dispersion of microspheres in ves-
sels in and around vital tumour tissue), or ‘intermediate’ (i.e. in some parts of the
sections, tumour vessels retain microspheres).
5.3 Results 
5.3.1 Tumour growth
5.3.1.1 Primary site
In the 10 auricles (in 5 rabbits) injected with a thawed cell suspension, only in 4/10
(40%) a tumour developed. Vitality of thawed cell suspensions was about 10%, con-
taining 10 - 20.106 vital cells.
In the 20 auricles injected with fresh cell suspensions, in 17/20 (85%) a tumour
developed. Vitality of fresh cell suspensions was in all cases over 50%. The auricles
that developed a tumour, had been injected with 6 - 24.106 vital cells. The 3 auri-
cles that did not show progressive tumour growth received 6.106 (two auricles) and
10.106 (one auricle) vital cells respectively.
Tumour-surface doubling-time (T) varied between 4.5 and 9.9 days (mean 7.1 ±
2.0 days) in all animals. Contrary to the standard deviation (Sd) of 2.0 days
between rabbits, the standard deviation between tumours in both auricles of the
same animal (Sd’) was only 0.65 days. The difference between Sd and Sd’ was sta-
tistically significant (p<0.025).
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In one case development of tumour vasculature was followed until a tumour surface
of 110 mm2 was reached (Figs. 5.4a-d). Pre-existing vascular architecture did not
change during neovascularisation of the tumour.
5.3.1.2 Metastatic disease
Microscopic first level lymph node metastases were encountered in the parotid of 2
rabbits killed at 3 and 14 days after transplantation. A single microscopic lung
metastasis was found in the rabbit killed 10 days after transplantation.
In the four rabbits sacrificed more than 5 weeks after transplantation, lymph nodes
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Figure 5.4. (A-D)
Development of tumour vessel
bed before implantation (A)
and at a tumour size of 16 (B),
42 (C), 110 (D) mm2
respectively. Note that the
structure of pre-existing vessels
remains unchanged. C=caudal
margin.
C C
C C
A B
C D
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in the parotid area became palpable from the 4th week on. All regional lymph nodes
and lungs proved to contain metastatic SCC at autopsy. Two rabbits, that did not
develop tumours in the auricles, showed tachypnea, loss of animal spirits, loss of
appetite and loss of weight (8.6% and 15.3% respectively) 9 weeks after injection of
thawed tumour cells, and were therefore sacrificed. At autopsy massive lung metas-
tases were found. No metastases were found at other sites.
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Table 5.1. Data on embolised rabbits
Rabbit sieving particle size(µm) arterial embolisation
no. 1) mesh(µm) num. vol. ligation2) results 3) 
6353 L no 5.4 22.3 no poor
6503 L no 3.1 61.6 no poor
R no 3.1 61.6 yes intermediate
6576 L >10 13.0 26.5 yes poor
R >10 13.0 26.5 mult. intermediate
6577 L >10 9.8 28.4 mult. diffusely good
R >10 10.2 48.0 mult. diffusely good (+necrosis)
1)L=Left auricle; R=Right auricle
2)yes = central artery distal to the tumour only; mult. = multiple non-tumour branches
3)poor = hardly any microspheres retained; intermediate = some retention of microspheres; good = diffuse dispersion of
microspheres
Figure 5.5.
Microscopy of tumour tissue
after embolisation. 
Dextran hydrogel microspheres
around the tumour (T) and in
the stroma (S). Original
magnification 50x, PAS stain.
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5.3.2 Embolisation study
Data on particle size and results are summarised in Table 5.1. Dextran hydrogels
stain highly PAS-positive and microspheres are easily detected in histological slides.
In the first two rabbits (no.’s 6353 and 6503) embolisation was poor. In the lungs
thromboemboli and alveolar edema was observed, though the animals were clinical-
ly well. Sieving the particles (mesh diameter: 10 µm) as well as ligation of the cen-
tral artery distally from the tumour and branches that perfuse non-tumour regions,
resulted in better embolisation (Fig.5.5). In these rabbits (no.’s 6576 and 6577)
microspheres still could be found in the lungs, resulting in some septal inflammato-
ry infiltrate, but alveoli were normally distended without edema. Judgement of dis-
persion of microspheres 21 days after the injection of rabbit no. 6577 was difficult
because of extensive tumour necrosis, as a result of the i.a. embolisation. In rabbit
no. 6577 some microspheres were found around a regional (parotid) lymph node
metastasis. No microspheres were observed in other tissues.
5.4 Discussion
In this auricle Vx2 SCC model, the response rate of subcutaneous transplantation was
85% when fresh, and only 40% when cryopreserved tumour cell suspensions were
used, most likely because of a poor recovery from storage in liquid nitrogen, resulting
in a cell viability of only 10%. The many dead cells injected may have had an immu-
nisation effect stimulating an effective immune response, which prevented outgrowth
of tumour. Failures of transplantation in this study occurred when 10.106 vital cells or
less were injected. Only Wagner [1994] reports a response rate of 100% using
5-10.106 cells intramuscularly in the hind limb. Davidson et al. [1986] using 5.106
cells intramuscularly in the hind limb, Tromberg et al. [1990] using 10.106 cells sub-
cutaneously in the auricle, Päuser et al. [1996] using 10-50.106 cells intrahepatically
and Harima et al. [1996] using 100.106 cells intramuscularly in the uterus do not
report their response rates explicitly. In contrast to muscle or the liver, to create a small
subcutaneous vesicle in the auricle, the maximum injectable volume is about 0.1 ml.
This demands a suspension of at least 100.106 vital cells per millilitre. We advise to
use at least 20.106 vital cells, and to prevent an unfavourable balance between vital
and necrotic cells as occurred in using our cryopreserved tumour suspensions. In
contrast to Schouwenburg et al. [1980], who used tumour fragments for implanta-
tion, like others [Davidson et al., 1986; Tromberg et al., 1990; Wagner et al., 1994;
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Harima et al., 1996; Päuser et al., 1996] we preferred injection of tumour suspen-
sions to prevent disruption of the vascular architecture of the auricle, which might
interfere with the i.a. embolisation study. The injection of suspensions, however, has
the disadvantage of possible leakage of cells i.v. or intra-lymphatically. This mecha-
nism might explain our observation of a micrometastasis, soon after tumour induc-
tion, in the lymph node (3 days) and lung (14 days). It can also explain the massive
lung metastases despite absence of tumour growth in the auricle in 2 animals.
In contrast to Tromberg et al. [1990] who used the dorsal medial portion of the auri-
cle as implantation site to study photodynamic therapy, we chose the dorsal lateral part
of the auricle. In this area perfusion shows to be mainly dependent on the caudal
auricular artery, whereas the medial portion also receives branches from the rostral
auricular artery. The model allows for accurate measurement of tumour size and good
assessment of the development of lymph node metastases.
In this Vx2 auricle model canulation of the superficially lying caudal auricular artery
without the aid of a microscope is easy: general anaesthesia is therefore not necessary,
in contrast to other models [Davidson et al., 1986; Schouwenburg et al., 1980]. Even
with a large auricular tumour mass the rabbits did not seem to be troubled, which
might very well be so in case of large hind limb tumours. Because of the invariable
development of lung metastases, we feel that, in the benefit of the animals’ well being,
termination of studies with this model has to be done within 8 to 10 weeks after
tumour transplantation.
Being aware of the simplification of reality using the mathematical growth model of
Hasenclever et al. [1996], the estimated Tumour-doubling-time (T) of 7.1 days cor-
responds well with the findings of Muckle and Dickson [1971], describing Vx2
tumours in thigh-muscles of male NZW rabbits. Like their data, we also find a con-
siderable variation of T between animals. We are of opinion that the implantation of
the Vx2 tumour in both auricles allows for a better comparison between the embolised
and the contralateral ‘control’ tumour than a control tumour in another animal,
because variation in T proved significantly larger between animals than between two
auricles (2.0 vs 0.65 days). Moreover, also others [Schouwenburg et al., 1986;
Davidson et al. 1986] stressed the importance of a model with bilaterally implanted
tumours, that allows for comparison of drug distribution between the regionally
embolised tumour and the contra-lateral control tumour, where exposure is to sys-
temic drug levels only.
As there is a substantial difference in speed of tumour growth between animals, in
contrast to others [Päuser et al., 1996, Harima et al., 1996, Tromberg et al., 1990]
we believe that timing of intervention should be dictated by the size of the tumour
instead of by a fixed time span after transplantation of the tumour. The finding, that
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pre-existing vascular architecture is not changed by newly developed blood vessels
that perfuse the tumour, makes the timing of i.a. embolisation independent of the
moment of tumour induction.
In the embolisation models of the liver [Päuser et al., 1996] and the uterus [Harima
et al., 1996] the organ-specific artery is used and non-tumour branches are ligated to
enhance the efficiency of embolisation. In our model, macroscopical ligation of non-
tumour branches is easily performed with the aid of methylene blue dye, because of
the translucency of the auricle.
The Vx2 SCC is surrounded by large irregular capillary-like blood vessels [Stewart
et al., 1959; Blanchard et al., 1965]. The diameter of microspheres to be used for
tumour embolisation has to be small enough to obtain a uniform dispersion of parti-
cles in and around the tumour, but has to be large enough to prevent spillage of parti-
cles to the lungs. This might in part explain the large variance of particle sizes used
for embolisation in literature: Mumper et al. [1991] use polylactic acid particles of
23.6 ± 4.9 µm for internal radiation, and Päuser et al. [1996] use starch particles
with a diameter of 30 to 50 µm for chemo embolisation of the rabbit liver. Okamoto
et al. [1985] use cisplatinum microcapsules of 396 ± 119 µm in humans with head
and neck cancer. These investigators however, did not report on histopathology of
lung tissues following their embolisation. This might be due to the fact, that particles
used are not easily visible by light microscopy. Dextran microspheres used in this
study, are easily detected with a PAS stain.
Small particles with a diameter characterised by a number weighted mean < 9µm
traverse the tumour capillary bed and induce microemboli with edema in the lungs.
The use of larger particles in combination with ligation of non-tumour branches
enhances the success of diffuse tumour embolisation and prevents lung edema. Yet,
microspheres were found in lung septa. Adverse effects from these microspheres will
be dictated by the anti-tumour drugs to be enclosed, because the toxicity of the dex-
tran hydrogel itself is low [Van Dijk-Wolthuis, 1997b].
It can be concluded that the Vx2 carcinoma in the rabbit auricle is suitable to be
used as an experimental head and neck SCC model particularly to study the effects
of intra arterial anti-tumour therapy using dextran hydrogel microspheres as
embolisation particles. Future studies with this model will have to establish the opti-
mal size and dosage of the microspheres. Thereafter the effects of controlled release
of different anti-tumour drugs from these microspheres can be evaluated.
As dextran hydrogels are developed for the controlled release of proteins and pep-
tides, the use of these particles as a carrier for a wide range of immuno-stimulating
drugs, such as interleukins and interferons, might add a new dimension to the field
of anti-tumour therapy.
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rabbit Vx2 head and neck cancer model
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Abstract
Introduction: Intra-arterial embolisation of unresectable malignant tumours with
biodegradable microspheres is an effective way of selective anti-tumour therapy.
Possible candidates are Dextran hydrogel (Dex) microspheres for chemo-embolisa-
tion and Holmium-166 poly(L-lactic acid) (166HoPLA) microspheres for radio-
embolisation. This study was performed to investigate the distribution of
intra-arterially injected microspheres both in-vivo and histologically in order to
establish an optimal size of particles for embolisation of head and neck tumours.
Materials and Methods: Twenty rabbits with Vx2 auricle tumours were
embolised via the caudal auricular artery with 3 different batches Dex and 1 batch
166HoPLA microspheres varying in size from 19 to 66 µm. Dex microspheres were
labelled with 99mTechnetium in 6 cases. The proportion of microspheres entrapped
in the tumour was measured with a gamma camera. The distribution of micros-
pheres around the primary tumour and spill of particles to lungs or other organs
was analysed on histological sections.
Results: The 19 µm 166HoPLA particles used for embolisation of liver tumours
proved inadequate for embolisation as 51% spilled to the lungs, whereas over 95%
of the 40-66 µm Dex microspheres were retained within the primary tumour area. 
Dex20 and Dex30 microspheres tended to be more evenly distributed throughout
the primary tumour. Particle density in lung tissues proved significantly lower for
the Dex50 group. In 2 rabbits of the Dex20 group stray emboli to the brain
occurred. 
Conclusion: The results of this investigation show that both Dextran hydrogel
and holmium-166 poly(L-lactic acid) microspheres are potential candidates for
embolisation of head and neck cancer. In future studies, present arterio-arteriolar
connections should be identified and occluded. Particles with a number weighted
mean size of at least 40 µm and a volume weighted mean size up to 70 µm should
be employed.
The authors thank Henny IJzerman, Maarten Gerrits, Alice van Dongen and Fred van het Schip of the
department of Nuclear Medicine, Okke Franssen and Jenny Cadée of the department of
Pharmaceutics, Jan Nico den Breejen of the Radionucleids Laboratory and Adri Versluis of the Animal
Department for their substantial contribution to this study. We also thank Bram van der Meijs for his
efforts in analysing the data.
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Size of microspheres for embolisation
6.1 Introduction
Intra-arterial (i.a.) embolisation of malignant tumours with biodegradable micro-
spheres containing anti-tumour drugs is considered to be one of the most effective
ways of selective anti-tumour therapy [Kato et al., 1994]. However, the optimal size
of microspheres for embolisation of head and neck tumours still has to be established.
On the one hand particles have to be small enough to create a diffuse distribution
throughout the tumour and on the other hand particles have to be large enough to
prevent them from spilling to the systemic circulation. The latter includes either the
venous circulation with spill to the lungs, or the collateral arterial system with stray
emboli to important neural structures. Dextran hydrogel (Dex) microspheres are
promising candidates because of their controllable degradation and property to
show a sustained release of pharmaceutically active drugs [Stenekes et al., 1998;
Franssen et al., 1999]. Diffuse distribution of these microspheres in and around
tumour tissue following i.a. injection has been demonstrated in a Vx2 head and
neck cancer model of the rabbit (Chapter 5). Radio-embolisation is considered an
effective treatment modality for unresectable primary hepatocellular carcinoma
[Novell and Hilson, 1994]. Radioactive holmium-166-poly(L-lactic acid)
(166HoPLA) microspheres that are especially developed for treatment of these
tumours [Mumper et al., 1991; Nijsen et al., 1999], might be equally suitable for
treatment of unresectable head and neck cancer.
The particle size used in several liver embolisation studies varies between 10 and
50 µm [Stribley et al., 1983; Lorelius et al., 1984; Pillai et al., 1991; Päuser et al.,
1996; Bastian et al., 1998]. Embolisation with 166HoPLA of rabbit liver tumours
proved successful with a particle diameter of 24 ± 5 µm [Mumper et al., 1991].
For chemo-embolisation of head and neck cancer, ethylcellulose particles with a
much larger size of 140-440 µm have been used [Yang et al., 1995; Kato et al.,
1996; Tomura et al., 1998].
The embolisation experiments described in this chapter evaluates the biodistribu-
tion of four available, differently sized batches of microspheres in a rabbit Vx2 head
and neck cancer model: Three batches Dex microspheres, of which a part was
labelled with radioactive 99mTechnetium (99mTc) and one batch 166HoPLA micros-
pheres. The distribution of microspheres in the tumour, the lungs and brain is
analysed both in-vivo with a gamma camera as well as histologically after sacrifice.
The results of these experiments are important for the development of future treat-
ment strategies based upon tumour embolisation of head and neck cancer.
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6.2 Materials and methods
6.2.1 Animal tumour model
Tumours were induced by injection of Vx2 carcinoma cells into the auricles of 20
adult female NZW rabbits as described in chapter 2.2.2. Tumours were embolised
when they reached a size of 4 cm2. During all experiments sedation and analgesia
was achieved with a mixture of fentanyl 0.315mg/ml and fluanisone 10mg/ml
(Hypnorm®, Janssen Cilag).
6.2.2 Embolisation particles
Dex microspheres were obtained from the Utrecht Institute for Pharmaceutical
Sciences and prepared as described by Stenekes et al. [1998]. The degree of
methacrylate substitution (i.e. the number of methacrylate groups per 100 glucopy-
ranose units) was 4 and the equilibrium water content of the dextran microspheres
was 40%. Three differently sized batches were available. They were prepared by
separating particles through different sieves of 20 µm (Dex20), 30 µm (Dex30),
50 µm (Dex50) to exclude smaller particles. A 100 µm sieve was used to exclude
larger particles.
166HoPLA microspheres were prepared at the Department of Nuclear medicine of
the University Medical Center, Utrecht as described by Nijsen et al. [1999]. The
available batch is routinely used for experimental radio-embolisation of the liver in
tumour bearing rats.
6.2.3 Radioactive labelling
To study biodistribution of Dex in-vivo, two batches of Dex (Dex20 and Dex50)
were labelled with 30 MBq 99mTcO4. The batch was only used if the percentage of
99mTcO4 leaking from microspheres in 1 hour was less than 10%.
99mTc labelled Dex microspheres were prepared according to the following protocol:
- Dex microspheres are suspended in 5 ml aquadest and centrifuged (Hettich
Rotanta®) for two cycles at 1000 rpm during 5 min.
- Resuspension of the pellet in 1 ml aquadest and perfusion with N2 gas during
30 min at room temperature.
- Addition of 5 µm(l SnCl2-solution (SnCl2.2H2O,30 mg/ml concentrated HCl)
and 30MBq 99mTcO4 in 1 ml 0.9% NaCl.
- Labelling for one hour while stirring at room temperature.
- Centrifugation (Hettich Rotanta®) at 2000 rpm during 5 min and determina-
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tion of labelling percentage, calculated according to the following equation:
Labelling percentage = (Activity of Microsphere pellet / Activity of
Microsphere pellet + Supernatant) x 100%.
- If labelling percentage is at least 90%: Resuspension of the labelled micro-
sphere pellet in 1.0 ml 0.9% NaCl and aspiration in a 2 ml syringe.
6.2.4 Particle size analysis
The actual particle size of the available batches was analysed by a model 770
AccuSizer (Particle Sizing Systems, Santa Barbara, California, USA) and expressed
in micrometers as the ‘number weighted mean’ diameter i.e. the ordinary arrhythmic
mean diameter of the particles, and the ‘volume weighted mean’ diameter, i.e. the
diameter corresponding to the mean volume of the particles [Edmundson, 1967].
6.2.5 Embolisation Experiments
Twenty auricle tumours were embolised with the 4 different batches of embolisation
particles by injecting microspheres following cannulation of the caudal auricular
artery (Table 6.1). In each experiment a total of 0.7-1.4 ml 0.9% NaCl solution was
used containing 50 mg Dex or 166HoPLA microspheres. Eight rabbits received
non-radioactive Dex microspheres. 
Experiments for evaluating the radioactive biodistribution of the different micros-
pheres were carried out with 12 animals divided into 4 groups:
1. Group I (n=3): 99m Tc-labelled Dex20
2. Group II (n=3): 99m Tc-labelled Dex50
3. Group III (n=3): Dex50 mixed with free 20 MBq 99mTc
4. Group IV (n=3): 166 HoPLA
Group III was added to verify possible leaching of 99mTc from Dex microspheres
in-vivo.
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Table 6.1. Number of animals that received different batches of microspheres
Batch Regular study Radionuclide study Total
non-radioactive 99mTc-label free99mTc
Dex20 4 3 7
Dex30 4 4
Dex50 3 3 6
166HoPLA 3 3
Total 8 9 3 20
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Biodistribution of radioactivity was monitored by a gamma camera immediately
after embolisation and 1 hour later in case of 99mTc-labelling and 24 hours later in
case of 166Ho-labelling.
6.2.6 Radionuclide imaging
All data were acquired with a gamma camera (Elscint®) interfaced to a computer
(Apex 609R, Elscint Ltd., Israel). A low energy, high-resolution collimator was
used. The rabbits were positioned prone and the field of view included the auricle,
carrying the tumour and the torso (Fig. 6.1). The activity generated from identical
rectangular ‘Regions of Interest’, superimposed over each auricle, the lungs and the
abdomen, was determined. Data were corrected for radioactive decay and the
acquisition time. If the activity from the embolised tumour overshadowed the activity
from the lungs (i.e. if the overflow correction of the gamma camera arrested the
acquisition time before 600 s), the embolised auricle was covered and a separate
image of the lungs was acquired (Fig. 6.3b).
6.2.7 Analysis of imaging
The relative portion (in percent) of labelled microspheres entrapped in the tumour
was calculated according to the following equation:
[1]Portion entrapped microspheres = {Activity tumour / Activity (tumour
+ lung)} x 100%.
Because free 99mTc is excreted via the kidneys into the bladder, the relative portion
(in percent) of entrapped free 99mTc in the tumour was calculated according to the
following equation:
[2]Portion entrapped free 99mTc = {Activity tumour / Activity (tumour + lung +
abdomen)} x 100%.
The portion entrapped microspheres was measured immediately after embolisation
(t1) and 1 or 24 hours later (t2), for 99mTc-labelled Dex or 166HoPLA micro-
spheres respectively. The percentage of microspheres leaking from the tumour in
due time was calculated according to the following equation:
[3]Leakage = 1 - (portion entrapped t2/ portion entrapped t1) x 100%.
Differences between groups were tested with a general linear model repeated meas-
ures procedure (repeated measures ANOVA).
6.2.8 Autopsy and histological preparation
One day after completion of the embolisation experiments, the rabbits were sacri-
ficed by i.v. injection of 2 ml pentobarbital 200 mg/ml (Euthesate®). The tumour-
bearing auricles and inflated lung specimens were dissected and fixed in 10%
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formaldehyde solution for histological examination.
Tissue samples were prepared for paraffin sectioning according to established
methods. Three slices (thickness 3-5mm) were taken perpendicular to the auricular
axis from the whole-embolised tumour: One proximal, one middle and one distal
section. One sample was taken from each lung lobe. Brain sections (anterior, middle
and posterior) were taken from two animals with neurological signs (see 6.3.3
Clinical observations). Sections were stained with HE and PAS, allowing better
detection of the carbohydrate Dex microspheres
6.2.9 Analysis of histology
6.2.9.1 Distribution of microspheres around the primary tumour
Tumour cross-sections were represented schematically as in Fig. 6.2. The number
of particles was counted in three distinct areas by using a grid meter under the light
microscope [Pillai et al., 1991]: Area 1 = within the tumour; Area 2 = immedi-
ately around the tumour within 2 mm from the tumour border. Area 3 = distant
from the tumour, i.e. > 2 mm from the tumour border. The 2 mm area was chosen
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Figure 6.1. 
Position of the rabbit on the
gamma camera during nuclear
imaging. Arrow indicates
embolised tumour.
Figure 6.2. 
Transverse histological section
through the auricular tumour
with Areas 1, 2 and 3 (see text).
Dotted line marks the 2mm
zone between Area 2 and 3.
PAS stain. T = tumour, C =
Cartilage.
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arbitrarily, based on the mean range of ß-energy from holmium-166 in tissue,
being 1 to 2 mm [Turner et al., 1994]. For each batch, the distribution of particles
in these 3 Areas was determined for each tumour section (proximal, middle and
distal) and presented as a percentage of all particles counted. If Area 2 could not be
determined reliably, particles were only scored being in- or outside the tumour, i.e.
Area 2 and 3 were lumped together versus Area 1. 166HoPLA particles do not
stain and proved difficult to detect within a dense peri-tumoural inflammatory infil-
trate. Because of unreliable visualisation of 166HoPLA particles in auricular sec-
tions, these measurements were not feasible and excluded from analysis.
Univariate ANOVA was used to determine significant differences in distribution of
microspheres between different batches Dex, different Areas 1-3 and different
tumour sections (proximal, middle and distal).
6.2.9.2 Spill of microspheres to lungs and brain
Particle size in lung and brain sections was measured by using a grid-meter under
the light microscope [Pillai et al., 1991] and specified in categories of 5 µm rang-
ing from 10 to 80 µm. The total surface of the sectional slides was estimated by
using a grid-meter. Particle density was defined as: Number of particles per category
divided by the total surface of the sections (in cm2). Differences in particle density
of lung tissue were determined with Student’s t-test for different batches of micros-
pheres. Particle density and distribution of microspheres in the brain were deter-
mined for the two rabbits with neurological signs.
6.3 Results
6.3.1 Particle size analysis
Number weighted mean and volume weighted mean diameters of the sieved batch-
es are summarised in Table 6.2. On average, the number weighted mean diameters
are 19, 40, 50 and 60 µm and the volume weighted mean diameters are 50, 72, 77
and 90 µm for 166HoPLA, Dex20, Dex30 and Dex50 respectively. Note that the
number weighted mean diameter of the 166HoPLA particles is 19 µm and much
smaller than the 40 µm of the Dex20 particles despite the use of the same sieve size
to separate small particles.
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6.3.2 Radionuclide imaging
The percentages of microspheres entrapped in the primary tumour immediately
after injection, after 1 hour for 99mTc-labelled Dex microspheres and after 24 hours
for 166HoPLA microspheres are shown in Table 6.3.
There was a significant difference the portion of radioactivity entrapped in the
tumour between Dex20 and Dex50 microspheres (Group I and II) on the one hand
and Dex50 microspheres with free 99mTc or 166HoPLA microspheres (Group III
and IV) on the other hand. Over 95% of the Dex20 and over 97% of the Dex50
microspheres was retained in the tumour whereas about 50% of the 166HoPLA
microspheres spilled to the lungs (Figure 6.3).
Less than 1.5% of the Dex microspheres and 7.5% of the 166HoPLA microspheres
leaked from the tumour in due time. Dex50 microspheres retained 46% of the free
99mTc initially, indicating an occlusion of vessels with stasis of intra-vascular fluids.
Almost half of this activity was washed out in one hour and excreted via the kidneys.
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Table 6.2. Particle size analysis of available batches of microspheres
Batch Sieve size (µm) Num. wt. mean ± sd (µm) Vol. wt. mean ± sd (µm)
166HoPLA 20-50 18.8 ± 10.8 50.4 ± 35.5
Dex20 20-100 39.5 ± 19.3 72.1 ± 27.9
Dex30 30-100 49.8 ± 19.4 77.0 ± 30.0
Dex50 50-100 66.4 ± 21.1 90.2 ± 30.8
Table 6.3. Percentage of injected dose entrapped within the primary tumour
T0=0 hour T1=1h / 24h T0 - T1
Group Microspheres Mean ± sd (%) Mean ± sd (%) Leakage (%)
I 99mTc-labelled Dex50 98.7 ± 0.70 97.4 ± 1.46 1.32
II 99mTc-labelled Dex20 97.1 ± 2.01 96.2 ± 2.34 0.92
III Dex 50 + Free 99mTc 46.2 ± 13.1** 25.3 ± 7.2** 45.1
IV 166HoPLA 52.7 ± 26.58* 48.7 ± 27.63* 7.59
Differences vs. Groups I and II: p< 0.05 (*) and p< 0.01 (**)
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6.3.3 Clinical observations
Two (10%) of the 20 rabbits showed neurological signs after recovery from their
sedation, consisting of a tendency to spin around their longitudinal axis with a verti-
cal ocular nystagm. One animal died spontaneously during the night, the other was
sacrificed as planned after 24 hours. Both rabbits had received Dex20 micros-
pheres. Both brains were autopsied. From one of these animals also liver and kidney
tissues were harvested.
6.3.4 Histology
6.3.4.1 Primary tumours
Microspheres tended to cluster within the larger vessels in and around the tumour,
rather than being uniformly dispersed throughout the capillaries. A significant dif-
ference in distribution of Dex particles in different Areas was found in only the
proximal sections of the tumours (Table 6.4): In groups Dex30 and Dex50, 28%
and only 1% of the particles was found within the tumour tissue, i.e. Area 1 respec-
tively. In groups Dex20 and Dex50, 60% and 25% of the particles was found within
2 mm of the tumour border (i.e. Area 1+2) respectively. No other differences
between the batches were found. When comparing the proximal, middle and distal
sections, the Dex20 and Dex30 microspheres tended to be more evenly distributed
throughout the tumour as a whole. However, the Dex50 spheres still distributed
fairly well in the three sections with 25, 60 and 90% of the particles lying within
2 mm of the tumour border respectively.
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Figure 6.3. 
Gamma camera images of the
auricle and lungs. 
A: 166HoPLA microspheres.
Note the heavy activity of
spilled particles in the lungs. 
B: 99mTc-labelled Dex50
microspheres. Combined image:
The acquisition time of the
inserted lung area is six times
longer (see text).
A B
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6.3.4.2 Lungs
Significant differences in particle density were found between Dex20, Dex30 and
Dex50 in each category of microsphere diameter up to 40 µm (Figs. 6.4 and 6.5).
The density of 166HoPLA particles in the lung was 4 to 6 times higher in comparison
with the Dex Groups, and even reached 13/cm2 in the 25 µm category (Fig. 6.5).
Only in the Dex50 Group, particle density did not exceed 0.25/cm2 in any category.
6.3.4.3 Brain, liver, spleen, kidney
In the rabbits with neurological signs, both hemispheres (i.e. both the embolised
and the contra-lateral side) contained microspheres. Particle density reached
4.0/cm2 in the 20 µm category. Also particles as large as 75 µm were found (Fig. 6.6).
However, no microspheres were found in liver, kidney and spleen tissue sections.
6.4 Discussion
The results of this study show that intra-arterial embolisation of the Vx2 rabbit
head and neck cancer model is not effective with 19 µm 166HoPLA microspheres
routinely used for embolisation of liver tumours, as over 50% of the particles is
spilled to the lungs. They also show that Dex microspheres with a number weighted
mean diameter of 40-66 µm are effectively entrapped in the primary tumour with
less than 5% spill to the lungs.
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Table 6.4. Mean percentage of particles found inside tumour (Area 1) or within 2 mm of tumour margin  (Area 1+2) 
Tumour Proximal section Middle section Distal section Total
Dex20 Area 1 14.4% ± 18.0 41.1% ± 25.8 21.1% ± 32.1 25.5% ± 27.4
Area 1+2 59.4% ± 29.2** 80.0% ± 21.9 83.4% ± 13.2 74.9% ± 23.4
Dex30 Area 1 27.6% ± 21.2* 45.0% ± 35.7 20.6% ± 9.7 30.1% ± 23.9
Dex50 Area 1 1.1% ± 1.8* 15.5% ± 23.6 49.3% ± 30.2 25.2% ± 30.3
Area 1+2 24.8% ± 7.6** 60.4% ± 27.6 89.5% ± 12.8 63.4% ± 31.3
differences: *p<0.05, Dex30 vs. Dex50; **p<0.1, Dex20 vs. Dex50
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Figure 6.4. 
Particle density in lung tissue
per category of sphere diameter
for Dex microspheres.
Significant differences
(p<0.05), *: between Dex20
and Dex30, **: between Dex20
and Dex50, ***: between
Dex30 and Dex50.
Figure 6.5. 
Particle density in lung tissue
per category of sphere diameter
for 166HoPLA microspheres.
Note difference in scale
compared to Fig. 6.4. 
*:significant differences
(p<0.05) between 166HoPLA
and all Dex Groups.
Figure 6.6. 
Particle density in brain tissue
per category of sphere diameter
for two animals with
neurological signs.
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As discussed in paragraph 4.2.2, three vessel-related variables can influence the
spill of microspheres to the lungs and stray emboli to other organs:
1. The structure of the tumour vessels itself.
2. Arterio-venous (AV) shunts in the organ in which the tumour grows.
3. Arterio-arteriolar (AA) connections in the organ in which the tumour grows.
Re-1. Like other tumours, the Vx2 tumour is known to induce the development of
a dilated capillary-like vasculature [Stewart et al., 1959; Blanchard et al., 1965].
Re-2. On AV shunt size in laboratory animals only scanty data are available. With
respect to this auricle tumour model, the observations of Grant [1930] are of inter-
est. He has described the presence of about 1 AV communication/mm2 in the rab-
bit’s auricle with an external size of 20-70 µm. Kim et al. [1962] mentioned the
presence AV shunts in various organs in the dog up to 50 µm in size, but these
accounted for less than 5% of the total flow.
These factors explain why the used batches 99m Tc-labelled Dex (with a number
weighted mean diameter of 40 to 66 µm on average) were all effectively entrapped
in the primary tumour with less than 5% spill to the lungs, whereas more than 50%
of the 19 µm 166HoPLA microspheres spilled to the lungs. Histological analysis
showed that up to a particle size of 40 µm Dex50 particles spilled even significantly
less to the lungs as compared to the Dex20 and Dex30 Groups.
Re-3. AA connections are known to be present between the caudal and rostral
auricular artery of the rabbit auricle and rabbits have an intact circle of Willis
[Barone et al., 1973], but no information exists about the size of these connections.
These connections may explain the occurrence of stray emboli to both hemispheres
in the two rabbits with neurological signs after infusion of Dex20 microspheres:
Retrograde flow of microspheres via the rostral auricular artery and external carotid
into the internal carotid, circle of Willis and both hemispheres. Because in the brain
particles up to a size of 75 µm were found, AA shunts in the tumour or in the auri-
cle must be at least of this calibre. Retrograde flow was limited to the carotid bifur-
cation and did not reach the aorta because no particles were found in liver, spleen or
kidney samples.
There is also less risk of retrograde flow if injection pressure is maintained below
the systolic blood pressure, which is 100 mmHg on average in adult rabbits
[Manning et al., 1994]. We did not control injection pressure in our study.
Stray emboli to the brain did not occur in the 166HoPLA Group despite massive
spill of particles to the lungs. This could be explained by the fact that small particles
obstruct AV shunts less effectively, resulting in a lower infusion pressure and less
risk of retrograde flow via AA connections. Moreover the number of animals in the
166HoPLA Group was smaller than in the Dex20 Group and apparently all spilled
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166HoPLA particles were effectively entrapped within the pulmonary vessels.
Prevention of stray emboli in this model was achieved by macroscopical ligation of
non-tumour branches as visualised with the aid of methylene blue dye. This has
been done in other animal embolisation studies [Päuser et al., 1996; Harima et al.,
1996], as well as in humans where coil embolisation is a method of eliminating
unwanted perfusion during i.a. infusions [McCarter et al., 1995]. In the head and
neck region, AA shunts connecting the internal and external carotid system can be
visualised during arteriography and occluded if present [Tomura et al., 1996].
Our study further shows that it is not sufficient to mention only the mesh size of the
used sieves to compare different batches of particles. The actual particle size has to
be expressed in number and volume weighted mean values [Edmundson, 1967].
The substantial differences in biodistribution between the 166HoPLA batch sieved
between 20-50 µm and the Dex20 batch sieved between 20-100 µm can be explained
by the differences in the actual particle size, being 19 µm vs. 40 µm and 50 µm vs.
72 µm for number and volume weighted means respectively. Differences in physico-
chemical properties between the Dex and 166HoPLA spheres as well as differences
in the sieving processes itself in the different institutions may have caused these dif-
ferences in particle size.
We realise that the diameter of microspheres measured in 7 µm histological slides
does not represent the real size of the spheres. Theoretically, the size of the
observed sphere segments should be corrected [Pahlplatz et al., 1995]. Assuming
an infinite number of measurements (over a thousand in this study), this correction
is applicable to all measurements of all batches. Therefore the conclusions concerning
differences found between the Dex20, Dex30 and Dex50 Groups are not substan-
tially influenced.
Our study also confirms that drug retention in the tumour can effectively be
enhanced by mixing cytotoxic agents with microspheres [Lorelius et al., 1984]:
One hour after embolisation with Dex50 microspheres mixed with free 99mTc
(Group III), still 25% of the free 99mTc was retained within the tumour. But when
drugs are slowly released from microspheres as represented by 99mTc-labelling
(Groups I and II), primary retention of anticancer drugs is more effective and
exceeds the 95%.
Considering the optimal particle size for tumour embolisation two different
philosophies exist: 1): ‘Use the smallest particles that will not penetrate to the
venous circulation’ [Stribley et al., 1983]. This statement holds true for embolisa-
tion of e.g. liver tumours, as stray emboli via collateral arteries are of less concern
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and entrapment of small particles in the liver vessel network seems highly effective.
The particle size used in several liver embolisation studies varies between 10 and 50 µm
[Stribley et al., 1983; Lorelius et al., 1984; Mumper et al., 1991; Pillai et al., 1991;
Päuser et al., 1996]. However, in a thorough distribution-study, Bastian et al.
[1997] conclude that a mean particle diameter of at least 40 µm is required to pre-
vent spill to the lungs and spleen. Their lung sections contained high concentra-
tions of particles smaller than 40 µm. These findings correspond well with the good
entrapment of Dex particles in our study and the significant increase of lung parti-
cle density below the 40 µm category.
Philosophy 2): ‘Use the largest microspheres that will not decrease the curative
effect of (chemo-) embolisation’ [Yang et al., 1995]. This philosophy could be true
for embolisation head and neck cancers, since the consequences of stray emboli to
important neural structures are detrimental. It might explain the use of chemo-
embolisation particles with an exceptionally large size of 140-440 µm as used by
others [Yang et al., 1995; Kato et al., 1996; Tomura et al., 1998]. However, it is of
doubt if this large size will avoid stray emboli to the brain in humans as e.g. the
middle meningeal artery has an average diameter of at least 500 µm. Our study
demonstrates that such a large size is not necessary to prevent spill to the lungs.
With a particle size of 40-66 µm, over 95% of the microspheres can be retained in
the tumour. Moreover, in our study the distribution of microspheres within 2
mm from the tumour border dropped from 60% to 25% in the proximal sections,
when using particles of 66 µm (Dex50) instead of 40 µm (Dex20). It is question-
able if very large (>100 µm) particles still can cause a diffuse tumour-embolisation
or merely get stuck in the feeding arterioles before even reaching the tumour. This
not only will allow collateral supply to take over, but also might block the infusion
pathway resulting in a higher infusion pressure with even more risk of retrograde
flow and stray emboli to the brain.
It is concluded that embolisation of this rabbit Vx2 head and neck cancer model is
ineffective with 19 µm 166HoPLA microspheres but shows optimal (>95%)
entrapment of 40-66 µm dextran hydrogel microspheres with a fair particle distri-
bution in and around the tumour. These dextran hydrogel microspheres, developed
for sustained release of pharmaceutically active anti-tumour drugs, can be labelled
effectively with radioactive 99mTechnetium to study their biodistribution.
Embolisation particles for this animal model should therefore ideally have a number
weighted mean size of at least 40 µm and a volume weighted mean size up to 70 µm.
The occurrence of stray emboli to the brain is a serious complication which
demands present arterio-arteriolar connections to be detected and ligated or occluded.
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Future embolisation studies will have to focus on the effects of embolisation on
tumour growth itself. Either larger sized batches 166HoPLA containing therapeutic
doses of radioactivity or dextran hydrogel microspheres containing chemo- or
immuno-therapeutic drugs are promising candidates. 
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Abstract
Introduction: Interstitial radiotherapy is an effective treatment modality against
head and neck cancer. Radioactive holmium-166 labelled poly(L-lactic acid)
(166HoPLA) microspheres could be applied as radio-embolisers.
Materials and methods: Twenty-two NZW rabbits with Vx2 squamous cell
carcinomas transplanted into the auricles were intra-arterially (i.a.) embolised with
radioactive and inactive HoPLA microspheres with a mean diameter of 38-80 µm.
The effects on tumour growth, the efficiency of i.a. infusion, the efficacy of reten-
tion of microspheres in the primary tumour and the excretion of free holmium-166
were analysed.
Results: Radio-embolisation induced 79% complete tumour remissions. Over 95%
of the microspheres was retained in the tumour and the leaching of holmium-166
was less than 0.1% in 2 days. The injection efficiency was not optimal, as 40% of
the microspheres was retained in the cannulation system. Arterio-arteriolar connec-
tions should be detected and closed prior to embolisation to prevent stray emboli
into the brain.
Conclusion: 166HoPLA microspheres with a diameter of 38-80 µm are promis-
ing candidates for future studies on radio-embolisation of unresectable head and
neck cancer.
The authors thank Maarten Gerrits, Sander Zielhuis and Alice van Dongen of the department of
Nuclear Medicine for their help in analysing the scintigraphic images. We thank Jenny Cadée of the
department of Pharmaceutics for sizing the microspheres, Mark Konijnenberg of Mallinckrodt
Medical b.v. Petten for calculating irradiation doses to the tumours, Peggy Adema of BARD Benelux
n.v. for supplying the infusion systems, Andries van der Bilt for the statistical analysis and Peter
Rothengatter for the photography. Finally, we thank and Jan Nico den Breejen of the Radionucleids
Laboratory, Adri Versluis of the Animal Department and Bram van der Meijs and Marc Kicken for
their help in performing the animal experiments.
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Embolisation with 166HoPLA microspheres
7.1 Introduction
Today’s interstitial radiotherapy represents a highly effective treatment modality
available to the head and neck oncologist, with the advantage that it allows delivery
of a high local dose of radiation to the tumour without destroying local anatomy or
inducing xerostomia. However, a major concern is the problem of dose inhomo-
geneity due to errors in source placement related to technical difficulties during
implantation and there is the risk of tumour seeding along the implantation tract
[Close et al., 1993; Podd et al., 1994]. Moreover, the long half-life and the high
gamma energy of frequently used radiochemicals such as iridium-192 and iodine-
125 lead to significant exposure of medical staff to radiation. These drawbacks, can
be circumvented by intra-arterial (i.a.) embolisation of the tumour with beta-emit-
ting isotopes. There is a recent revival of the interest in i.a. anti-tumour therapies in
the management of oral cancer [Kovács et al., 1999]. Also chemo-embolisation of
head and neck cancer has proven an effective therapeutic option in the hands of
several groups [Tomura et al., 1998; Kato et al., 1996].
I.a. embolisation of unresectable primary hepatocellular carcinoma and hepatic
metastases with radioactive biodegradable microspheres is nowadays considered an
effective treatment modality [Novell and Hilson, 1994]. Neutron-activated holmi-
um-166 is a beta-emitter (Emax=1.84 MeV) with radiotherapeutic properties
appropriate for therapy and a short physical half-life of 26.8 hours, that also emits
photons (81 keV, 6.2%) suitable for gamma imaging. Holmium-166 labelled
poly(L-lactic acid) (166HoPLA) microspheres have especially been developed for
radio-embolisation of such liver malignancies [Nijsen et al., 1999].
Up to now, no reports exists about the experimental radio-embolisation of head and
neck cancer. We have described a Vx2 head and neck cancer model of the rabbit
that is suitable for studying effects of i.a. tumour embolisation (chapter 5).
However, 166HoPLA microspheres sieved between 20 and 50 µm used for emboli-
sation of liver tumours, have proven to be too small for embolisation of this head
and neck cancer model because 50% of the radioactivity spilled to the lungs (chap-
ter 6). To evaluate the effects of radio-embolisation on tumour growth in the Vx2
rabbit model we performed the present study with larger sized 166HoPLA micros-
pheres, sieved between 50 and 70 µm.
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As the effectiveness of treatment depends on the administration of microspheres
and retention of radioactivity in the primary tumour, the following technical items
were also addressed:
1. The efficiency of i.a. infusion of 166HoPLA microsphere suspensions.
2. The efficacy of retention of these 166HoPLA microspheres within the primary
tumour.
3. The leaching of free holmium-166(166Ho) into urine and faeces.
7.2 Materials and methods
7.2.1 Animal tumour model
Vx2 auricle carcinomas were induced as described in chapter 2.2.2. Single tumours
were induced in 8 rabbits and twin tumours (i.e. into both auricles) were induced in
14 rabbits. Sedation and analgesia during experiments is described in chapter 2.2.4.
7.2.2 Microspheres
Inactive 165HoPLA batches were sieved between 50 and 70 µm resulting in a num-
ber weighted mean diameter of 38.2 µm and a volume weighted mean diameter of
80.2 µm (model 770 Accusizer®, Particle sizing Systems, Santa Barbara, California
USA). Radioactive 166HoPLA microspheres were prepared at the Department of
Nuclear Medicine of the University Medical Center Utrecht, as described by
Nijsen et al.[1999].
Batches for infusion were prepared by dissolving the microspheres in 0.9% NaCI
with 4% modified gelatine (Gelofusine®, Vifor Medical SA, Switzerland) to retard
sedimentation of the particles. The total volume was 0.8 ml per batch. The radioac-
tivity of each batch was maintained between 60 and 80MBq to attain a therapeutic
tumour dose [Stabin and Konijenberg, 2000]. Each batch contained 55 mg of
microspheres on average.
7.2.3 Embolisation experiment
Of the 22 animals, 15 rabbits received radioactive 166HoPLA microspheres and
7 rabbits received inactive 165HoPLA microspheres. The 14 contra-lateral twin
tumours were not treated and served as controls. Auricle tumours were embolised
after reaching a surface area of 4 cm2, by injecting the microsphere suspension via
the caudal auricular artery as described in chapter 5. In summary: After skin inci-
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sion and exposure of the caudal auricular artery, cannulation was performed with an
Abbocath® cannula (Abbott, Ireland). A T-shaped extension set of a Per-Q-Cath®
catheter (Bard Access Systems, USA) was connected to the i.a. cannula onto which
both the syringe for infusion of methylene blue dye (2 mg/ml) and the syringe con-
taining the suspension of the microspheres were connected (Fig. 7.1). Selective per-
fusion of the tumour region was achieved by ligation of macroscopically visible
arterial branches to the rostral half of the auricle. The microsphere suspension was
injected after vigorous shaking, to prevent sedimentation. The catheter and the
syringe were repeatedly and carefully flushed in an attempt to clear the whole can-
nulation system from retained particles. The wound was closed after removal of the
catheter and the whole cannulation system was checked for retained microspheres
(see 7.2.5). Gamma camera imaging of the 166HoPLA treated rabbits was per-
formed straight after embolisation and 24 hours later. Animals were sacrificed 6
weeks after embolisation or earlier in case of progressive disease with signs of pain
or distress as described in chapter 2.2.4.
7.2.4 Evaluation of tumour growth, histopathological investigation and statistics
The primary tumour size was measured with callipers in two dimensions and
recorded as surface area (A, cm2) three times a week. At autopsy the primary
tumour or the site in the auricle where it regressed, was excised. Enlarged draining
lymph nodes in the parotid, retromandibular and cervical area were collected and
their number was recorded. Thoracal and abdominal organs were inspected for the
presence of metastasis or embolisation sequelae. A slice of each lung lobe and frag-
ments of the liver, spleen and kidney were removed. In case of neurological signs,
samples of both cerebral hemispheres were removed. All tissues were placed in 10%
buffered formalin and paraffin sections (5 µm) were prepared. Sections were
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Figure 7.1.
Cannulated caudal auricular
artery and connection of
syringes with methylene blue
dye and 166HoPLA
microspheres.
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stained with haematoxylin and eosin and studied by an experienced pathologist to
confirm or exclude the presence of tumour cells.
To determine significant differences in tumour growth between the radioactive
166HoPLA group, the inactive 165HoPLA group and the Control tumours
Student’s t-test was used. For these three groups tumour response was categorised
at autopsy according to the following definitions:
Complete Remission (CR) = histologically confirmed absence of tumour.
Partial Remission (PR) = over 50% tumour remission in size, 
but histological presence of vital tumour cells.
Stable Disease (SD) = 0 - 50% tumour remission.
Progressive Disease (PD) = progressive tumour growth.
Differences of tumour response and differences in number and size of lymph node
and lung metastases between groups were tested with a chi-square test.
7.2.5 Efficiency of intra-arterial microsphere infusion
The radioactivity retained in the removed cannulation system, was measured in a
low-background gamma counter (Tobor®, Nuclear-Chicago, USA) and corrected
for decay using the time of injection as the activity reference time. The injected dose
was defined as:
[1] Injected dose = (activity prepared) - (activity retained in the cannulation 
system).
Efficiency of injection was represented as a percentage of the total radioactivity pre-
pared in the batch, using the following equation:
[2] Injection efficiency = (Injected dose/Activity prepared) x100%.
7.2.6 Nuclear imaging of rabbits
All scintigrams were acquired on a gamma camera (Elscint®) interfaced to a com-
puter (Apex 609R, Elscint Ltd., Israel). A low energy, high-resolution collimator
was used. The rabbits were positioned prone and the field of view included the
auricle tumour and torso. The activity generated from identical rectangular
Regions of Interest (ROI), superimposed over each auricle and thorax, was deter-
mined.
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7.2.7 Retention of microspheres in the primary tumour
The relative amount (in percentage) of microspheres entrapped in the tumour was
calculated according to the following equation:
[3] Percentage entrapped = {Activity tumour/Activity (tumour + lung +
abdomen)} x100%.
The percentage of entrapped microspheres was measured immediately after
embolisation (t1) and 1 day later (t 2). The percentage of microspheres leaking from
the tumour in due time was calculated by the following equation:
[4] Leakage = (1 - percentage entrapped t2/percentage entrapped t1) x100%.
7.2.8 Leaching of 166Ho in urine and faeces
All urine and faeces produced by rabbits embolised with radioactive 166HoPLA
was collected separately the first and second day after embolisation, to test for the
presence of free 166Ho. Radioactivity in these samples was measured with the low-
background gamma counter, corrected for background radiation and decay, and
expressed as a percentage of the injected dose.
7.3 Results
7.3.1 Embolisation and tumour growth
The effects of embolisation on tumour growth are summarised in Table 7.1 and Fig.
7.2. One animal that died from stray emboli to the brain (see 7.3.2 Systemic effects)
was excluded, leaving 21 rabbits for analysis. Embolisation proved a highly effective
anti-tumour treatment resulting in 79-86% complete remissions. There was a signif-
icant difference in complete remissions between embolised and control tumours but
not among the two treatment groups themselves (Table 7.1). Also 8/14 (57%) of the
contra-lateral control-tumours regressed simultaneously with the embolised primary
tumours. Regression of a control tumour occurred only in case of remission of the
treated tumour. Tumour growth curves showed this same pattern (Fig. 7.2). The
tumour size differed significantly between treated and control tumours, but the
remission curve of the tumours treated with radioactive 166HoPLA ran parallel to
the curve of the inactive 165HoPLA group. Clinical images depicting effects of
radio-embolisation on tumour growth are presented in Figs. 7.3 A-D.
No differences in development of lymph node metastases were observed between
the groups (Table 7.2). Lymph node metastases were found in 29-43% of the
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autopsies. In some neck nodes related to regressed primary tumours, histological
changes suggesting regression of metastases were observed. These consisted of
fields with foamy macrophages and syncitial giant cells indicating phagocytosis of
necrotic cells. Lung metastases were seen in only one rabbit treated with
166HoPLA and in one with 165HoPLA microspheres.
7.3.2 Systemic effects
One out of the 22 embolised rabbits died because of the complications of stray
emboli to the brain. Because this animal belonged to the radioactive 166HoPLA
group, phosphorous plate images (i.e. organographs) of tumour sections and vis-
ceral organs could be obtained (Figs. 7.4 and 7.5). The tumour sections showed a
diffuse distribution of radioactivity throughout the whole primary tumour. Also
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Table 7.1. Primary tumour growth of embolised and control tumours.
166HoPLA 165HoPLA Controls
n=14 n=7 n=14
CR 11 (79%) 6 (86%) 8 (57%)*
PR 2 (14%) 1 (14%) 0
SD 0 0 0
PD 1 ( 7%) 0 6 (43%)*
CR = complete remission ; PR = partial remission; SD = stable disease; PD = progressive disease.
* Significant difference between controls and 166HoPLA/165HoPLA groups.
Figure  7.2.
Tumour growth curves of
treated and control tumours;
Day 0 = day of embolisation.
At day 10 a distinction is made
between control tumours with
progressive disease (PD) or
with complete remission (CR).
Significant differences
(p<0.01) in tumour size
between controls and treated
tumours (t-test).


  


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Figure  7.3.
Vx2 auricle tumours. 
A: Typical situation at the start
of embolisation.
B: 2 weeks after embolisation
with progressive growth of the
control tumour and remission
of embolised tumour.
C: or arrested growth of the
control tumour and remission
of the embolised tumour.
D: 6 weeks after embolisation
with complete remission of both
the treated and control tumours.
Arrow indicates embolised
tumour.
A
B
C
D
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activity in the rostral auricular artery could be recognised (Fig. 7.4, arrow), which
explained the mechanism of stray emboli to the brain via arterio-arteriolar connec-
tions in the auricle and retrograde flow via the rostral auricular artery into the
carotid artery. Of the visceral organs, only the lungs contained 166HoPLA particles
(Fig. 7.5). They contained 6.6% of the injected dose, which proved the largest spill
to the lungs of all animals treated (see 7.3.4).
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Table 7.2. Lymph node metastases of embolised and control tumours
166HoPLA 165HoPLA Controls
n=14 n=7 n=14
Present 5 (36%) 2 (29%) 6 (43%)
Figure  7.4.
Rabbit with stray emboli to the
brain. Organograph of transverse
tumour sections perpendicular to
the long axis of the auricle. Note
diffuse activity in and around the
primary tumour (T). The activity
via an arteriolar connection into
the rostral auricular artery is
indicated with an arrow.
Figure  7.5.
Rabbit with stray emboli to the
brain. Organograph of the
lungs. Note clusters of
radioactivity from spilled
particles.
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Apart from the brain tissues of the one rabbit that died from stray emboli, no
adverse reactions were seen in other tissues. Particularly the lung sections did not
show sequelae of the 4% spilled microspheres, neither with respect to vascular
occlusion nor with respect to irradiation damage.
7.3.3 Efficiency of microsphere injection
The efficiency with which the microsphere suspension could be injected intra-arte-
rially was 61.1 ± 16.0% (range 33-87%). Thus, about 40% of the microspheres
was retained within the infusion system and did not reach the tumour. It resulted in
an average injected dose of 34.2 MBq in 33 mg of microspheres.
7.3.4 Retention of microspheres in the primary tumour
Immediately after embolisation on average 96.5 ± 1.4% (range 93.4 - 98.5%) of
the injected 166HoPLA microspheres was retained at the site of the primary
tumour. After 24 h the relative activity entrapped was 97.3 ± 0.8%. Apparently no
leakage of microspheres from the primary tumour occurred after embolisation.
7.3.5 Leaching of 166Ho in urine and faeces
Activity of 166Ho in faeces and urine is summarised in Table 7.3. The total activity
excreted 48 h after embolisation was 0.44 ± 0.06‰ (range 0.18 - 0.94‰) of the
injected dose. Activity of 166Ho found in urine was about 6 times higher than in
faeces.
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Table 7.3. 166Ho excretion in faeces and urine in promillage of the injected dose
Faeces ± sem (‰) Urine ± sem (‰) Total ± sem (‰)
24 hours 0.03 ± 0.008 0.27 ± 0.33
48 hours 0.03 ± 0.007 0.11 ± 0.20
Total 0.06 ± 0.012 0.38 ± 0.48 0.44 ± 0.06
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7.4 Discussion
7.4.1 Effects on tumour growth
Our study shows that the i.a. infusion of HoPLA microspheres with a mean dia-
meter of 38-80 µm is very effective in inducing complete remissions of primary
tumours in this Vx2 head and neck cancer model. As no differences between the
166HoPLA and 165HoPLA groups were found, the addition of irradiation
appeared not to add to tumour remission in this animal model. This can be
explained by an inefficient infusion of the microspheres resulting in an insufficient
injected dose. Because, on average, 40% of the radioactivity was retained in the
infusion system, only 35 MBq entered the primary tumour. This injected dose is
too low to achieve a Tumour Control Probability of 95% [Briesmeister, 1977;
Stabin and Konijnenberg, 2000]. On the other hand, a remission of 80% following
embolisation with inactive 165HoPLA microspheres leaves little room for the dis-
crimination of additional effects from irradiation. Another more likely explanation
is the high sensitivity of the Vx2 carcinoma to vascular occlusion following emboli-
sation. Indeed, Yoshikawa et al. [1994] could induce regression of Vx2 limb
tumours after one week of repeated daily embolisation with starch microspheres
(that degrade within 40 minutes). They demonstrated that this anti-tumour effect is
due to the phenomenon of ischemia-and-reperfusion injury.
To imitate the situation in humans, superselective radio-embolisation should ideally
be performed on large Vx2 tumours transplanted into the mouth or pharynx of the
animal. This option is both ethically unacceptable and technically, even in rabbits,
difficult. For that reason, the Vx2 model of tongue cancer described by Matsumoto
et al. [1999] was not applicable in our situation. Their treatment started when
tumours were still small. Moreover, the physical condition of control rabbits with
tongue tumours over 10 cm3 was not reportedin their study.
Our study also shows that the use of a twin tumour model in which a non-treated
contra-lateral tumour acts as a control tumour has its drawbacks, as more than 50%
of the control tumours regressed simultaneously with the embolised tumours. Twin
tumours models have also been used by others [Schouwenburg et al., 1980;
Karanfilian et al., 1982; Everse et al., 1997]. Schouwenburg et al.[1980] and
Karanfilian et al.[1982] used contra-lateral auricle tumours as controls in rat carci-
noma models for i.a. chemotherapy. They attributed growth inhibition of the con-
tra-lateral side to exposure of systemic anti-tumour drug levels. Everse et al.
[1997] however, used a twin-lymphoma model in mice to underscore the systemic
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effects of immuno-modulation following IL-2 therapy. Also the Vx2 tumour is
immunogeneic as it responds to local IL-2 therapy (chapter 3).
The embolisation in our study caused extensive ischemic necrosis of the treated
tumours, which possibly led to a massive presentation of Vx2 tumour antigens and
an effective stimulation of the immune system known as concomitant immunity.
This mechanism could also explain the regression of metastases found in some
lymph nodes. Further discussion of this phenomenon lies beyond the purpose of
this study.
7.4.2 Efficiency of injection
A significant practical problem in administering micro particles is their tendency to
settle quickly in the injection vehicles and to clump in the syringe or cannulation
system. This problem of enhanced sedimentation seems to be frequently encoun-
tered as reported on the internet (http://www.biogeltech.com/research.html) but to
our knowledge has never been quantified in literature. Our injection efficiency was
61% despite adding methylcellulose as injection vehicle. Most particles were
retained in niches at the transition of the catheter to the cannula. Quick sedimenta-
tion of glass microspheres is a well-known problem attributed to their high density
of 3.3 g/ml which accounts for significant variations in doses administered
[Ehrhardt and Day, 1987; Mumper et al., 1991]. Though the density of
166HoPLA is much lower (1.4 g/ml), agitation of the solution during injection as
well as repeated flushing of the cannula system has been advised by others [Bastian
et al., 1998; Turner et al., 1994] and was carried out during our experiments.
However, we did not control the flow rate to create a laminar flow [Mumper et al.,
1991]. In future studies an overdose of about 40% should be taken into account
when using the present infusion system.
7.4.3 Efficacy of microsphere retention
Retention of the 166HoPLA microspheres prepared for this study proved highly
efficient with over 95% entrapment at the primary tumour site. It is comparable
with the 94.5% retention of 166HoPLA microspheres (diameter 24 µm) in rabbit
Vx2 liver tumours [Mumper et al., 1991] and the 94.5-98.5% entrapment of yttri-
um-90 glass microspheres (diameter 22 µm) in human liver tumours [Andrews et
al., 1994]. Although Turner et al. [1994] obtained 99.99% entrapment of even
smaller 166Ho-resin microspheres (diameter 13 ± 2 µm) in pigs, the livers in their
model did not contain tumours. Entrapment of microspheres might be better in
normal tissues because tumours induce capillary-like distended vessels [Van Es et
al., 1999].
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After 24 h, the portion of entrapped microspheres was slightly higher than immedi-
ately after embolisation (97.3% vs 96.5%). Though well within the limits of varia-
tion, it could be explained by a partial washout of some very small particles spilled to
the lungs. In the previous study (chapter 6) with dextran hydrogel microspheres of a
comparable size, a subsequent leaking of microspheres from the embolised tumour
of 1% was observed. Retention of these microspheres was 96.2 % and consistent
with the findings in this study.
The microspheres spilled to the lungs tend cluster in vessels as also observed by oth-
ers [Bastian et al., 1998; Muller and Rossier, 1951]. Our organograph of the lungs
of the rabbit that died from brain emboli is comparable to the findings of Muller
and Rossier [1951] after i.v. injections of 198Au microparticles (diameter 30-50 µm)
in rabbits. No post-irradiation sequelae were observed at autopsy in this study, prob-
ably because lung tissues received at most 1.5 MBq. Yan et al.[1993] did not find
pulmonary changes after pathological examination of rabbits infused with 1480 MBq
99Yttrium-glass microspheres, an injected dose 20 times higher than in our study.
The organograph of the auricle tumour sections shows good dose homogeneity due
to an even distribution of the 166HoPLA microspheres in and around the whole
primary tumour.
The occurrence of stray emboli to the brain is a well-known and serious complica-
tion following embolisation of head and neck lesions. It can not be prevented by the
use of larger microspheres, as in humans stray emboli also occur with particles
measuring 300-2,500 µm [Latchaw and Gold, 1979]. Therefore, unwanted
embolisation into other arterial channels should be avoided by:
1. Detection and closure of non-tumour arterial branches, as was carried out in our
study with methylene blue dye and tying up the vessels. This can also be per-
formed in humans by e.g. coil embolisation [Andrews et al., 1994; McCarter et
al., 1995].
2. The use of a balloon catheter to prevent potential reflux. In our study the injected
artery was exposed and the infusion cannula was tied, making reflux impossible.
The following measures might further minimise unwanted embolisation:
1. Prevention of over-embolisation by incorporating a maximum of radioactivity in
the aliquot of microspheres to be injected and monitoring the flow rate with flu-
oroscopy.
2. Monitoring of injection pressure and keeping it below the average blood pressure.
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7.4.4 Leaching of 166Ho in faeces and urine
The excretion of 166Ho found in our study is below the arbitrary limit of 0.1% of
the injected dose after two half-lives as posed by Ehrhardt and Day [1987]. It is
comparable to the 1.6% leaching found by Nijsen et al. [1999] after 192 h incuba-
tion in liver homogenate, but lower than the 5.5% after 144 h found in vivo by
Mumper et al. [1991]. A different rate of biodegradation or resorption of the
166HoPLA spheres because of a different crystallinity might explain these differ-
ences. Our 166HoPLA spheres degrade slowly as no substantial resorption of the
particles was noted 42 days after embolisation.
It is concluded that 166HoPLA microspheres with a mean diameter of 38-80 µm
are promising candidates for future studies on radio-embolisation of unresectable
head and neck cancer. Embolisation induced 79-86% complete primary tumour
remissions, over 95% of the particles was retained in the primary tumour and leach-
ing of 166Ho in urine and faeces was minimal. However, the injection efficiency
should be optimised because 40% of the microspheres was retained in the cannula-
tion system. Arterio-arteriolar connections should be carefully detected and closed
to prevent stray emboli into the brain. The fact that this Vx2 tumour is highly sensi-
tive to vascular occlusion should be kept in mind in future radio-embolisation stud-
ies because it makes assessment of the additive value of irradiation difficult.
Furthermore, the purported immunogeneic nature of the Vx2 carcinoma renders
contra-lateral tumours less ideal as non-treated controls because of systemic con-
comitant anti-tumour activity.
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Summary, discussion and conclusions
8.1 Summary and general discussion
Advanced stage oral and oropharyngeal carcinomas have a disappointingly low sur-
vival rate, which has not improved substantially for the last two decades.
Conventional treatment still consists of surgery, radiotherapy and chemotherapy or a
combination of these modalities. In view of its increasing incidence and failure of
preventive measures, there is a need for the development of new treatment strategies
against this disease. The aim of this thesis has been to make a contribution to this.
An overview of alternative treatment modalities against Head and Neck Squamous
Cell Carcinoma (HNSCC) is presented in chapter 1. To test these modalities, ani-
mal cancer models are necessary. Disadvantages of models currently used to test new
loco-regional treatment strategies against HNSCC are discussed. Attention is
focussed on the transplantable Vx2 Squamous Cell Carcinoma (SCC) as it was felt
that transplantation of this tumour into the rabbit auricle would render a suitable
HNSCC animal model.
The development of a Vx2 HNSCC model and evaluation of its biologic behaviour
in terms of tumour take-rate and development of metastases is described in chapter 2.
Two groups of New Zealand White rabbits received either subcutaneous injections
of Vx2 suspensions (group S) or solid Vx2 pieces (group P) into both auricles. The
tumour take-rate was recorded. Sacrifice took place at various times after transplan-
tation. At autopsy, the size of the primary tumours and of lymph node, lung and
other metastases were assessed. The tumour take-rate in group S and P was 78%
and 59% respectively. The elapsed time after transplantation and the maximal size of
the tumours that regressed spontaneously was significantly different between the two
groups and amounted 83 ± 7 mm2 at 10.4 ± 1.6 days for group S and 243 ± 30
mm2 at 20.9 ± 2.0 days for group P, respectively. Four weeks after transplantation,
more than 90% of the necks in both groups contained lymph node metastases. There
was a trend (p=0.14) for a higher incidence of lung metastases in group S compared
to group P (47% vs. 14%). Metastases at other sites were rarely seen (less than 5%).
A significant correlation (p=0.02) between weight loss and the size of lung metas-
tases was found. It is concluded that transplantation of Vx2 tumour cell suspensions
into both auricles renders a model for loco-regional disease which mimics the bio-
logic behaviour of HNSCC in humans and in which anti-tumour regimens against
both the primary tumour and lymph node metastases can be tested.
Regarding the technique of tumour grafting, subcutaneous transplantation of freshly
prepared Vx2 cell suspensions in this model with at least 20.106 vital cells gave the
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best results. With fresh cell suspensions the tumour take-rate was 78-85%. The
transplantation of thawed Vx2 suspensions (see chapter 5) or solid Vx2 pieces into
the auricle yielded worse take-rates of 40-59% respectively, which might be
explained by the induction of anti-tumour immunity by transplanted dead Vx2 cells
at this site [Förg et al., 1998]. Development of artificially created metastases fol-
lowing injection of Vx2 suspensions [Gadeholt-Göthlin and Göthlin, 1995],
apparently did not play a substantial role in this model.
The effects of local interleukin-2 (IL-2) immune-therapy on the Vx2 HNSCC
model are described in chapter 3. A regimen of peri-tumoural IL-2 that appeared
optimal in murine tumour models [Den Otter et al., 1996] was applied. Treatment
started when the surface area of one of the bilaterally implanted tumours exceeded
2 cm2. In 4/12 (33%) rabbits the treated primary tumours regressed completely,
simultaneously with the non-treated contra-lateral tumours. Also metastases in
draining lymph nodes of both treated and untreated primary tumours regressed in
three of these animals. Three (25%) of all 12 treated animals were cured. Tumour
cells subsequently injected in the cured animals did not result in new tumour
growth. Histology of regressing tumours in cured cases showed an active granulo-
matous reaction with a histiocytic response, splitting up of tumour islands, and
obstruction of blood vessels with fibrin thrombi. These findings indicate both a
local and a systemic effect of IL-2 in the Vx2 auricle SCC model. The effects of
peri-tumoural IL-2 therapy appeared similar to the effects observed following i.a.
embolisation of the Vx2 tumour with inactive poly(L-lactic acid) microspheres (see
chapter 7): Successful embolisation of one tumour induced a simultaneous regres-
sion of 57% of the contra-lateral control tumours. Therefore, this Vx2 HNSCC
model is suitable to demonstrate the induction of an effective systemic immune
response against the Vx2 tumour which results in tumour rejection at another site
[Maas et al., 1991]. The induction of this immune response probably is preceded
by ischemic necrosis of the Vx2 tumour [Yoshikawa et al., 1994]. This study shows
that it is not permitted to use a contra-lateral auricle tumour as independent intra-
animal control, because a local treatment of the index tumour that generates necro-
sis, will frequently induce a immune-mediated regression of also the non-treated
control tumour.
Various aspects of the application of intra-arterial (i.a.) anti-cancer therapy are dis-
cussed in chapter 4. Because there is a farmacokinetic rationale for the application
of intra-arterially infused embolisation particles in tumour treatment, an overview
of available embolisation particles is given. Attention is focussed on existing chemo-
and radio-embolisation therapies. Potential strategies for the application of emboli-
sation-therapies against HNSCC are given. Prerequisites that are necessary to be
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addressed in animal studies, are discussed.
The second purpose of the study was the application of the Vx2 auricle SCC model
in the development of new loco-regional treatment strategies against HNSCC,
based on i.a. infusion of micro-particles as carriers for anti-tumour drugs.
Attention is focussed on growth speed of the Vx2 SCC tumours in chapter 5. Also
a technique for i.a. tumour perfusion is presented and the effects of i.a. embolisa-
tion of the Vx2 auricle SCC model with Dextran hydrogel (Dex) microspheres are
analysed. During the exponential growth phase, the tumour-surface doubling-time
was 7.1 ± 2.0 days. Standard deviation in growth of the tumours was significantly
larger between separate animals than between tumours growing in the left and right
auricle of each individual animal (2.0 vs. 0.65 days).
The caudal auricular artery perfuses the caudal half of the external ear and proved
to be suitable for macroscopic cannulation. Histological evaluation showed, that the
use of Dex microspheres of at least 25 µm in combination with ligation of branches
from the central auricular artery that do not perfuse the tumour, yielded a diffuse
embolisation of the Vx2 tumour. It is concluded that this Vx2 auricle SCC tumour
model can be used in further studies to optimise particle size and dosage for
embolisation as well as to evaluate the effects of either different anti-neoplastic
drugs, slowly released by controlled degradation of Dex microspheres or embolisa-
tion particles containing radionuclides.
The distribution of i.a. injected microspheres is investigated both in-vivo as well as
histologically in chapter 6, in order to determine an optimal size of particles for
embolisation of head and neck tumours. Rabbits with Vx2 auricle tumours were
embolised via the caudal auricular artery with available batches Dex and holmium-
166 labelled poly(L-lactic acid) (166HoPLA) microspheres, varying in size from
19 to 66 µm. Dex microspheres were additionally labelled with 99mTechnetium.
The proportion of microspheres entrapped in the tumour was measured with a
gamma camera. The distribution of microspheres around the primary tumour and
spill of particles to lungs or other organs was analysed on histological sections. The
19 µm 166HoPLA particles proved inadequate for embolisation as 51% of the parti-
cles spilled to the lungs, whereas over 95% of the 40-66 µm Dex microspheres was
retained within the primary tumour area. With 66 µm microspheres the deposition
of particles in lung tissues proved significantly lower, but particles of this size
showed a decreased deposition of microspheres directly around the target tumour.
The results of this investigation showed that particles with a mean size of at least 40
µm should be employed, to prevent substantial spill to the lungs. Microspheres of
sizes over 100 µm as used for chemo-embolisation of HNSCC in humans [Kato et
al., 1994; Tomura et al., 1998] cannot be used in this Vx2 auricle SCC model,
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because these large particles get stuck in the feeding arterioles before reaching the
tumour.
Of the 44 rabbits embolised in this study, 3(7%) developed neurological signs. In
these animals microspheres were found in brain tissue and ophthalmic vessels. It
appeared to be due to arterio-arterial connections between the caudal and rostral
auricular artery, which were not detected and occluded. The inadvertent spill of
microspheres into the brain or eyes via arterio-arteriolar connections is a well-
known sequel of tumour embolisation in the head and neck area in humans
[Latchaw and Gold, 1979; Braun et al., 1985; Mames et al., 1991]. As injection pres-
sure was not monitored in this model, a too high pressure could have resulted in retro-
grade flow of microspheres into the internal carotid artery. Possibly, also fluoroscopy
could effectively detect stray emboli in future studies [Latchaw and Gold, 1979].
The long-term effects of embolisation of the Vx2 auricle SCC model with radioac-
tive 166 HoPLA microspheres are reported in chapter 7. The effects of embolisa-
tion on tumour growth, the efficiency of intra-arterial infusion of microspheres, the
efficacy of retention of spheres in the primary tumour and the excretion of free
166Ho in faeces and urine were analysed. Radio-embolisation induced 78% tumour
remissions. More than 95% of the microspheres were retained in the tumour and
the leaching of free 166Ho was less than 0.1% in 2 days. However, 40% of the parti-
cles retained in the cannulation system due to enhanced sedimentation. It is con-
cluded that these 166HoPLA microspheres with a diameter between 40 and 80 µm,
are promising candidates for future studies on radio-embolisation of unresectable
head and neck cancer. However, also inactive HoPLA microspheres induced
remissions of the target tumour as well as non-treated contra-lateral control
tumours (see also chapter 3). Therefore, the additional effects of irradiation follow-
ing embolisation of the rabbit Vx2 auricle SCC model are difficult to discern,
because the Vx2 tumour is highly sensitive to ischemia and reperfusion injury
[Yoshikawa et al.,1994].
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8.2 Final conclusions
- Transplantation of the Vx2 SCC cell-line into the rabbit auricle renders an animal
tumour model that mimics the behaviour of HNSCC in humans, with over 90%
lymph node metastases after 4 weeks, 47% lung metastases after 5-10 weeks and
less than 5% metastases at other sites.
- Success of transplantation is around 80% with freshly prepared Vx2 SCC cell-
suspensions and significantly better than with solid tumour pieces or thawed,
cryo-preserved suspensions.
- The tumour-surface doubling-time of Vx2 SCC auricle tumours in NZW rabbits
is 7.1± 2.0 days. Standard deviation of growth speed is significantly larger
between separate animals than between separate tumours within the same animal.
- Repeated daily peri-tumoural IL-2 injections induce a systemic anti-tumour
activity with regression of 25% of the treated primary tumours simultaneously
with non-treated control tumours and lymph node metastases.
- Employment of an intra-individual Vx2 SCC control tumour to evaluate effects
of local tumour treatment is not permitted because of the development of a sys-
temic anti-tumour immune response in the animal.
- With cannulation of the caudal auricular artery and ligation of branches that do
not supply the tumour, a regional perfusion of Vx2 SCC tumours in the dorso-
caudal side of the auricle is obtained.
- The optimal particle size for embolisation of Vx2 auricle tumours is about 40 µm
in number- and 70 µm in volume-weighted means respectively. Smaller particles
shunt to the lungs while larger particles disperse less favourable around the
tumour.
- The Vx2 tumour is highly sensitive to vascular occlusion following i.a. embolisa-
tion. This makes it difficult to discern the additional effects of irradiation follow-
ing radio-embolisation.
- Sedimentation of holmium-166 labelled poly(L-lactic acid) (166HoPLA) micro-
spheres accounts for retention of 40% of the particles in the cannulation system.
- In 7% of all Vx2 SCC auricle tumour-embolisation procedures, inadvertent spill
of microspheres into the rabbit brain occurred via arterio-arteriolar connections.
- The leaching of free holmium-166 from 166HoPLA microspheres is less than
0.1% after twice its half-life.
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8.3 Suggestions for further research
There is a need for clinical and experimental studies to assess the efficacy of various
new treatment strategies against oral and oropharyngeal cancer. Attention will have
to focus on combinations of the conventional triad of surgery, chemotherapy and
radiology with novel therapies as multi-modality immune-therapy, inhibition of
angio-genesis and genetic engineering.
The rabbit Vx2 auricle SCC model developed in this study can be used in the
future:
1. To get better insight in the patho-fysiology of head and neck cancer, such as
metastatic spread and immune reactivity.
2. To further evaluate the possible applications of new treatment strategies against
head and neck cancer.
Future embolisation studies must establish whether the 40-80 µm microspheres
employed in this investigation are also optimal for oral and oropharyngeal SCC in
humans. Attention must be paid to identification and occlusion of arterio-arteriolar
connections and the injection pressure should be monitored to prevent stray emboli.
The dextran hydrogel microspheres are primarily suited for controlled release of
immunoglobulins instead of small chemotherapeutic drugs such as cisplatinum.
They may be applied either intra-arterially or peri-tumourally, for prolonged release
of e.g. immune-stimulating proteins that have a short in-vivo half-life. 
The radioactive 166HoPLA microspheres are promising candidates for future studies.
They can be applied as intra-arterial radionuclide therapy for inoperable tumours
either with curative intent or as palliation. Aspects concerning calculation of the
appropriate tumour dose, efficiency of infusion of the microspheres and prevention
of stray emboli to the brain have to be addressed. Peri-tumoural injection of these
microspheres for palliation of recurrent tumours is another possible application
worth to be investigated. 
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9.0 Samenvatting
De overleving na behandeling van uitgebreide mondholte- en oropharynx-carcino-
men is teleurstellend en is de afgelopen 20 jaar nauwelijks verbeterd. Gezien de
jaarlijks toenemende incidentie van de ziekte en het falen van preventieve maatrege-
len is er behoefte aan de ontwikkeling van nieuwe behandelstrategieën. De gebrui-
kelijke behandeling bestaat nog altijd uit operatie, bestraling en chemotherapie of
een combinatie hiervan. In Hoofdstuk 1 wordt een overzicht van diverse behandel-
mogelijkheden tegen het Plaveisel Cel Carcinoom in het Hoofd-Hals gebied
(PCCHH) gegeven. Teneinde nieuwe vormen van behandelingen te testen zijn
diermodellen nodig. Momenteel gebruikte diermodellen worden besproken en spe-
ciale aandacht is er voor het transplanteerbare Vx2 plaveiselcel carcinoom (PCC) in
het konijn.
Het primaire doel van deze studie is te evalueren of transplantatie van dit Vx2 PCC
naar het oor van het konijn een geschikt diermodel oplevert om nieuwe loco-regio-
nale behandelmogelijkheden voor het PCCHH te testen.
In Hoofdstuk 2 wordt de ontwikkeling van een Vx2 PCC tumor model en de evaluatie
van het biologische gedrag ervan voor wat betreft succes van transplantatie en de
ontwikkeling van lymfeklier- en longmetastasen, beschreven. Twee groepen New
Zealand White konijnen ontvingen ofwel subcutaan injecties van Vx2 cel-
suspensies (groep S) ofwel solide Vx2 brokjes (groep P) in beide oorschelpen. De
dieren werden gedood op verschillende tijdstippen na tumor transplantatie. Bij
obductie werden de afmetingen van de primaire tumor, van de lymfklieren en van
longmetastasen vastgesteld. Bij spontane tumor remissie werd de maximale omvang
van de tumor en het tijdstip waarop deze optrad vastgelegd. Het succes van tumor
transplantatie bedroeg 78% en 59% in respectievelijk groep S en P. Indien regressie
optrad, waren de maximale omvang van de tumor en het tijdstip waarop regressie
begon, significant verschillend tussen groep S en P: respectievelijk 83 ±7 mm2 op
10,4 ± 1,6 dagen en 243 ± 30 mm2 op 20.9 ± 2.0 dagen. Ontwikkeling van lym-
fekliermetastasen was niet verschillend in beide groepen. In groep P en S werden
na 4 weken in meer dan 90% van de gevallen halsklier metastasen aangetroffen. Er
was een geringe neiging (p=0,14) voor het optreden van meer longmetastasen in
groep S vergeleken met groep P (47% vs. 14%). Er was een positieve correlatie tus-
sen gewichtsverlies van het dier en de omvang van longmetastasen. Transplantatie
van de Vx2 tumor cellijn naar beide oorschelpen levert een succesvol PCCHH
model voor loco-regionale ziekte op, waarin tumorbehandelingen gericht op zowel
de primaire tumor als lymfeklier metastasen kan worden getest. Transplantatie met
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tumorbrokjes of celsuspensies die ingevroren zijn geweest (Hoofdstuk 5) wordt
niet aanbevolen omdat dan het transplantatiesucces laag is.
In Hoofdstuk 3 wordt beschreven hoe het konijn Vx2 tumormodel is gebruikt, om
de effecten van een locale immuun-behandeling met interleukine-2 (IL-2) te
testen. Peritumorale IL-2 behandeling werd gestart zodra één van de bilateraal
getransplanteerde tumoren groter dan 2 cm2 was. In 4/12 (33%) van de konijnen
trad complete regressie op van de behandelde primaire tumor, tegelijkertijd met
regressie van de niet behandelde contra-laterale controle-tumor. Ook metastasen in
drainerende lymfeklieren gingen in regressie. Drie (25%) van de 12 behandelde
dieren konden worden genezen. Tumorcellen opnieuw geïnjecteerd in de eenmaal
genezen dieren leidde niet tot nieuwe tumorgroei. Histologie van de in regressie
gegane tumoren van de genezen dieren, toonde een actieve granulomateuze reactie
met een histiocytaire component, het opsplitsen van tumor in kleine eilandjes en
obstructie van bloedvaten door fibrine trombi. Deze bevindingen demonstreren
zowel een locaal als systemisch therapeutisch effect van het gebruikte IL-2 regime
bij dit Vx2 carcinoommodel.
Een vergelijkbare simultane regressie van de contra-laterale controle-tumoren trad
ook op na embolisatie-behandeling zonder IL-2 toediening (Hoofdstuk 7).
Mogelijke oorzaak hiervan is een door necrotisch tumorweefsel opgewekte
immuunreactie die de controle-tumor doet verdwijnen. Dit neveneffect betekent
dat een 2e contra-laterale Vx2 tumor niet gebruikt kan worden als controle voor
beoordeling van het effect van een locale therapie op de behandelde tumor in het-
zelfde konijn. 
In Hoofdstuk 4 worden verschillende aspecten van de toepassing van intra-arteriële,
ook wel regionale anti-tumor therapie besproken. Omdat er een farmacokinetische
basis is voor toepassing van intra-arteriële infusie van microbolletjes als tumorbehan-
deling, wordt een overzicht gegeven van beschikbare deeltjes voor intra-arteriële
embolisatie. Aandacht wordt m.n. gericht op reeds bestaande therapieën van
chemo-embolisatie en radio-embolisatie buiten het hoofd-hals gebied. Mogelijke
strategieën voor toepassing van embolisatie behandeling tegen het PCCHH, alsmede
de voorwaarden die nodig zijn voor verdere dierproeven, worden besproken.
In Hoofdstuk 5 is er aandacht voor de groeisnelheid van de Vx2 tumor in de oor-
schelp. Een techniek voor de selectieve intra-arteriële tumorperfusie wordt gepre-
senteerd en de effecten van intra-arteriële embolisatie van dit Vx2 oorschelp PCC
model met dextraan hydrogel microbolletjes worden geanalyseerd. Tijdens de fase
van exponentiele groei blijkt de tumor-oppervlakte verdubbelingstijd 7,0 ± 2,0
dagen. Standaarddeviatie van de groei van de tumoren blijkt significant groter tus-
sen twee afzonderlijke dieren, dan tussen twee tumoren in beide oren van hetzelfde
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dier (2,0 vs 0,65 dagen). De arteria auricularis caudalis blijkt de caudale helft van
de oorschelp van het konijn te perfunderen en is geschikt voor macroscopische can-
nulatie. Histologisch onderzoek laat zien dat een combinatie van dextran hydrogel
microbolletjes van tenminste 25 µm in diameter met het onderbinden van arteria
auricularis centralis-takken die de tumor niet perfunderen, noodzakelijk is om een
diffuse embolisatie van het Vx2 carcinoom te verkrijgen. Dit Vx2 tumormodel
blijkt bruikbaar voor verdere studies waarin de partikelgrootte en de dosering
benodigd voor embolisatie, worden geoptimaliseerd. Vervolgens kunnen dan de
effecten van ofwel verschillende chemotherapeutica die langzaam door gecontro-
leerde degradatie van dextran microspheren worden afgegeven, ofwel radioactieve
microbolletjes worden geëvalueerd.
In Hoofdstuk 6 wordt de distributie van intra-arterieel geïnjecteerde microbolletjes
verder onderzocht om tot een optimale afmeting van de bolletjes voor embolisatie
van hoofd-hals tumoren te komen. Konijnen met Vx2 oorschelp carcinomen wor-
den geëmboliseerd via de arteria auricularis caudalis met dextran hydrogel of hol-
mium-166 poly(L-lactic acid) (166HoPLA) microbolletjes, die in grootte variëren
van 19 tot 66 µm. Een deel van de dextran hydrogel bolletjes wordt gelabeld met
99mTechnetium. De hoeveelheid microbolletjes die in de tumor vastloopt, wordt
gemeten met behulp van een gamma camera. De distributie van bolletjes rondom
de primaire tumor en het verlies van bolletjes naar de long en andere organen,
wordt ook histologisch beoordeeld. De 19 µm 166HoPLA bolletjes die normaal
voor leverembolisatie worden gebruikt, blijken ongeschikt voor embolisatie in dit
model, omdat 51% van de deeltjes doorschiet naar de long. Daarentegen blijft meer
dan 95% van de 40 tot 66 µm dextran hydrogel bolletjes wel goed in de primaire
tumor hangen. Bij grotere microbolletjes is de partikel-dichtheid in het longweefsel
significant lager, maar wordt de distributie rondom de primaire tumor ongunstiger.
In 2 konijnen die geëmboliseerd werden met 40 µm microbolletjes ontstonden
emboliën op afstand in het brein, ten gevolge van arterio-arteriolaire verbindingen.
De resultaten van dit onderzoek laten zien dat zowel dextran hydrogel als
166HoPLA microbolletjes geschikte kandidaten zijn voor embolisatie van hoofd-
hals tumoren. Deeltjes met een gemiddelde diameter van 40-70 µm geven het beste
resultaat om doorschieten naar de longen te verhinderen. De distributie van grotere
deeltjes rondom de tumor is ongunstiger.
In Hoofdstuk 7 worden de lange termijn effecten van embolisatie van het Vx2 oor-
schelp PCC model met radioactieve en inactieve holmium-gelabelde poly(L-
lactic acid) microbolletjes besproken. Beoordeeld worden zowel de effecten van
embolisatie op tumorgroei als het rendement van intra-arteriële infusie van micro-
bolletjes en de efficiëntie van het blijven hangen van bolletjes in de primaire tumor.
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De uitscheiding van vrij holmium-166 wordt vastgesteld. De radioembolisatie
resulteert in 78% remissie van primaire tumoren. Meer dan 95% van de bolletjes
blijkt vast te lopen in het tumorvaatblad en de lekkage van holmium-166 is minder
dan 0,1% in 2 dagen. Echter, het rendement van de infusie van bolletjes moet ver-
beterd worden, omdat bijna 40% van de deeltjes achter blijft in de canulatiesysteem
t.g.v. sedimentatie van de partikels. De conclusie is dat 166HoPLA microbolletjes
met een aantal, respectievelijk volume gewogen gemiddelde van 40 en 80 µm veel-
belovende kandidaten zijn voor toekomstige toepassing als radioembolisatie van
niet-resectabele hoofd-hals tumoren. Het Vx2 oorschelp PCC model leent zich
echter minder goed voor embolisatie, omdat ook bij embolisatie met niet-actieve
microbolletjes complete remissies van zowel de primaire als contralaterale controle
tumoren werden verkregen, hetgeen wijst op de inductie van een systemische
immuunreactie in het konijn na unilaterale tumornecrose. 
In Hoofdstuk 8 worden de bevindingen van de voorliggende studies samengevat en 
bediscussieerd. Met name is er aandacht voor de inductie van een systemische
immuunreactie en wordt gesproken over aspecten van ongewenste embolisatie op
afstand. Er wordt afgesloten met het bespreken van mogelijkheden voor toekomsti-
ge studies.
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Dis die blond,
dis die blou:
dis die veld,
dis die lug;
en ’n voël draai bowe in eensame vlug -
dis al.
J.F.E. Celliers
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